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SUMMARY 
5.  This report is an update to the OECD Health Working Paper No. 22, Health Care Quality 
Indicators Project: Initial Indicators Report that was based on data collected between 2003 and 2005 and 
released in 20064. That report presented the OECDs initial work on developing a set of health care quality 
indicators that could be used to raise questions about differences in quality of care across countries. The 
2006 report covered 21 initial indicators with data provided by 24 countries. It identified 17 of these 
indicators as being fit for international comparisons of which 4 were identified as needing further work5. 
Following the release of that report in March 2006, the OECD undertook a second round of data collection 
on the initial indicator set and also gathered data for the first time on new indicators in a questionnaire sent 
to participating HCQI countries. This paper reports on the results of that second round of data collection. 
Data is presented here on an augmented indicator set considered fit for the purpose of making international 
comparisons on quality of health care. The data is comprised of 19 indicators (17 initial indicators plus 2 
new ones). The paper also presents the data provided on 7 other indicators that are not yet considered fit 
for international comparison. In this round of data collection, data were reported by 32 countries.  
6.  The Secretariat and collaborating HCQI country experts carried out several data comparability 
analyses on the new indicators for which data had been gathered. Certain comparability issues were 
discussed with the HCQI Project Expert Group at its meeting in Paris in October 2006. These issues 
included: 
• The use of data which were not nationally representative  
• Presentation of administrative versus survey data for cancer screening 
• Harmonising data recall periods for cancer survival and screening 
• The use of a truncated standard population for age adjustment 
7.  The results of the above analysis are presented in detail in this paper. However, an overall view 
of data comparability and possible improvement can be offered. It is clear from the analysis that significant 
progress has been made within the HCQI Project and by individual member countries in improving data 
comparability on the set of indicators from the HCQI Project since the first data collection in 2003. For 
example, on a range of survey indicators (such as cancer screening), countries have been able to alter 
national reporting standards to provide the OECD with comparable data. In the area of mortality rates for 
                                                     
4 Mattke S, Kelley E, Scherer P, Hurst J, Gil Lapetra M and the Members of the HCQI Expert Group (2006), Health 
Care Quality Indicators Project: Initial Indicators Report, OECD Health Working Paper No. 22, OECD, Paris,  
http://www.oecd.org/dataoecd/1/34/36262514.pdf.  
 
5 The 21 indicators (those labelled fit for international comparison and evaluated as not fit in column 2 of Table 
2, below) were described as 17 indicators in OECD Health Working Paper No. 22. That is because a group of three 
related indicators for incidence of vaccine preventable diseases and a group of three related indicators for coverage 
for basic vaccination programme were each listed as one indicator respectively. The six components of these two 
groups are now considered separately.  
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acute myocardial infarction (AMI) and stroke, country estimates have become significantly more 
comparable since the first data collection. What is also clear is that both gaps in data and persistent data 
comparability issues remain within the indicator set. For example, there are a number of countries where 
nationally representative data for indicators such as cancer survival are not yet available. In other instances, 
countries have not been able to furnish the OECD with indicators that match the age or recall period (for 
survey data) specifications, making differences between countries difficult to interpret. However, member 
countries continue to be supportive of the Secretariats efforts to investigate these data comparability 
issues. With this support, the Secretariat plans to continue to improve the existing indicators while at the 
same time work on developing new indicators based on comparable data. 
8.  As noted above, this paper presents three groups of indicators: 
a) All of the initial 17 indicators that were reported as being fit for international comparison in Health 
Working Paper No. 22, which were updated during the 2006 data collection. They are: 
• Breast cancer five-year survival rate 
• Mammography screening rate 
• Cervical cancer five-year survival rate 
• Cervical cancer screening rate 
• Colorectal cancer five-year survival rate 
• Incidence of vaccine preventable diseases (Pertussis, measles, and hepatitis B) 
• Coverage for basic vaccination programme, age 2, (Pertussis, measles, and hepatitis B) 
• Asthma mortality rate, ages 5-39 
• In-hospital mortality rate within 30 days of hospital admission for acute myocardial infarction 
• In-hospital mortality rate within 30 days of hospital admission for stroke 
• Waiting times for surgery after hip fracture, over age 65  
• Influenza vaccination, over age 65 
• Smoking rate 
b) Following discussions from the October 2006 meeting, two new indicators tested in the 2006 data 
collection round that, were judged by the HCQI Expert Group as mature enough to be added to the 
initial set:  
• Retinal exams in diabetics  This indicator was included in the first HCQI questionnaires (in 
2004 and 2005) but was not considered fit until the 2006 data collection round.  
• Asthma admission rate  This indicator was collected for the first time through the 2006 
questionnaire. 
c) Seven indicators were not yet considered suitable for inclusion in the HCQI data set for international 
comparison but were recommended for additional sensitivity analysis to find ways to improve 
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comparability. Among them, three indicators were collected in the 2003-2005 questionnaire have seen 
no substantial improvements for comparability and thus are still considered  not yet suitable for 
international comparison. These are: 
• Annual HbA1c testing for patients with diabetics 
• Patients with diabetics with poor glucose control 
• Major amputations in diabetics 
9. Four other indicators were collected for the first time through the 2006 questionnaire:  
• Post-operative hip fracture or fall 
• Transfusion reaction 
• Uncontrolled diabetes admission rate 
• Hypertension admission rate 
10. The first group of indicators listed above is presented with definitions and updated data. For the 
second and third groups of indicators, the report reviews detailed information on the scientific soundness, 
importance, availability of data and the international comparability of the data for each indicator.  
11. The smoking rate remains in the indicator set. This indicator was initially adopted since it is the 
risk factor which countries attempt to affect as they institute efforts through the health care delivery system 
to change tobacco consumption. There has been much discussion on this indicator because of its 
dependence on certain factors outside the control of the health system. It is therefore considered a 
relatively less valid indicator of quality of health care than the other indicators considered fit for 
international comparisons. The Expert Group will examine other, more health care-related indicators of 
smoking cessation. At this point, however, these indicators are not available from a wide enough group of 
countries. Therefore, for the moment, the smoking rate continues to be retained among the 19 indicators in 
the 2006 HCQI indicator set. 
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RESUMÉ 
12. Le présent rapport est une version actualisée du Document de travail de lOCDE sur la santé n 22 
intitulé Health Care Quality Indicators Project : Initial Indicators Report, établi sur la base des données 
rassemblées en 2003/2005 et publié en 20066. Ce rapport présentait les travaux initiaux de lOCDE 
concernant lélaboration dune série dindicateurs sur la qualité des soins de santé qui pourraient être 
utilisés pour tenter dexpliquer les différences en matière de qualité de soins entre les pays. Le 
rapport 2006 portait sur 21 « indicateurs initiaux » pour lesquels 24 pays avaient communiqué des 
données ; il a été estimé que 17 de ces indicateurs se prêtaient à des comparaisons internationales et que 
quatre dentre eux nécessitaient des travaux approfondis7. A la suite de la publication du rapport en 
mars 2006, lOCDE a entamé un deuxième cycle de collecte de données relatives à la série initiale 
dindicateurs et a entrepris de recueillir pour la première fois des données sur de nouveaux indicateurs par 
le biais dun questionnaire adressé aux pays participants au projet HCQI. Le présent rapport fait état des 
résultats du deuxième cycle de collecte de données. Il contient des données sur la série élargie 
dindicateurs considérés comme se prêtant à des comparaisons internationales, soit des données portant sur 
19 indicateurs (17 indicateurs existants et 2 nouveaux). Il présente également les données fournies en ce 
qui concerne 7 autres indicateurs dont on estime quils ne se prêtent pas encore à des comparaisons 
internationales. Les données communiquées émanent cette fois de 32 pays (des pays de lUE qui ne sont 
pas membres de lOCDE ont été invités à participer au projet8). 
13. Dans le cadre de létude des nouveaux indicateurs au sujet desquels des données ont été réunies, 
le Secrétariat et les experts nationaux collaborant au projet HCQI ont mené plusieurs analyses touchant la 
comparabilité des données. Certaines questions de comparabilité ont été examinées avec le Groupe 
dexperts du Projet HCQI lors de la réunion de ce dernier à Paris en octobre 2006. Il sagit des questions 
suivantes : 
• Lutilisation de données non représentatives au plan national 
• La présentation de données administratives par opposition à des données denquêtes en ce qui 
concerne le dépistage du cancer 
                                                     
6  Mattke S, Kelley E, Scherer P, Hurst J, Gil Lapetra M et les membres du Groupe dexperts du Projet HCQI. Health 
Care Quality Indicators Project: Initial Indicators Report. Document de travail sur la santé no. 22. (Paris, France: 
OCDE). 2006. http://www.oecd.org/dataoecd/1/34/36262514.pdf. 
 
7 Les 21 indicateurs (voir la colonne 1 du tableau 2) étaient en fait présentés comme 17 indicateurs dans le 
Document de travail de lOCDE sur la santé no. 22. En effet un groupe de trois indicateurs relatifs à l« incidence des 
maladies pouvant être prévenues par la vaccination et un groupe de trois indicateurs relatifs à la couverture des 
programmes de vaccination de base apparaissaient respectivement dans le document en tant quun seul indicateur. 
Les six indicateurs considérés dans ces deux groupes sont désormais distincts. 
 
8 Un appui financier de la Commission européenne a été utilisé afin de favoriser louverture vers des États européens 
non membres de lOCDE et dencourager leur participation au projet. A ce jour, trois des huit pays concernés 
prennent désormais part au projet. 
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• Lharmonisation des périodes de référence des données relatives au taux de survie et au dépistage 
du cancer 
• Lutilisation dune population standard tronquée à des fins dajustement en fonction de lâge 
14. Les résultats des analyses susmentionnées sont présentés de façon détaillée dans le rapport. Cela 
étant, on peut dores donner une idée générale de la comparabilité des données et dire si celle-ci sest 
améliorée. Il ressort clairement de lanalyse des questions de comparabilité des données existantes et des 
données nouvelles que dimportants progrès ont été réalisés dans le cadre du Projet HCQI ainsi que par 
certains pays membres en ce qui concerne la comparabilité des données afférentes à lensemble des 
indicateurs considérés dans le Projet HCQI depuis la première collecte effectuée en 2003. Par exemple, 
sagissant dun ensemble dindicateurs reposant sur des enquêtes (tel que le dépistage du cancer), les pays 
ont été à même de modifier leurs normes nationales de notification afin de fournir à lOCDE des données 
comparables. Pour ce qui est des taux de mortalité après un infarctus aigu du myocarde ou après un 
accident vasculaire cérébral, la comparabilité des estimations des pays sest beaucoup améliorée depuis la 
première collecte de données. Il apparaît par ailleurs clairement que certains problèmes de comparabilité 
des données concernant la série dindicateurs retenus dans le projet HCQI nont pu encore être résolus. 
Ainsi, dans un certain nombre dentre eux, des données représentatives au plan national relatif à des 
indicateurs tels que le taux de survie au cancer ne sont pas encore disponibles. Dans dautres cas, les pays 
nont pas été en mesure de communiquer à lOCDE des données correspondant aux spécifications en 
matière dâge ou de période de référence (pour les données denquêtes), doù des difficultés pour 
interpréter les différences entre pays. Cela étant, les pays membres sintéressent à la comparabilité des 
données et ont soutenu les efforts déployés par le Secrétariat pour étudier les questions sy rapportant. 
Grâce à ce soutien, le Secrétariat envisage daffiner les indicateurs existants tout en travaillant à 
lélaboration de nouveaux indicateurs sappuyant sur des données comparables. 
15. Comme on la vu ci-dessus, trois groupes dindicateurs sont présentés dans le rapport : 
a)  Lensemble des 17 indicateurs initiaux considérés comme se prêtant à des comparaisons 
internationales dans le Document de travail sur la santé n° 22, mis à jour à loccasion de la collecte de 
données de 2006. Il sagit des indicateurs suivants : 
• Taux de survie à cinq ans au cancer du sein 
• Taux de dépistage par mammographie 
• Taux de survie à cinq ans au cancer du col de lutérus 
• Taux de dépistage du cancer du col de lutérus 
• Taux de survie à cinq ans au cancer colorectal  
• Incidence des maladies pouvant être prévenues par la vaccination (coqueluche, rougeole et 
hépatite B) 
• Couverture des programmes de vaccination de base, à lâge de deux ans, (coqueluche, rougeole et 
hépatite B) 
• Taux de mortalité pour cause dasthme entre 5 et 39 ans 
• Taux de mortalité à 30 jours hors hôpital/à lhôpital après un infarctus aigu du myocarde 
• Taux de mortalité à 30 jours hors hôpital/à lhôpital après un accident vasculaire cérébral 
• Temps dattente pour une opération après une fracture de la hanche, à 65 ans et plus 
• Vaccination contre la grippe pour les adultes de plus de 65 ans 
DELSA/HEA/WD/HWP(2007)4 
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• Taux de tabagisme 
b) Deux nouveaux indicateurs, testés lors du cycle de collecte de données de 2006 et jugés par le 
Groupe dexperts du Projet HCQI, à la suite des débats qui se sont déroulés lors de la réunion 
doctobre 2006, comme étant suffisamment élaborés pour être ajoutés à lensemble initial. 
• Examen de la rétine chez les patients diabétiques  cet indicateur figurait dans les questionnaires 
initiaux du Projet HCQI (en 2004 et 2005) mais nétait pas considéré comme approprié jusquà 
présent. 
• Taux dhospitalisation des adultes pour cause dasthme  des données relatives à cet indicateur 
ont été collectées pour la première fois dans le questionnaire de 2006. 
c) Sept indicateurs envisagés dans le projet HCQI dont on estime quils ne sont pas prêts à être 
inclus dans la série car ils ne se prêtent à des comparaisons internationales, mais pour lesquels il a été 
recommandé de procéder à des analyses de sensibilité supplémentaires afin de trouver des moyens 
daméliorer la comparabilité des données. Des données ont été rassemblées sur trois dentre eux pour 
les questionnaires de 2003 à 2005 mais, faute dune amélioration sensible de leur comparabilité, on 
considère que ces indicateurs ne se prêtent toujours pas à des comparaisons internationales. Il sagit des 
indicateurs suivants : 
• Dosage de lHbA1c chez les personnes diabétiques 
• Contrôle insuffisant de la glycémie chez les personnes diabétiques 
• Amputations majeures chez les personnes diabétiques 
16. Quatre dentre eux ont fait lobjet dune collecte de données pour la première fois dans le cadre 
du questionnaire de 2006 : 
• Fracture de la hanche ou chute post-opératoire 
• Réaction à la transfusion  
• Taux dhospitalisation pour diabète non contrôlé 
• Taux dhospitalisation pour hypertension 
17. Les indicateurs du premier groupe sont accompagnés de leur définition et de données actualisées. 
Sagissant des indicateurs des deuxième et troisième groupes, le rapport examine des informations 
détaillées concernant la validité scientifique, limportance et la disponibilité des données ainsi que la 
comparabilité internationale de ces dernières pour chacun deux. 
18. Le taux de tabagisme continue de figurer dans la série dindicateurs du Projet HCQI considérée 
dans le présent rapport. Cet indicateur a été initialement retenu car il représente laspect essentiel sur lequel 
les pays sefforcent dinfluer lorsquils sattachent à modifier le comportement des fumeurs par le biais du 
système de soins de santé. Beaucoup de questions ont été soulevées au sujet de cet indicateur et du fait 
quil dépend de nombreux facteurs qui échappent au contrôle du système de santé. Il sagit donc dun 
indicateur relativement moins représentatif de la qualité des soins de santé. Le Groupe dexperts examinera 
dautres indicateurs concernant larrêt du tabac qui sont davantage liés aux soins de santé. Cela étant, à ce 
stade, ces indicateurs ne sont pas disponibles dans un groupe suffisamment important de pays. Le taux de 
tabagisme continue donc de figurer au nombre des 19 indicateurs de la série retenue pour 2006 dans le 
cadre du projet HCQI. 
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INTRODUCTION 
 
Health Care Quality Indicator Project: purpose and initial steps 
19. Quality of health care delivery is a topic of concern throughout the member countries of the 
OECD. Articles on shortcomings in care or on comparative differences in quality across countries have 
become more frequent in the popular press. Efforts to improve the measurement of quality of care through 
the development of quality indicators have become more present in the literature and in policy forums 
worldwide (IOM, 2001; Sawicki, 2005; Roland, 2004; AHRQ, 2005). Many of these efforts target specific 
disease areas in one particular country while others compare across countries, but target particular 
conditions (Ramirez, 2005). The quality indicator set reported on here is one of the few efforts9 which have 
attempted to examine quality of care across clinical conditions for more than one country. 
20. The long-term objective of the Health Care Quality Indicator (HCQI) Project is to develop a set 
of indicators that can be used to raise questions on health care quality and that can be reliably reported 
across countries using comparable data. The indicators are intended to help raise questions for further 
investigations of differences in quality of care across countries. In light of its endeavour, the indicators of 
the HCQI Project are conceived as a living set in which indicators transit through different stages of 
maturity until they are considered fit for the purpose of international comparisons. These stages arrive from 
the joint effort between the participating countries and the Secretariat to improve the quality and the 
quantity of available data. At the core of the project rests the conviction that to enhance the international 
comparability of health care quality it is indispensable to have a thorough and methodical work plan for the 
refinement and standardisation of health care information along with the steady encouragement of 
information systems development at the national level. Table 2 illustrates the process of broadening the 
set of indicators hitherto, showing the list of indicators involved in each data collection round and their 
assessed status in terms of fitness for use. 
21. The OECD HCQI project began in 2001, building on two previous international initiatives to 
develop indicators of health care quality across countries. One of these, initiated by the Commonwealth 
Fund involved five countries (Australia, Canada, New Zealand, United Kingdom and United States). 
Another, initiated by the Nordic Council of Ministers, included another six countries (Denmark, Finland, 
Iceland, Norway, Sweden and Greenland). Initially a group of 19 countries (including ten of those listed 
under the two initiatives mentioned above) accepted the OECDs invitation to join the HCQI project. A 
preliminary list of indicators was derived from the work of these two earlier initiatives. Based on expert 
judgement, the HCQI Country Expert group chose 21 indicators out of that list, considering them as 
scientifically sound and important. These indicators had also shown an acceptable degree of comparability 
                                                     
9 First Report and Recommendations of the Commonwealth Funds International Working Group on Quality 
Indicators a Report to Health Ministers of Australia, Canada, New Zealand, the United Kingdom, and the United 
States. June 2004. The Commonwealth Fund. (no. 752).  
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across countries in the context of the previous exercises. Data collection for these 21 indicators was 
conducted across participating countries to prove its feasibility. Various checks were undertaken of the 
indicators specifications across countries to establish their individual fitness for the purpose of 
international comparisons.  
22. The indicator selection criteria applied in the process of creating the original and current indicator 
list are summarised here. For an indicator to be a useful tool for evidence-based policy decisions, two 
conditions should be met. First, it has to capture an important performance aspect. Second, it must be 
scientifically sound.  
23.  The importance of an indicator can be further broken down into three dimensions: 
• Impact on health. What is the impact on health associated with this problem? Does the measure 
address areas in which there is a clear gap between the actual and potential levels of health? The 
impact on health is quantified where data is available for each indicator by using mortality and 
morbidity estimates from the World Health Organization for the EURO A10 group of countries, 
(Murray, 2001). This group of countries includes most of the countries participating in the OECD 
HCQI Project.  
• Policy importance. Are policymakers and consumers concerned about this area? Although this 
dimension is difficult to quantify objectively, the cost associated with the condition covered by 
each indicator is used to indicate the economic importance related to each indicator. Where 
suitable evidence on costs exists, it is also presented for each indicator.  
• Susceptibility to being influenced by the health care system. Can the health care system 
meaningfully address this aspect or problem? Does the health care system have an impact on the 
indicator independent of confounders like patient risk? Will changes in the indicator give 
information about success or failure of policy changes? This dimension is discussed based on a 
review of the relevant literature demonstrating that the health system can influence each 
indicator. 
The scientific soundness of each indicator can also be broken down into three dimensions: 
• Face validity. Does the measure make sense logically and clinically? The face validity of each 
indicator in this report is based on the basic clinical rationale for the indicator and on past usage 
of the indicator in national or other quality reporting activities. 
• Content validity. Does the measure capture meaningful aspects of the quality of care? Content 
validity is assessed through a literature review of studies relevant to each indicator. 
• Reliability. Does the measure provide stable results across various populations and 
circumstances? Reliability of each indicator is assessed through a literature review of studies 
assessing the stability of results across populations or circumstances. 
24. The application of these criteria to the initial indicator set of the HCQI Project had been carried 
out as part of the two predecessor projects to the HCQI Project, mentioned above. For the Commonwealth 
Fund work, a rating system was used to rank each indicator based on the above criteria. Indicators which 
                                                     
10 WHO EURO A countries include Andorra, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, 
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San 
Marino, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom. 
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ranked highly on these criteria were retained in the measure set. This rating process was reviewed by the 
OECD Secretariat and then by the HCQI Expert Group as it began its work on selecting indicators.  
25. The initial gathering of information and analysis was carried out from 2003 to 2005; new 
countries have continued to join the project, providing additional data for the analysis. The indicators 
collected during this period are listed in the first column of Table 2. Of the indicators, 17 of the 21 tested 
were considered fit for the purpose of international comparisons, but 4 of them (those related to diabetes 
care) were regarded as not yet ready, either due to their lack of availability across a sufficient number of 
countries (the experts agreed on a threshold of at least 10 countries able to provide data on the indicator) or 
some comparability issues not yet overcome. The data collected for the 21 indicators, together with the 
analysis of their fitness for international comparisons, were published as OECD Health Working Paper No. 
22, Health Care Quality Indicators Project: Initial Indicators Report (Mattke et al., 2006). 
26. The set of indicators resulting from the initial compilation effort was judged by the HCQI Expert 
Group as being too limited for comprehensive comparisons of the quality of health care across countries. 
Therefore the HCQI Expert Group instituted a process to identify important gaps in the areas of health care 
for which indicators had been developed, judging by the burden of disease being tackled, health care 
utilisation rates and costs. Country experts were asked to rate a set of health care condition areas in terms 
of importance. This rating process yielded 5 priority areas for the development of additional HCQI 
indicators11: 
• Cardiac care 
• Diabetes care  
• Primary care and prevention 
• Mental health  
• Patient safety 
27.  Five international expert panels were commissioned to propose relevant and scientifically sound 
measures for each of these areas12. The result was a list of 86 indicators considered as valid and reliable to 
report on the quality of care in these priority areas.  
General methods for the indicator set of the HCQI Project 
28. Following the release of the five expert panel reports recommending the 86 indicators in the 5 
priority areas, an availability survey was conducted across the participating countries to find out whether 
10 or more countries would be able to collect the data for each indicator. The 86 indicators included a few 
already being collected in OECD Health Data as well as some being gathered as part of the initial indicator 
set at the time when the recommendations were issued.  
                                                     
11 For a detailed description of this decision making process please consult the monographic supplement published by 
International Journal for Quality in Health Care; September 2006 Volume 18 supplement I. 
 
12 The five reports were published as OECD Health Technical Paper Nos. 14 - 18. The reports are downloadable from 
the HCQI web page www.oecd.org/health/hcqi. An overall picture of the process and a summary of the 
recommendations produced by the 5 panels can also be found in the monographic supplement published by the 
International Journal for Quality in Health Care, 2006, Vol.18 (suppl. 1).   
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29. Questionnaires were sent out to 23 countries in March 2005 and replies were received from 
March 2005 through November 2005.13 The questionnaires asked countries, on a measure by measure 
basis, to respond for each indicator in one of five ways. The response possibilities were as set out in Table 
1. 
Table 1. Example of questionnaire response categories 
Your response  
Indicator is currently collected  
Indicator could be constructed from available data  
A variant of this indicator could be constructed (Please 
describe nature of the variation below) 
 
Data for this indicator might become available in the next 
three years 
 
Availability of this 
indicator in your 
country 
Unlikely to become available  
Additional notes 
and details 
 
Analysis steps and criteria for selecting indicators 
30. In assessing whether an indicator met the threshold of 10 or more countries which could supply 
the data, the Secretariat considered both the number of countries that stated that an indicator was currently 
collected and the number of countries that stated that an indicator could be constructed from available 
data.  
Summary of the results 
31. The following findings are based on country responses: 5 indicators out of the recommended 86 
were currently collected in 10 countries or more, 3 in diabetes care (lower extremity amputations rates, 
annual eye exam and poor HbA1c control already included in the initial indicators) and 2 in primary care 
and prevention (smoking rate and low birth weight rate  with these two already collected by OECD 
Health Data). Of the remaining indicators in these two fields and all indicators proposed for cardiac care, 
mental health care and patient safety, none met the criterion of currently collected in 10 countries or 
more. Eighteen additional indicators could be constructed from available data from 10 or more countries. 
This brought the total number of indicators available to 23 (none for mental health14), broken down as 
follows: 
• two for the area of cardiac care (CABG in-hospital mortality rate and PTCA in-hospital 
mortality) 
• three for diabetes care (lower extremity amputations rates, annual eye exam and poor HbA1c 
control  already included in the initial indicators data collection, though not fit for international 
comparisons due to problems in national representativeness of data and other comparability 
issues) 
                                                     
13 The Slovak Republic only recently joined the HCQI project and therefore did not take part in the survey. The 
findings will be updated as any additional country information is provided. 
 
14 Note that for two mental health indicators nine countries stated that the data were available or that they could 
construct the indicator from available data. These two are: MH7 (hospital readmissions for psychiatric patients) and 
MH12 (mortality for persons with severe psychiatric disorders). 
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• nine for patient safety (problems with childbirth, obstetric trauma-vaginal, obstetrics trauma-
caesarean section, post-operative hip fracture, foreign body left in during procedure, birth 
trauma-injury to neonate, complications of anaesthesia, transfusion reaction and wrong blood 
type) 
• nine for primary care and prevention (smoking rate, diabetes prevalence, low birth weight rate, 
obesity prevalence  already collected by OECD Health Data, abortion rates, prevalence of 
immunisable conditions, physical activity, gonorrhoea/Chlamydia rates and hospitalisation for 
ambulatory-care sensitive conditions) 
32. Based on the above findings, the Expert Group discussed the possibility of adding a small 
number of these new indicators to the 2006 data collection, taking into account both their importance and 
availability. With the input of the members of the Primary Care and Prevention and Patient Safety panels, 
five additional indicators were recommended by the HCQI Expert Group for data collection as part of the 
HCQI 2006 questionnaire: a) asthma admission rate; b) hypertension admission rate; c) diabetes admission 
rate  these three being preventable causes of hospitalisation (or ambulatory-care sensitive conditions); d) 
post-operative hip fracture or fall and e) transfusion reaction rate. These indicators were selected for two 
reasons. First, the 3 indicators of preventable hospitalisations were deemed to be among the most tested of 
the indicators with broad data availability across countries. Second, patient safety was an area selected as 
high priority for work in 2006 by the Expert Group, thus the 2006 data collection would allow for an initial 
testing of the feasibility of international comparisons on two safety indicators using administrative data. 
When these 5 new indicators were added to the previous 21, the resulting collection exhausted the 
indicators that had broad consensus and for which comparable data across countries was available. Table 2 
summarises the original collection of 21 indicators and the latest collection of 26, distinguishing between 
those that are deemed fit for international comparison and those that are not yet deemed fit on grounds of 
comparability.  
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Table 2. Composition and evolution of the HCQI set of indicators 
Indicator 2003-2005 set of indicators as published in OECD HWP No. 22 2006 set of indicators 
Breast cancer five-year survival rate fit for international comparison fit for international comparison 
Mammography screening rate fit for international comparison fit for international comparison 
Cervical cancer five-year survival rate fit for international comparison fit for international comparison 
Cervical cancer screening rate fit for international comparison fit for international comparison 
Colorectal cancer five-year survival rate fit for international comparison fit for international comparison 
Incidence of vaccine preventable diseases 
(Pertussis, measles, and hepatitis B) fit for international comparison fit for international comparison 
Coverage for basic vaccination programme, 
age 2  
(Pertussis, measles, and hepatitis B) 
fit for international comparison fit for international comparison 
Asthma mortality rate, ages 5-39 fit for international comparison fit for international comparison 
In-hospital mortality rate within 30 days of 
hospital admission for AMI fit for international comparison fit for international comparison 
In-hospital mortality rate within 30 days of 
hospital admission for stroke fit for international comparison fit for international comparison 
In-hospital waiting time for surgery after hip 
fracture, over age 65 fit for international comparison fit for international comparison 
Influenza vaccination, over 65 fit for international comparison fit for international comparison 
Smoking rate fit for international comparison fit for international comparison 
Retinal exam in diabetics evaluated as not fit fit for international comparison 
Asthma admission rate not reviewed fit for international comparison 
Annual HbA1c test for diabetics evaluated as not fit evaluated as not fit 
HbA1c level indicating poor glucose control evaluated as not fit evaluated as not fit 
Major amputations in diabetics evaluated as not fit evaluated as not fit 
Post-operative hip fracture rate not reviewed evaluated as not fit 
Transfusion reaction rate not reviewed evaluated as not fit 
Uncontrolled diabetes admission rate not reviewed evaluated as not fit 
Hypertension admission rate not reviewed evaluated as not fit 
 
33. The HCQI Expert Group has agreed to conduct developmental work in each of the priority areas, 
establishing specific expert subgroups for each of them sequentially. Based on the results of the data 
availability survey and on a review of the clinical and policy importance and scientific soundness ratings 
given to the indicators, the HCQI Expert Group at its 2005 meeting recommended that the initial focus 
areas would be patient safety and mental health. Both subgroups were formed in April 2006 and important 
progress in addressing methodological issues has been and continues to be made.  
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DATA COMPARABILITY ISSUES  
34. In OECD Health Working Paper No. 22 on the Initial Indicators for the HCQI Project, an 
extensive examination of a range of data comparability issues was reported. Data comparability issues 
persist in the current indicator set requiring further investigation. These issues were discussed at the recent 
HCQI Experts Meeting in October 2006. These issues include:  
• the use of non-nationally representative data  
• presentation of administrative versus survey data for cancer screening 
• harmonising data recall periods for cancer survival and screening 
• the use of a truncated standard population for age adjustment 
35.  The use of non-nationally representative data In Health Working Paper No. 22, the OECD 
Secretariat published data from countries that was not strictly nationally representative. This was an 
explicit recommendation of the HCQI Expert Group in 2004, when several countries stated that they were 
unable to provide nationally representative data for cancer survival. At the time, the HCQI Expert Group 
discussed this and recommended that non-nationally representative data should be included where 
countries provided a written statement that the data was broadly generalisable to the nation as a whole. The 
HCQI Expert Group reviewed this decision in October 16-17, 2006 and recommended that non-nationally 
representative data should be presented separately in the working paper, noting the reason why the data 
was presented in a separate note. It was hoped that this solution would avoid confusing comparisons 
between nationally representative and non-nationally representative data. 
36.  Presentation of administrative versus survey data for cancer screening In Health Working Paper 
No. 22, data were presented on cancer screening for breast and cervical cancer. In many cases, these data 
came from varying sources across countries, namely administrative and programmatic data or household 
surveys. In the analysis reported in Health Working Paper No. 22, there appeared to be a systematic 
difference between these two data sources, in that administrative records often provided lower estimates 
than survey data. The most recent round of data collection in 2006 shows that there no longer appears to be 
a systematic difference between these two data sources (see Figure 1 below.) However, the broader 
literature continues to report differences between administrative records and surveys.  
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Figure 1. Findings on differences between administrative and survey data for cancer screening 
Screening programs versus surveys: cervical cancer screening rates
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37. Harmonising data recall periods for cancer survival and screening An additional issue with the 
cancer screening and cancer survival data is that recall periods differ widely across countries. In the area of 
cancer survival, countries also have widely varying time periods from which they are presenting data, since 
many countries do not compile their cancer survival statistics annually, but rather every 3 or 5 years, 
depending on the periodicity of the data system. Data will be reported according to the most recent data 
available in the survival interval in order to simplify data presentation. The Secretariat will further work 
with countries to attempt to harmonise these data year differences, using the EUROCARE15 data as one 
guide since EUROCARE countries have already attempted to agree on data years. For cancer screening, 
many countries have reported data simply according to national survey specifications. That is, if the 
question on the national survey and the national report for cancer screening is How often in the last year 
did you receive a screening for cervical cancer? then this was the data reported, despite the fact that this 
does not correspond to the indicator specification16.  
                                                     
15  The EUROCARE project (European cancer registries study on cancer patients survival and care) is an 
international collaborative study on the survival of cancer patients in Europe. It currently involves 67 population-
based cancer registries operating in 22 European countries. EUROCARE has been promoted by the European 
Community.  
 
16 The indicator specification for the numerator for breast cancer is Number of women 50-69 reporting of having 
received a bilateral mammography within the past year or number of women 50-69 screened through an organised 
program within the past year. The indicator specification for the numerator for cervical cancer screening is Number 
of women 20-69 reporting cervical cancer screening within the past 3 years or number of women aged 20-69 screened 
through an organised program within the past 3 years. 
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38. In October 2006, the HCQI Experts agreed that countries should try to harmonise these data over 
the next year so that the 2008 data collection would represent more comparable data. It was agreed, 
however, that the data should be presented as collected, with appropriate notes on differing recall and data 
years.  
39. The use of a truncated standard population for age adjustment Age standardisation is necessary 
since a countrys age structure, depending on the nature of the disease and the structure of the population, 
can influence the international comparison of health system performance. For example, if Country As 
population is notably older as a whole than Country Bs population, we would expect there to be higher 
rates of chronic diseases and thus the population, as a whole, may appear sicker. This may cause 
apparent differences in performance for diseases whose incidence and prognosis depends on the age at 
diagnosis. Such apparent differences are not within the control of the health system, and adjustments for 
them should be made when comparing performance levels on quality indicators across countries. The same 
holds true for longitudinal comparisons within one country if the countrys age structure changes 
significantly over time.  
40. To account for such differences in age structure, age adjustments are made based on standardised 
populations. The resulting age-adjusted rates reflect a countrys hypothetical performance on a standard 
population and should thus be viewed as relative indexes rather than actual measures. These adjustments 
can become extremely important when examining data over time and comparing performance across 
geographical areas. Many national reports on quality of care use some form of age adjustment to account 
for changes over time in the age structure of the population (CIHI, 2004). 
41. An analysis of the impact of age standardisation was undertaken as part of OECD Health 
Working Paper No. 22. The findings indicated that there appeared to be virtually no difference in 
countries relative rankings using either a 1980 or 2005 OECD standard population in calculating cancer 
survival rates. Secondly, there appeared to be only small differences in the ranking of countries between 
the use of a 1980 OECD standard population and the disease specific EUROCARE cancer population for 
relative survival rates. There was, however, some modest influence in the ranking of countries between the 
use of the 1980 OECD standard population and the EUROCARE cancer population in terms of observed 
survival. Relative survival rates are the ratio of the disease-specific mortality to overall mortality in a given 
population. The above findings, therefore, are not surprising as these relative survival rates control to some 
degree for differences in the age structure of the general population. Lastly, it appears that the use of a 
truncated version of the 1980 OECD standard population (at age 45+, thus shaping the age structure more 
closely to a disease specific population) provides estimates moderately different from those based on the 
EUROCARE cancer population, although the differences were more important for some types of cancers 
(cervical cancer) than for others. The recommendation at that point was to keep the 1980 OECD standard 
population as reference for standardisation in 2006 data collection and start exploring more specialised 
adjustment approaches for both relative and observed survival rates. 
42. Working Paper No. 22 introduced also a recommendation to consider the need to apply age 
standardisation to the calculation of case fatality rates. So far, the Secretariat has suggested to countries to 
provide age standardised data or specific age groups rates for the two case fatality rate indicators, however, 
it has not been set as a requisite to accept data in any of the data collections hitherto due to the inability of 
several countries to provide data with this level of disaggregation. However the potential impact of this 
lack of age standardisation is not minor. In a presentation to the HCQI Experts Group in October 2006, 
Dr. Max Köster, one of Swedens representatives in the Expert Group, presented findings from an analysis 
examining this issue for AMI and stroke survival rates. This analysis looked at Swedish data and compared 
different adjustments by age and discussed whether all ages should be included. He showed how 98% of 
the deaths for ischemic stroke occurred in age groups of 45+. However, in the 1980 OECD standard 
population that was used in the HCQI Initial Indicators Report, only 31% of the population is found in this 
age group. This means that variations in small numbers of deaths in the younger age groups can have a 
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major impact if the standard population for age adjustment differs sharply in structure from the age pattern 
of mortality. The analysis presented two different scenarios for the same data; in Scenario A none of the 8 
cases presented among the population 10-14 years old dies in the 30 days following diagnosis. In scenario 
B one of the cases ends fatally. The specific fatality rate for this group would actually rise from 0 to 12.5%, 
and due to the weight attached to this segment of population in 1980 OECD population the corresponding 
standardised rate will increase from 3.66% in scenario A to 4.70% in B. (Table 2). 
Table 3. 2004 Admission based ischemic stroke case fatality in Sweden 
 
Ages 
Number of 
admissions 
"True" 
weights 
Incidence 
distribution 
Accum 
true 
weight 
(%) 
Fatality 
rate 
scenario 
A17 
Fatality 
rate 
scenario 
B 18 
Weights 
1980 
Accum 
1980 
weight 
(%) 
Rates 
standardised 
to OECD 1980 
Scenario A 
TOTAL 35323 100,00% 9,18% 9,18% 100,00 
3.66% 
 0- 4 32 0,09% 12,50% 12,50% 7,94 Scenario B 
 5- 9 6 0,02% 0,00% 0,00% 8,09 4.70% 
10-14 8 0,02% 0,00% 12,50% 8,30 
15-19 13 0,04% 0,00% 0,00% 8,56 
20-24 36 0,10% 5,56% 5,56% 8,20 
25-29 53 0,15% 1,89% 1,89% 7,81 
30-34 73 0,21% 6,85% 6,85% 7,63 
35-39 155 0,44% 0,65% 0,65% 6,31 
40-44 256 0,72% 
1.81 
2,34% 2,34% 5,83 
68.67 
45-49 422 1,19% 2,37% 2,37% 5,56 
50-54 736 2,08% 2,45% 2,45% 5,46 
55-59 1612 4,56% 3,41% 3,41% 5,08 
60-64 2416 6,84% 2,90% 2,90% 3,89 
65-69 3045 8,62% 4,47% 4,47% 3,88 
70-74 4312 12,21% 6,52% 6,52% 3,18 
75-79 6292 17,81% 7,69% 7,69% 2,26 
80-84 7649 21,65% 10,52% 10,52% 1,23 
85- 8207 23,23% 
98.19 
16,61% 16,61% 0,77 
31.31 
 
 
 
The recommendation issued by the Expert Group is that, for the OECDs HCQI 2008 data collection, a 
new OECD standard population, truncated at ages below 45, should be developed, tested and disseminated 
to participating countries for age adjustment of survival and mortality rates. This will serve as a better 
approximation to a disease-specific population. The Secretariat has developed an updated standard OECD 
reference population for 2005, to account for the changes in age structure across OECD countries in the 
last decades. This population will serve as the basis for the proposed truncation exercise. 
                                                     
17 0 cases resulting in death in the group 10-14 
18 1 case resulting in death in the group 10-14 
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 INITIAL (2003-2005) INDICATORS: 2006 SPECIFICATIONS AND DATA RESULTS  
43. This section of the report presents data updated in 2006 for the 2003-2005 set of indicators. The 
indicators listed in this section are the initial HCQI indicators published in OECD Health Working Paper 
No. 22. They are listed in column 1 of Table 2 above. A full discussion of the scientific soundness and 
clinical importance of the indicators presented in this section is presented in OECD Health Working Paper 
No. 22 (http://www.oecd.org/dataoecd/1/34/36262514.pdf) and is not repeated here.  
44. As mentioned earlier, it is clear that while the indicators listed in this section have met the HCQI 
criteria for being scientifically sound, clinically important and having comparable data across countries, 
this does not mean that they are free of data comparability issues. This paper reports fully on the data 
comparability for all indicators. The OECD Secretariat will continue to work with countries to improve the 
comparability of the indicators listed in this section.  
45. The following table summarises the data availability for all the indicators presented in this 
section of the report.  
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Table 4. Availability of data for Initial (2003-2005) Indicators presented in this section 
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Australia                                   
Austria                                   
Belgium                                   
Canada                                   
Czech Republic                                   
Denmark                                   
Finland                                   
France                                   
Germany                                   
Greece                                   
Hungary                                   
Iceland                                   
Ireland                                   
Italy                                   
Japan                                   
Korea                                   
Mexico                                   
Netherlands                                   
New Zealand                                   
Norway                                   
Poland                                   
Portugal                                   
Slovak Republic                                   
Spain                                   
Sweden                                   
Switzerland                                   
Turkey                                   
United Kingdom                                   
United States                                   
 
Non-OECD EU countries 
Cyprus19                                   
Latvia                                   
Malta                                   
 (Blank/white cells indicate unavailability of data; grey cells available but not updated data for this paper and black cell indicate updated data)
                                                     
19 See footnotes 2 and 3 on page 3. 
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Breast cancer five-year survival rate 
Operational Definition 
A. 5-year observed survival rate (OSR), breast cancer (Diagnostic code: ICD-9 C:174.xx, ICD 10: C50.x) 
 Numerator: Number of women diagnosed with breast cancer surviving five years after 
diagnosis.  
 Denominator: Number of women diagnosed with breast cancer. 
B. 5-year relative survival rate (RSR), breast cancer (Diagnostic code: ICD-9 C:174.xx, ICD 10: C50.x) 
Numerator: Observed rate of women diagnosed with breast cancer surviving five years after 
diagnosis.  
Denominator: Expected survival rate of a comparable group from the general population. 
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Table 5. Breast cancer five-year survival rate 
Crude rates Age-standardised rates Crude rates
Age-standardised 
rates
Australia 1998-2002 80.8 (80.5-81.2) 86.6 (86.3-87.0) 2003 21.1
1992-1997 76.5 (76.2-76.8) 77.0 (74.6-78.8) 82.8 (82.4-83.1) 80.0 (77.8-81.8)
Canada 1998-2003 79.0 (78.0-79.0) 81.0 (80.0-83.0) 86.0 (86.0-87.0) 84.0 (82.0-85.0) 2002 23.7
1997-2002 78.0 (78.0-79.0) 79.0 (78.0-81.0) 86.0 (86.0-87.0) 82.0 (81.0-84.0)
Czech Republic 1994-1998 66.6 (65.9-67.2) 75.7 (74.9-76.4) 2004 25.5
Denmark 2001-2005 77.0 (75.0-78.0) 85.0 (84.0-87.0) 2001 32.8
Finland 1999-2003 80.0 (79.0-81.0) 88.4 (87.5-89.3) 2004 19.1
1995-2000 76.2 (74.5-77.8) 85.6 (83.7-87.4)
France 1990-1994 70.6 (n.a-n.a) 79.7 (n.a-n.a) 2003 23.5
1985-1989 73.0 (n.a-n.a) 81.0 (78.2-81.3)
Germany 1993-1997 69.0 (67.0-71.0) 78.0 (76.0-80.0) 2004 24.5
Iceland 1996-2000 80.8 (n.a-n.a) 89.4 (85.5-93.3) 2004 23.9
1995-1999 80.4 (n.a-n.a) 88.8 (85.3-92.4)
1993-1997 77.1 (n.a-n.a) 85.6 (85.3-92.4)
Ireland 1999-2004 72.6 (70.4-74.6) 79.7 (77.3-81.9) 2005 28.4
1998-2002 63.5 (62.5-64.6) 75.3 (73.5-77.1)
1994-1998 65.0 (64.0-66.0) 73.0 (71.0-74.0)
Italy 1995-1999 77.0 (76.0-77.0) 85.0 (84.0-85.0) 2002 22.6
1990-1994 74.0 (n.a-n.a) 81.0 (79.9-81.2)
Japan 1993-1996 83.1 (82.3-83.9) 2004 10.4
Korea 1998-2002 82.6 (82.1-83.1) 84.6 (84.0-85.1) 2004 5.6
Mexico 1997-2001 52.0 (n.a-n.a) 1995 11.8
1997-1998 47.0 (n.a-n.a)
Netherlands1 1996-2000 75.1 (74.2-76.2) 83.3 (82.2-84.4) 2004 27.7
1993-1997 74.0 (72.0-76.0) 82.0 (80.0-84.0)
New Zealand 1998-2003 75.9 (75.1-76.7) 78.7 (77.8-79.6) 83.5 (82.6-84.4) 81.2 (80.3-82.1) 2001 26.4
1994-1999 70.9 (69.8-72.0) 71.0 (68.8-73.2) 79.5 (78.2-80.8) 76.8 (75.2-78.4)
Norway 1998-2003 72.1 (71.3-72.9) 82.8 (81.9-83.7) 2004 20.1
1996-2001 73.9 (72.0-75.7) 86.6 (84.5-88.8)
1995-1999 73.2 (72.4-74.0) 83.6 (82.7-84.5)
Slovak Republic 1998-2002 72.0 (n.a-n.a) 2002 22.1
Sweden 1999-2004 77.8 (77.2-78.5) 87.0 (86.3-87.7) 2002 19.6
1996-2001 75.3 (74.1-76.4) 84.7 (83.4-86.0)
Switzerland 1990-1994 73.0 (n.a-n.a) 81.0 (n.a-n.a) 2004 23.0
United Kingdom 1998-2001 77.0 (76.2-77.8) 80.0 (79.9-80.8) 2004 26.0
1995-1999 75.0 (74.9-75.7) 82.0 (n.a-n.a) 78.9 (78.2-79.7)
United States 1998-2002 79.3 (78.7-79.9) 88.9 (88.3-89.5) 2002 22.0
1992-1996 83.0 (80.2-84.9) 86.0 (83.0-88.0)
Mortality per 
100 000 women
Breast cancer
5-year survival rates
Country Data year
OSR (95% CI) RSR (95% CI)
Data year Rate
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Crude rates Age-standardised rates Crude rates
Age-standardised 
rates
Latvia 1999-2003 59.5 (n.a-n.a) 66.6 (n.a-n.a) 2005 32.5
Malta 1998-2002 78.0 (73.0-82.0) 2005 28.1
1993-1994 74.8 (69.0-81.0)
Data year Rate
Non-OECD EU countries
Country Data year
OSR (95% CI) RSR (95% CI)
Mortality per 100 000 
women
 
Notes: 
Reference population for age-standardised rates: OECD 1980, except for France, Ireland, Italy and Malta who refer to the Eurocare-3 
population and the Slovak Republic to the Standard European population. 
CI stands for "Confidence Interval". Observed survival rates are an estimation of the probability of a patient having survived five years 
after being diagnosed of cancer based on the actual data available. Relative survival rates adjusts this probability of surviving a 
cancer diagnosis by the general probability of surviving attributable to any member of the same age group independently of whether 
they do suffer cancer Thus the 95% confidence interval (CI) illustrates the degree of variability associated with these estimates. Wide 
confidence intervals indicate high variability, therefore, these estimates should be interpreted with due caution. When estimates are 
based on a small number of cases, it is more likely that observed differences are due to random, rather than systematic influences. 
"n.a" stands for "no data available". 
1. Data is not national, but has been weighted by the incidence they represent upon the nation. See Sources and Methods for more 
information. 
Source: HCQI Project, 2007. Mortality data: OECD Health Data 2007, July 07
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Breast cancer five-year survival rate, sources and methods 
Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
Australia Australian Institute for Health and Welfare & 
National Breast Cancer Centre 2006. Breast 
Cancer in Australia: an overview, 2006. AIHW 
cat. no. CAN 29. Canberra: AIHW. 
  20+     1980 OECD 
population 
  
Canada Canadian Cancer Registry Canadian 
data coded 
using ICDO-
3 (not ICD 
9/10) 
15-99   Yes 1980 OECD 
population 
Missing cases treated as: we rely on 
record linkage for vital status (i.e. passive 
follow-up) and as such we cannot identify 
cases lost to follow-up. So we don't 
"handle" them in any way. Practically 
speaking there will be people who die 
outside of the country and whose death is 
not recorded in the national mortality 
database. 
Czech 
Republic 
National Cancer Registry of the Czech 
Republic; Vital Statistics (Czech Statistical 
Office) 
    1980-1998 Yes   Missing cases treated as: survivors 
Denmark National Cancer Registry ICD-10 C50   From 1977 Yes   Missing cases treated as: dropped out. 
The calculations are based on unique 
identifiers, why few people are lost to 
follow-up. The Update is based on the 
National Hospital Register for patients 
diagnosed in 2001 and reported in 2005. 
Finland Finnish Cancer Register ICD-10 C50   1953-2004 Yes   Missing cases treated as: No losses to 
follow-up 
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Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
France EUROCARE-3: Electronic availability of 
EUROCARE 3 data: a tool for further analysis P 
Roazzi, Annals of Oncology 14 150-155, 2003. 
National death causes database/Available 
Eurostat database. 
ICD-10 C50 15+   4 regional registries: 
Calvados, Côte dOr, 
Isère, Bas-Rhin 
representing 
3.199.575 persons, 
i.e. 5.6% of French 
population in 1990. 
Generalisable. 
  ICSS population 
Germany Saarland Cancer Registry ICD-9 174 15-89   State of Saarland. 
Not generalisable 
  Includes only: Saarland residents, 15 and 
89 yrs at diagnosis, with 
invasive/malignant cases, first primaries. 
Saarland residents at time of diagnosis, 
age at time of diagnosis between ages 
15-89. Date of diagnosis 1993-1997. 
Follow-up to December 2000. 
Iceland Icelandic Cancer Registry ICD-10 C50   1955-1995 Yes   Missing cases treated as: non-survivors 
Ireland NCRI. Irish National Cancer Registry ICD-10 C50 15-99     Eurocare 3 
standard 
patient 
populations 
Missing cases treated as: Follow up is 
passive, by means of matching registered 
cases to death certificates.  Currently 
matching completed to 31 December 
2003 (censoring date) and patients not 
matched by this date (known to have died 
by this date) are assumed to be alive 
Italy Registro Nazionale Tumori ICD-10 C50 14+   Yes   Missing cases treated as: dropped out 
Japan Tsukuma H, Ajiki W, Ioka A, Oshima A, and 
Research Group of Population-Based Cancer 
Registry of Japan, Survival of cancer patients 
diagnosed in 1993-96: collaborative study of 
population-based cancer registries in Japan, 
Japanese Journal of Clinical Oncology, 36: 602-
607, 2006 
ICD-9 174           
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Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
Korea Korea Central Cancer Registry Source of 
mortality data: Annual Report on the Cause of 
Death Statistics. Korea National Statistical 
Office, 2006. 
ICD-10 C50     Yes   Missing cases treated as: dropped out 1. 
The Korea Central Cancer Registry has 
been collaborating with the Korean Breast 
Cancer Societys breast cancer registry to 
produce national breast cancer statistics. 
2. Since our cancer incidence DB is under 
review of the International Agency for 
Research on Cancer (IARC), statistical 
figures may change after the completion 
of the review. 
Mexico Estadistica de Casos de Cancer de Mama: 
Servicio de Oncologia Mamaria Hospital de 
Ginecobstetricia No. 4 Luis Castelazo Ayala. 
Source of mortality data: Sistema Institucional 
de Mortalidad (SISMOR). 
ICD-10 C50     No. By size it's 
generalisable to 
national level. This 
Hospital covered 22% 
of total cases of 
breast cancer in the 
country 
  Missing cases treated as: non-survivors 
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Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
Netherlands National Institute of Public Health and the 
Environment. Source of Mortality: Statline. 
Voorbrug: Statistics Netherlands, 2006 Website 
http://statline.cbs.nl/StatWeb/Start.asp?lp=Sear
ch/Search&LA=EN&DM=SLEN. 
ICD-10 C50 All   No. In the 
Netherlands, the 
National Cancer 
Registry of the 
Association of 
Comprehensive 
Cancer Centres 
(CCC) delivers 
incidence rates. 
However, survival 
rates can not be 
calculated for the 
whole country. At this 
moment, three 
Comprehensive 
Cancer Centres have 
data on cancer 
survival. In a few 
years, all CCCs will 
deliver data on 
cancer survival. Data 
therefore cover over 
40% of Dutch 
population. Data have 
been weighted by the 
incidence of the CCC 
into the total 
incidence of the 
country. 
  Missing cases treated as: the CCCs 
obtain data of persons in the population 
who died. These data are obtained from 
the Municipal Basis Registry, which is to a 
large extent complete. Patients, of whom 
no death report is obtained, are still alive. 
Emigrants are censored. Overall, almost 
100% of follow-up is complete. 
New 
Zealand 
New Zealand Cancer Registry (NZCR). Source 
of mortality data: NZHIS Mortality data 
collection 
ICD-10-AM 
(Australian 
Modification
) C50 
  1994-2006 Yes OECD 
standard 
population 
1980 (only for 
relative rates) 
Missing cases treated as: passive follow-
up, no losses DCO (Death certificate 
only) cases were excluded 
Norway Cancer Registry of Norway ICD-10 C50         Missing cases treated as: dropped out 
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Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
Slovak 
Republic 
National cancer registry ICD-10 C50     Yes standard 
European 
population 
Missing cases treated as: returned to the 
reporting units for correction, therefore we 
do not have missing cases. 
Sweden The Swedish Cancer Register ICD-9 174   1960-1998 yes   Missing cases treated as: censored in a 
survival analyses (actuarial method) 
The age profile of the England and Wales 
cancer population differs from the OECD 
population. 
United 
Kingdom 
Office for National Statistics/Department of 
Health 
ICD-9 174 15-99   Data are for England OECD 1980 
For instance, 51% of the adult population 
is age 15-39, but only 6.1% of breast 
cancer cases are in this age group.  
United 
States 
Surveillance Epidemiology and End Results 
(SEER) Program (www.seer.cancer.gov) 
SEER*Stat Database: Incidence - SEER 9 
Regs Public-Use, Nov 2004 Sub (1973-2002), 
National Cancer Institute, DCCPS, Surveillance 
Research Program, Cancer Statistics Branch, 
released April 1, 2005, based on the November 
2004 submission 
        OECD 1980   
 
Non-OECD EU countries 
Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
Latvia Cancer Registry. Source of mortality data: 
National Death Causes Database. 
ICD-10 C50     Yes   Missing cases treated as: In the 
calculation from "missing cases" 1/2 
treated as survivors and other 1/2 as non-
survivors 
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Non-OECD EU countries 
Country Source Diagnosis 
Code 
Age 
groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population 
Comments 
Malta Malta National Cancer Registry: 
http://www.sahha.gov.mt/pages.aspx?page=91   
Source of mortality data: WHO-HFA: 
http://data.euro.who.int/hfadb/ 
          Mortality figures are age-standardised 
using European Standard Population 
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Mammography screening rate 
Operational Definition 
Numerator: Number of women ages 50-69 reporting having received a bilateral mammography 
within the past year.  
Denominator: Number of women ages 50-69 answering survey questions on mammography or 
eligible for organised screening programme. 
Table 6. Mammography screening rate 
2000 2001 2002 2003 2004 2005 2006
Australia 56.9 57.1 56.1 55.6 screening program
Belgium 38 50 50 56 56 screening program
Finland 88 87.7 screening program
Hungary1 26.7 28.9 48.3 60.2 55.1 screening program
Iceland2 61 62 62 62 61 61 screening program
Ireland3 78.4 79.5 77.1 76.6 screening program
Japan 1.2 1.7 2.1 2.6 4.1 screening program
Netherlands 78.7 78.8 78.8 80.4 81.7 81.9 screening program
New Zealand3 63 screening program
Norway 98 screening program
Portugal 60.1 screening program
Sweden5 83.6 screening program
United Kingdom3 69.3 70.2 69.8 69.3 69 69.5 screening program
Canada 69.5 70.6 70.4 survey
Czech Republic 26.6 survey
France 55 72.8 survey
Italy4 29 59 survey
Korea 33.6 survey
Mexico 22.1 63.5 survey
Poland 15.4 survey
Slovak Republic 6.9 9.1 11.4 12.4 14.8 17.1 Survey
Switzerland 27 survey
United States 62.2 60.8 survey
% women 50-69 screened 
Country Survey or screening
 
Country Year %
Malta2 2002 57.3
Survey or screening
survey
Non-OECD EU countries
 
 
Notes: 
1. 45-65 years. 
2. 40-69 years. 
3. 50-64 years. 
4. 55-69 years.  
5. 50-74 years. 
Source: HCQI Project, 2007 
Mammography screening rate, sources and methods 
http://www.ecosante.org/OCDEENG/370010.html 
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Cervical cancer five-year survival rate 
Operational Definition 
A. 5-year observed survival rate (OSR), cervical cancer (Diagnostic code: ICD-9 C:180.xx; ICD-10: 
C53.x) 
 
Numerator: Number of women diagnosed with cervical cancer surviving five years after diagnosis.  
Denominator: Number of women diagnosed with cervical cancer. 
 
B. 5-year relative survival rate (RSR), cervical cancer (Diagnostic code: ICD-9 C:180.xx; ICD-10: C53.x) 
 
Numerator: Observed rate of women diagnosed with cervical cancer surviving five years after 
diagnosis  
Denominator: Expected survival rate of a comparable group from the general population 
 
 DELSA/HEA/WD/HWP(2007)4 
 37
Table 7. Cervical cancer five-year survival rate 
Crude rates Age-standardised rates Crude rates
Age-standardised 
rates
Australia 1992-1997 72.8 (71.4-74.1) 75.7 (74.3-77.0) 74.6 (73.2-75.9) 77.6 (76.9-79.0) 2003 1.9
Canada 1998-2003 70.0 (67.0-73.0) 74.0 (71.0-77.0) 73.0 (70.0-76.0) 76.0 (73.0-78.0) 2002 1.8
1997-2002 68.0 (65.0-71.0) 72.0 (70.0-75.0) 70.0 (67.0-73.0) 74.0 (71.0-77.0)
Czech Republic 1994-1998 63.7 (62.4-65.0) 68.4 (67.0-69.8) 2004 5.4
Denmark 2001-2005 70.0 (66.0-75.0) 73.0 (68.0-77.0) 2001 3.8
Finland 1999-2003 63.8 (56.0-71.5) 70.7 (62.0-78.7) 2004 1.4
1995-2001 60.0 (55.0-65.0) 65.7 (60.8-70.7)
France 1990-1994 62.7 (n.a-n.a) 65.9 (n.a-n.a) 2003 1.8
1985-1989 59.0 (n.a-n.a) 64.0 (61.8-70.1)
Germany 1993-1997 62.0 (57.0-67.0) 66.0 (61.0-71.0) 2004 2.5
Iceland 1996-2000 74.1 (n.a-n.a) 76.4 (64.6-88.2) 2004 1.4
1995-1999 74.0 (n.a-n.a) 76.6 (66.0-87.3)
1993-1997 73.3 (n.a-n.a) 76.3 (65.7-86.9)
Ireland 1999-2004 68.0 (59.9-74.8) 70.4 (62.0-77.4) 2005 3.4
1998-2002 55.0 (50.9-59.1) 58.9 (54.0-63.9)
1994-1998 60.0 (55.0-63.0) 62.0 (58.0-66.0)
Italy 1995-1999 61.0 (60.0-63.0) 66.0 (64.0-68.0) 2002 0.8
1990-1994 59.0 (n.a-n.a) 64.0 (64.5-68.7)
Japan 1993-1996 70.5 (69.1-71.9) 2004 2.4
Korea 1998-2002 77.4 (76.7-78.0) 80.1 (79.4-80.7) 2004 4.5
Mexico 1997-2001 40.7 (n.a-n.a) 1995 17.7
1997-1998 30.1 (n.a-n.a)
Netherlands1 1996-2000 66.8 (62.6-70.8) 70.4 (65.9-74.6) 2004 1.8
1993-1997 <60 yrs: 75.0 (67.0-83.0)
>60 yrs: 46.0 (32.0-60.0)
<60 yrs: 76.0 (68.0-84.0)
>60 yrs: 55.0 (39.0-71.0)
New Zealand 1998-2003 71.8 (69.0-74.6) 75.7 (73.0-78.4) 75.6 (72.7-78.6) 79.9 (77.2-82.6) 2001 2.8
1994-1999 66.8 (63.5-70.1) 69.3 (62.9-75.7) 70.5 (67.1-74.0) 72.9 (70.1-75.8)
Norway 1998-2003 68.3 (66.1-70.5) 73.2 (70.9-75.5) 2004 2.5
1996-2001 62.3 (56.8-67.8) 67.9 (61.8-74.0)
1995-1999 67.9 (65.5-70.3) 72.7 (70.2-75.2)
Slovak Republic 1998-2002 75.0 (n.a-n.a) 2002 5.9
Sweden 1999-2004 65.2 (62.8-67.5) 70.7 (68.1-73.3) 2002 2.4
1996-2001 66.0 (61.6-70.5) 69.2 (64.5-73.9)
Switzerland 1990-1994 66.0 (n.a-n.a) 72.0 (n.a-n.a) 2004 1.6
United Kingdom 1998-2001 70.0 (n.a-n.a) 72.0 (n.a-n.a) 2004 2.5
1995-1999 68.0 (n.a-n.a) 67.0 (n.a-n.a) 62.9 (60.4-65.4)
United States 1998-2002 67.8 (65.6-69.9) 72.0 (69.8-74.1) 2002 2.2
1994-1998 73.6 (70.1-77.1) 75.4 (69.4-81.5)
Data year Rate
Mortality per 
100 000 women
Cervical cancer
5-year survival rates
Country Data year
OSR (95% CI) RSR (95% CI)
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Crude rates Age-standardised rates Crude rates
Age-standardised 
rates
Latvia 1999-2003 50.0 (n.a-n.a) 58.9 (n.a-n.a) 2005 8.4
Malta 1993-1994 64.0 (52.0-81.0) 2005 1.0
Data year Rate
Non-OECD EU countries
Country Data year
OSR (95% CI) RSR (95% CI)
Mortality per 100 000 
women
 
Notes: 
CI stands for "Confidence Interval". Observed survival rates are an estimation of the probability of a patient still alive five years after 
being diagnosed of cancer based on the actual data available. Relative survival rates adjusts this probability of surviving a cancer 
diagnosis by the general probability of surviving attributable to any member of the same age group independently of whether they do 
suffer cancer Thus the 95% confidence interval (CI) illustrates the degree of variability associated with these estimates. Wide 
confidence intervals indicate high variability, therefore, these estimates should be interpreted with due caution. When estimates are 
based on a small number of cases, it is more likely that observed differences are due to random, rather than systematic influences. 
Reference population for age-standardised rates: OECD 1980, except for France, Ireland, Italy and Malta who refer to the Eurocare-3 
population and the Slovak Republic to the Standard European population. 
n.a stands for "no data available. 
1. Data is not national, but has been weighted by the incidence they represent upon the nation. See Sources and Methods for more 
information. 
Source: HCQI Project, 2007. Mortality data: OECD Health Data 2007, July 07 
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Cervical cancer five-year survival rate, sources and methods 
Country Source Diagnosis Code Age 
groups 
included 
Additional 
years 
Is this a national registry? Reference 
population 
Comments 
Canada Canadian Cancer Registry Canadian data coded 
using ICDO-3 (not 
ICD 9/10) 
15-99   Yes 1980 OECD 
population 
Missing cases treated as: we rely on record 
linkage for vital status (i.e. passive follow-
up) and as such we cannot identify cases 
lost to follow-up. So we don't "handle" them 
in any way. Practically speaking there will 
be people who die outside of the country 
and whose death is not recorded in the 
national mortality database. 
Czech 
Republic 
National Cancer Registry 
of the Czech Republic; 
Vital Statistics (Czech 
Statistical Office) 
ICD-10 C53   1980-1998 Yes   Missing cases treated as: survivors 
Denmark National Cancer Registry ICD-10 C53   1977 Yes   Missing cases treated as: dropped out. The 
calculations are based on unique 
identifiers, why few people are lost to 
follow-up. 
Finland Finnish Cancer Register ICD-10 C53   1953-2004 Yes   Very few cases are behind each age group 
in "Age specific rate" - 0-6 cases except for 
25-39 years old (29 cases) Figures are 
therefore very coincidental. Missing cases 
treated as: no losses to follow-up 
France EUROCARE-3: Electronic 
availability of EUROCARE 
3 data: a tool for further 
analysis P Roazzi, Annals 
of Oncology 14 150-155, 
2003. National death 
causes database/Available 
Eurostat Database. 
ICD-10 C53 15+   3 regional registries : 
Calvados, Côte dOr, Bas-
Rhin, representing 2,162.000 
persons, i.e. 3,8 % of French 
population in 1990 
ICSS population French network of cancer registries survival 
data fro 1988 to 1997 follow-up to 2002 will 
be published soon 
Germany Saarland Cancer Registry ICD-9 180 15-89   State of Saarland. Not 
generalisable 
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Country Source Diagnosis Code Age 
groups 
included 
Additional 
years 
Is this a national registry? Reference 
population 
Comments 
Iceland Icelandic Cancer Registry ICD-10 C53   1955-1995 Yes   Missing cases treated as: non-survivors 
Ireland NCRI. Irish National 
Cancer Registry 
ICD-10 C53 15-99     Eurocare 3 
standard patient 
populations 
Missing cases treated as: follow up is 
passive, by means of matching registered 
cases to death certificates. Currently 
matching completed to 31 December 2003 
(censoring date) and patients not matched 
by this date (known to have died by this 
date) are assumed to be alive 
Italy Registro Nazionale Tumori ICD-10 C53 14+   Yes   Missing cases treated as: dropped out 
Japan Tsukuma H, Ajiki W, Ioka 
A, Oshima A, and 
Research Group of 
Population-Based Cancer 
Registry of Japan, Survival 
of cancer patients 
diagnosed in 1993-96: 
collaborative study of 
population-based cancer 
registries in Japan, 
Japanese Journal of 
Clinical Oncology, 36: 602-
607, 2006 
ICD-9 180         Includes both cervical and endometrial 
cancer 
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Country Source Diagnosis Code Age 
groups 
included 
Additional 
years 
Is this a national registry? Reference 
population 
Comments 
Korea Korea Central Cancer 
Registry Source of 
mortality data: Annual 
Report on the Cause of 
Death Statistics. Korea 
National Statistical Office, 
2006. 
ICD-10 C53     Yes   1. The Korea Central Cancer Registry has 
been collaborating with the Gynaecologic 
Oncology Committee of Korean Society of 
Obstetrics and Gynaecology to produce 
national cervical cancer statistics. 2. Since 
our cancer incidence DB is under review of 
the International Agency for Research on 
Cancer (IARC), statistical figures may 
change after the completion of the review. 
Missing cases treated as: dropped out 
Mexico SUAVE: Sistema Unico 
Automatizado de Vigilancia 
Epidemiologica IMSS. 
Source of mortality data: 
Sistema Nacional de 
Mortalidad IMSS 
(SISMOR). 
ICD-10 C53     Yes   We can not obtain rates by age group, 
because data are total cases not disclosed, 
we will obtain this information near the 
2006 close. Missing cases treated as: non-
survivors 
Netherlands National Institute of Public 
Health and the 
Environment. Source of 
Mortality data: Statline. 
Voorbrug: Statistics 
Netherlands, 2006 Website 
http://statline.cbs.nl/StatW
eb/Start.asp?lp=Search/Se
arch&LA=EN&DM=SLEN. 
ICD-10 C53 All   No. In the Netherlands, the 
National Cancer Registry of 
the Association of 
Comprehensive Cancer 
Centres (CCC) delivers 
incidence rates. However, 
survival rates can not be 
calculated for the whole 
country. At this moment, three 
Comprehensive Cancer 
Centres have data on cancer 
survival. In a few years, all 
CCCs will deliver data on 
cancer survival. Data 
therefore cover over 40% of 
Dutch population. Data have 
been weighted by the 
incidence of the CCC into the 
total incidence of the country. 
  Missing cases treated as: the CCCs obtain 
data of persons in the population who died. 
These data are obtained from the Municipal 
Basis Registry, which is to a large extent 
complete. Patients, of whom no death 
report is obtained, are still alive. Emigrants 
are censored. Overall, almost 100% of 
follow-up is complete. 
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Country Source Diagnosis Code Age 
groups 
included 
Additional 
years 
Is this a national registry? Reference 
population 
Comments 
New 
Zealand 
New Zealand Cancer 
Registry (NZCR). Source 
of mortality data: NZHIS 
Mortality data collection 
1998-2006 
ICD-10-AM 
(Australian 
Modification) C53 
  1994-2006 Yes OECD standard 
population 1980 
(only for relative 
rates) 
Missing cases treated as: passive follow-
up, no losses. DCO (Death certificate only) 
cases were excluded 
Norway Cancer Registry of Norway ICD-10 C53     Yes   Missing cases treated as: Dropped out 
Slovak 
Republic 
National cancer registry ICD-10 C53   Since 
1970 
Yes standard 
European 
population 
Diagnosed in 1998; survival 31.12.2002 
Missing cases treated as: returned to the 
reporting units for correction, therefore we 
do not have missing cases. 
Sweden The Swedish Cancer 
Register 
ICD-9 180   1961-2002 yes   Missing cases treated as: censored in a 
survival analyses (actuarial method) 
United 
Kingdom 
Office for National 
Statistics/Department of 
Health 
ICD-9 180 15-99   Data are for England OECD 1980   
United 
States 
Surveillance Epidemiology 
and End Results (SEER) 
Program 
(www.seer.cancer.gov) 
SEER*Stat 
      Generalisable to nation OECD 1980   
 
Non-OECD EU countries 
Country Source Diagnosis Code Age 
groups 
included 
Additional 
years 
Is this a national registry? Reference 
population 
Comments 
Latvia Cancer Registry. Source of 
mortality data: National 
Death Causes Database. 
ICD-10 C53     Yes   Missing cases treated as: In the calculation 
from "missing cases" 1/2 treated as 
survivors and other 1/2 as non-survivors. 
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Non-OECD EU countries 
Country Source Diagnosis Code Age 
groups 
included 
Additional 
years 
Is this a national registry? Reference 
population 
Comments 
Malta Eurocare-3: Survival of 
Cancer Patients in 
Eurocare: the EUROCARE-
3 Study, Annals of 
Oncology, Vol. 14, 2003, 
Supplement 5. Source of 
mortality data:  WHO-HFA: 
http://data.euro.who.int/hfad
b/  
          Mortality figures are age-standardised 
using European Standard Population 
 
DELSA/HEA/WD/HWP(2007)4 
 44
Cervical cancer screening rate 
Operational Definition 
Numerator: Number of women ages 20-69 reporting cervical cancer screening within the past 3 
years or number of women age 20-69 screened for cervical cancer through an organised programme. 
Denominator: Number of women ages 20-69 answering survey question or participating in an 
organised screening programme. 
Table 8.  Cervical cancer screening rate 
2000 2001 2002 2003 2004 2005 2006
Australia 61.1 61 60.6 60.5 2 screening program
Belgium1 59.5 63.2 61 61 63.1 3 screening program
Finland4 67.5 71.8 71.5 5 screening program
Germany5 55.9 5 screening program
Hungary6 28.4 27.3 27.3 27.5 28.1 3 screening program
Iceland 74 74 74 74 73 72 3 screening program
Ireland7 70.1 65.5 60.9 5 screening program
Mexico9 38.9 37.1 screening program
Netherlands10 66.9 67.1 66.4 68.8 68.9 69.6 5 screening program
New Zealand 73.1 72.7 72.2 72 3 screening program
Norway11 70.3 72.5 3 screening program
Sweden12 72 5 screening program
United Kingdom13 67.2 66.1 71.2 70.8 70.3 69.7 69.8 3.5 screening program
Canada2 72.7 74.1 72.8 3 survey
Czech Republic3 38.8 1 survey
Denmark 69.7 69.4 3 survey
France 54 74.9 2 survey
Italy8 45.1 36.7 3 survey
Japan 22.6 23.7 1 survey
Korea 40.6 2 survey
Poland 49 survey
United States 84.8 82.6 3 survey
% women 20-69 screened 
Country Recall period (years)
Survey or 
screening
Notes: 
1. 25-64 years. 
2. 18-69 years. 
3. 15+ years. 
4. 30-60 years. 
5. 20-45 years. 
6. 25-65 years. 
7. 20-60 years. 
8. 25-69 years. 
9. 25-64 years for 2002; 20-69 years for 2005. 
10. 18-64 for 2001-2004 data, 30-60 other years. 
11. 25-67 years. 
12. 23-60 years. 
13. 25-64 years. 
Source: OECD Health Data 2007, July 07 
 
Country Year % Recall period (years)
Screening 
Program
Malta 67.3 2002 3 survey
Non-OECD EU countries
 
Source: Health Interview Survey: http://www.sahha.gov.mt/pages.aspx?page=383 
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Cervical cancer screening rate, sources and method 
http://www.ecosante.org/OCDEENG/370020.html 
Colorectal cancer five-year survival rate  
Operational Definition 
A. 5-year observed survival rate (OSR), colorectal cancer (Diagnostic code: ICD-9 C:153.xx, 154.xx; ICD-
10: C18.xx, C19.xx, C20.xx) 
Numerator: Number of people diagnosed with colorectal cancer surviving five years after  diagnosis.  
Denominator: Number of people diagnosed with colorectal cancer. 
B. 5-year relative survival rate (RSR), colorectal cancer (Diagnostic code: ICD-9 C:153.xx, 154.xx; ICD-
10: C18.xx, C19.xx, C20.xx) 
Numerator: Observed rate of people diagnosed with colorectal cancer surviving five years after 
diagnosis. 
Denominator: Expected survival rate of a comparable group from the general population. 
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Table 9. Colorectal cancer five-year survival rate 
Crude rates Age-standardised rates Crude rates Age-standardised rates
Australia 1992-1997 56.0 (53.9-57.8) 59.0 (57.1-64.0) 58.5 (59.2-57.8) 62.0 (59.9-64.0) 2003 18.2
1998-2003 50.0 (49.0-51.0) 60.0 (57.0-63.0) 60.0 (59.0-60.0) 63.0 (60.0-65.0) 2002 18.4
1997-2002 50.0 (49.0-51.0) 59.0 (56.0-62.0) 60.0 (59.0-61.0) 62.0 (59.0-65.0)
Czech Republic 1994-1998 32.1 (31.4-32.9) 41.2 (40.3-42.2) 2004 33.9
Denmark 2001-2005 colon: 41.0 (39.0-44.0)rectum: 44.0 (40.0-47.0)
colon: 51.0 (48.0-54.0)
rectum: 54.0 (50.0-57.0) 2001 27.3
1999-2003 47.0 (46.0-49.0) 59.2 (57.7-60.7) 2004 12.6
1995-2000 43.1 (40.7-45.5) 56.3 (53.3-59.4)
1990-1994
men: 45.5 (n.a-n.a)
women: 54.1 (n.a-n.a)
men: 55.8 (53.4-58.2)
women: 61.7 (59.3-64.1) 2003 17.8
1985-1989 41. 0(n.a-n.a) 53.0 (n.a-n.a)
Germany 1993-1997 men: 43.0 (41.0-45.0)women: 45.0 (42.0-47.0)
men: 55.0 (52.0-58.0)
women: 56.0 (53.0-59.0) 2004 20.5
1996-2000
men: 47.8 (n.a-n.a)
women: 43.6 (n.a-n.a)
men: 60.2 (51.5-68.9)
women: 52.9 (43.5-62.3) 2004 13.8
1995-1999
men: 46.5 (n.a-n.a)
women: 42.7 (n.a-na.)
men: 58.9 (51.0-66.8)
women: 52.5 (44.0-61.0)
1993-1997
men: 40.1 (n.a-n.a)
women: 43.6 (n.a-n.a)
men: 51.1 (42.7-59.6)
women: 53.5 (44.7-62.4)
1999-2004
men: 41.5 (38.4-44.6)
women: 39.5 (36.0-43.1)
men: 52.2 (48.3-56.1)
women: 47.8 (43.5-52.1) 2005 21.0
1998-2002
men: 34.1 (32.3-35.8)
women: 41.1 (39.1-43.0)
men: 47.3 (44.5-50.0)
women: 51.2 (48.6-44.5)
1994-1998 41.0 (n.a-n.a) 62.0 (58.0-66.0)
1995-1999 46.0 (46.0-47.0) 57.0 (57.0-58.0) 2002 17.7
1990-1994 42.0 (n.a-n.a) 52.0 (n.a-n.a)
Japan 1993-1996
all: 67.5 (67.2-67.8)
men: 69.5 (69.1-69.9)
women: 64.6 (64.2-65.0) 2004 18.0
Korea 1998-2002 53.7 (53.2-54.2) 60.2 (59.6-60.7) 2004 15.2
Mexico 1997-1998 47.5 (n.a-n.a) 1995 4.9
1996-2000
all: 45.6 (42.5-48.6)
men: 44.1 (41.2-47.1)
women: 47.1 (43.9-50.1)
all: 56.7 (52.8-60.6)
men: 56.4 (52.4-60.2)
women: 57.1 (53.2-60.9) 2004 20.3
1993-1997
colon: 48.0 (46.0-50.0)
rectal: 46.0 (42.0-50.0)
colon: 60.0 (56.0-64.0)
rectal: 56.0 (52.0-60.0)
1998-2003
all: 49.2 (48.4-50.1)
men: 47.5 (46.3-48.8)
women: 51.0 (49.8-52.3)
58.5 (57.4-59.6)
all: 60.4 (59.3-61.5)
men: 59.0 (57.4-60.5)
women: 61.8 (60.3-63.4)
all: 61.2 (60.1-62.3)
men: 63.3 (61.7-64.9)
women: 59.7 (58.1-61.3) 2001 27.2
1994-1999 47.6 (46.5-48.6) 52.8 (51.1-54.6) 58.9 (57.6-60.2) 60.8 (58.0-63.6)
1998-2003 43.1 (42.3-43.9) 56.6 (55.6-57.7) 2004 23.1
1996-2001 44.0 (42.1-45.8) 59.8 (57.3-62.3)
1995-1999 43.8 (43.0-44.6) 57.3 (56.2-58.3)
Slovak Republic 1998-2002
men: 51.0 (n.a-n.a) 
women: 54.0 (n.a-na.) 2002 31.0
1999-2004 46.4 (45.6-47.2) 58.4 (57.4-59.4) 2002 17.2
1996-2001 45.9 (44.4-47.4) 58.3 (56.5-60.2)
Switzerland 1990-1994
men: 48.0 (n.a-n.a)
women: 51.0 (n.a-n.a)
men: 59.0 (n.a-n.a)
women: 62.0 (n.a-n.a) 2004 14.2
1998-2001 55.0 (54.9-55.1) 57.0 (56.9-57.1) 2004 17.9
1995-1999 53.0 (52.9-53.0) 49.0 (n.a-n.a) 48.5 (47.3-49.6)
1998-2002
all: 50.9 (50.1-51.6)
men: 51.0 (49.8-52.1)
women: 50.7 (49.7-51.7)
all: 64.4 (63.4-65.3)
men: 65.2 (63.8-66.6)
women: 63.7 (62.3-65.1) 2002 16.3
1994-1998 54.0 (n.a-n.a) 58.0 (n.a-n.a)
RateCountry
Finland
France
Colorectal cancer
5-year survival rates
Mortality per 
100 000 women
Data year
OSR (95% CI)
Data year
Canada
RSR (95% CI)
Iceland
Ireland
Sweden
United Kingdom2
United States
Italy
Netherlands1
New Zealand
Norway
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Crude rates Age-standardised rates Crude rates Age-standardised rates
Latvia 1999-2003 28.9 (n.a-n.a) 36.2 (n.a-n.a) 2005 30.1
Malta 1998-2002 men: 54.0 (45.0-62.0)
women: 49.0 (41.0-57.0)
2005
men: 23.8
women: 
15.6
1993-1994
men: 39.0 (28.0-53.0)
women: 54.0 (43.0-68.0)
Mortality per 100 000 
womenNon-OECD EU countries
Country Data year
OSR (95% CI) RSR (95% CI)
Data year Rate
 
Notes: 
CI stands for "Confidence Interval". Observed survival rates are an estimation of the probability of a patient to be alive five years after 
being diagnosed of cancer based on the actual data available. Relative survival rates adjusts this probability of surviving a cancer 
diagnosis by the general probability of surviving attributable to any member of the same age group independently of whether they do 
suffer cancer Thus the 95% confidence interval (CI) illustrates the degree of variability associated with these estimates. Wide 
confidence intervals indicate high variability, therefore, these estimates should be interpreted with due caution. When estimates are 
based on a small number of cases, it is more likely that observed differences are due to random, rather than systematic influences. 
n.a stands for "no data available". 
Reference population for age-standardised rates: OECD 1980, except for France, Ireland, Italy and Malta who refer to the Eurocare-3 
population and the Slovak Republic to the Standard European population. 
1. Data are not national, but have been weighted by the incidence they represent. See Sources and Methods for more information. 
2. Data refer to colon cancer. 
Source: HCQI Indicators, 2007. Mortality data: OECD Health Data 2007, July 07 
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Colorectal cancer five-year survival rate, sources and methods 
Country Source Diagnosis Code 
Age groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population Comments 
Canada Canadian Cancer Registry Canadian 
data coded 
using ICDO-3 
(not ICD 
9/10) 
15-99  Yes 1980 OECD 
population 
Missing cases treated as: we rely on record 
linkage for vital status (i.e. passive follow-up) 
and as such we cannot identify cases lost to 
follow-up. So we don't "handle" them in any 
way. Practically speaking there will be people 
who die outside of the country and whose 
death is not recorded in the national mortality 
database. 
Czech 
Republic 
National Cancer Registry of the Czech 
Republic; Vital Statistics (Czech Statistical 
Office) 
ICD-10 C18, 
C19, C20. 
 1980-1998 Yes  Data relates to men only, values for women 
are also available. Also available separately 
data for colon and rectum cancer. 
 
 
Missing cases treated as: survivors 
Denmark National Cancer Registry ICD-10 C18, 
C19, C20 
 1981-1995   Missing cases are dropped out. 
Finland Finnish Cancer Register ICD-10 C18, 
C19, C20. 
 1953-2004 Yes  Missing cases treated as: no losses to follow-
up 
 
France EUROCARE-3: Electronic availability of 
EUROCARE 3 data: a tool for further 
analysis (P Roazzi Annals of Oncology 14 
150-155, 2003.) 
National death causes database/Available 
Eurostat Databse 
 
ICD-10 C18. 15+  Population: 3 regional 
registries: Calvados, 
Côte dOr, Bas-Rhin, 
representing 2,162.000 
persons, i.e. 3.8% of 
French population in 
1990. Generalisable to 
nation. 
ICSS 
population 
French network of cancer registries survival 
data fro 1988 to 1997 follow-up to 2002 will be 
published soon 
Germany Saarland Cancer Registry ICD-9 153, 
154 
15-89  Population: Data refer 
to the region of 
Saarland, thus it is not 
representative for all 
Germany 
 
 Date of diagnosis in the years 19931997, 
Follow-up for deaths was to December 31, 
2000. 
 
Iceland Icelandic Cancer Registry ICD-10 C18, 
C19, C20 
 1955-1995 Yes  Missing cases treated as: non-survivors 
Ireland NCRI. Irish National Cancer Registry 
 
ICD-10 C18, 
C19, C20 
15-99   Eurocare 3 
standard 
Missing cases treated as: follow up is passive, 
by means of matching registered cases to 
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Country Source Diagnosis Code 
Age groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population Comments 
patient 
populations 
death certificates. Currently matching 
completed to 31 December 2003 (censoring 
date) and patients not matched by this date 
(known to have died by this date) are 
assumed to be alive 
Italy Registro Nazionale Tumori 
 
ICD-10 C18, 
C19, C20. 
14+  Yes  Missing cases treated as: dropped out 
Japan Tsukuma H, Ajiki W, Ioka A, Oshima A, 
and Research Group of Population-Based 
Cancer Registry of Japan, Survival of 
cancer patients diagnosed in 1993-96: 
collaborative study of population-based 
cancer registries in Japan, Japanese 
Journal of Clinical Oncology, 36: 602-607, 
2006 
ICD-9 
153,154 
     
Korea 
 
Korea Central Cancer Registry 
 
Source of mortality data: Annual Report on 
the Cause of Death Statistics. Korea 
National Statistical Office, 2006. 
ICD-10 C18, 
C19, C20. 
 
  Yes  Since our cancer incidence DB is under review 
of the International Agency for Research on 
Cancer (IARC), statistical figures may change 
after the completion of the review. 
 
Missing cases treated as: dropped out  
Netherlands 
 
National Institute of Public Health and the 
Environment. 
 
Source of Mortality data: Statline. 
Voorbrug: Statistics Netherlands, 2006 
Website 
http://statline.cbs.nl/StatWeb/Start.asp?lp=
Search/Search&LA=EN&DM=SLEN. 
 
. 
ICD-10 C18-
20. 
 
All  No. In the Netherlands, 
the National Cancer 
Registry of the 
Association of 
Comprehensive Cancer 
Centres (CCC) delivers 
incidence rates. 
However, survival rates 
can not be calculated 
for the whole country. 
At this moment, three 
Comprehensive Cancer 
Centres have data on 
cancer survival. In a 
few years, all CCCs 
will deliver data on 
cancer survival. Data 
therefore cover over 
 Missing cases treated as: the CCCs obtain 
data of persons in the population who died. 
These data are obtained from the Municipal 
Basis Registry, which is to a large extent 
complete. Patients, of whom no death report is 
obtained, are still alive. Emigrants are 
censored. Overall, almost 100% of follow-up is 
complete. 
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Country Source Diagnosis Code 
Age groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population Comments 
40% of Dutch 
population. Data have 
been weighted by the 
incidence of the CCC 
into the total incidence 
of the country. 
 
New 
Zealand 
 
New Zealand Cancer Registry (NZCR). 
 
Source of mortality data: NZHIS Mortality 
data collection 1998-2006 
 
 
ICD-10-AM 
(Australian 
Modification) 
C18-C20 
(excluding 
anus and 
anal canal). 
 1994-2006 Yes OECD 
standard 
population 
1980 (only for 
relative rates) 
DCO (Death certificate only) cases were 
excluded 
 
Missing cases treated as: passive follow-up, 
no losses 
Norway 
 
Cancer Registry of Norway
 
 
ICD-10 C18, 
C19, C20. 
 
  Yes  Missing cases treated as: dropped out 
Slovak 
Republic 
 
National cancer registry ICD-10 C18, 
C19, C20. 
 
 Since 1970 Yes standard 
European 
population 
Missing cases treated as: returned to the 
reporting units for correction, therefore we do 
not have missing cases. 
 
Sweden 
 
The Swedish Cancer Register ICD-9 153, 
154 
 1961-2002 Yes  Missing cases treated as: censored in a 
survival analyses (actuarial method) 
United 
Kingdom 
 
Office for National Statistics/Department of 
Health 
ICD-9 153, 
154 
15-99  Population: Data for 
England.  The age 
profile of the England & 
Wales cancer 
population is nothing 
like the OECD 
population. For 
instance, 51% of the 
adult OECD population 
is age 15-39, but only 
1.3% of colorectal 
cancer cases are in this 
age group. 
OECD 1980  
United 
States 
 
Surveillance Epidemiology and End 
Results (SEER) Program 
(www.seer.cancer.gov) SEER*Stat  
 
   Generalisable to nation OECD 1980  
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Country Source Diagnosis Code 
Age groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population Comments 
 
 
 
Non-OECD EU countries 
Country Source Diagnosis Code 
Age groups 
included 
Additional 
years 
Is this a national 
registry? 
Reference 
population Comments 
Latvia 
 
Cancer Registry 
 
Source of mortality data: National Death 
Causes Database. 
 
ICD-10 C18, 
C19, C20. 
  Yes  Missing cases treated as: In the calculation 
from "missing cases" 1/2 treated as survivors 
and other 1/2 as non-survivors. 
 
Malta 
 
Malta National Cancer Registry: 
http://www.sahha.gov.mt/pages.aspx?pag
e=91 
Mortality Source: Malta National Cancer 
Registry: 
http://www.sahha.gov.mt/pages.aspx?pag
e=91 
 
     Mortality figures are age-standardised using 
European Standard Population 
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Incidence of vaccine preventable diseases (Pertussis, measles, hepatitis B) 
Operational Definition 
Numerator: Number of reported cases. 
Denominator: Total 100 000 population. 
Table 10. Incidence of vaccine preventable diseases (Pertussis, measles, hepatitis B) 
Country Data year Hepatitis B Measles Pertussis
Australia 2006 1.80 0.70 65.80
2005 1.10 0.00 51.80
2004 1.40 0.20 42.50
2003 1.70 0.50 25.70
2002 2.10 0.20 28.30
2001 2.10 0.70 48.00
2000 2.10 0.60 31.30
Austria 2005 7.00 0.10 1.60
2000 3.30 0.00 1.40
Canada 2004 2.70 0.03 8.79
1999 4.20 0.10 20.00
Czech Republic 2005 3.50 0.00 5.40
Denmark 2005 0.50 0.04 2.40
2004 0.80 0.00 4.22
Finland 2005 0.63 0.02 10.54
2001 2.40 0.02 6.10
France 2003 <1 7.00 NA
2001 5.00 12.00 NA
Germany 2004 1.50 0.15 NA
2001 2.90 7.30 NA
Iceland1 2005 NA 0.00 2.00
2004 NA 0.00 0.30
2002 NA 0.00 4.00
Ireland 2005 2.29 NA NA
Italy 2004 2.02 1.18 2.31
2003 2.24 20.90 2.23
2002 2.35 31.15 4.45
Japan 2005 NA 4.7 8.7
2004 NA 9.45 10.23
2003 NA 60.90 11.00
2000 NA 27.00 1.41
Mexico 2005 0.59 0.01 0.33
2004 0.65 0.06 0.13
2001 NA 0.00 0.20
Netherlands 2005 1.83 0.02 40.04
2004 1.80 0.07 55.95
2003 2.03 0.02 16.65
2002 1.70 0.02 36.39
2001 1.30 0.11 43.54
2000 NA 6.40 30.36
1999 NA 14.98 39.71
1998 NA 0.06 14.34
1997 NA 0.13 25.28  
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Country Data year Hepatitis B Measles Pertussis
New Zealand 2005 1.60 0.50 72.80
2000 2.10 1.80 NA
Norway2 2005 3.10 0.00 120.00
2004 4.10 0.20 170.00
2001 4.50 0.10 57.30
Poland 2005 1.70 0.03 5.04
Portugal 2005 0.92 0.07 0.74
2003 1.13 0.07 0.03
2001 2.03 0.26 0.01
Slovak Republic 2005 1.90 0.00 0.30
2004 2.06 0.04 NA
Spain 2004 1.93 0.07 1.34
2001 2.24 0.37 2.32
Sweden 2005 2.40 0.10 15.10
2004 2.90 0.10 17.50
2002 19.40 0.10 15.10
Switzerland3 2005 2.00 2.00 56.00
2001 2.10 10.00 80.00
United Kingdom 2004 2.29 4.44 0.95
2003 2.18 4.71 0.77
United States 2004 2.10 0.00 8.90
2003 2.61 0.02 4.04
2000 6.30 0.00 2.70
cont.
 
 
Country Data year Hepatitis B Measles Pertussis
Cyprus4 2005 0.80 0.10 0.80
Latvia 2005 7.40 0.09 1.10
Malta 2005 3.22 1.49 1.75
Non-OECD EU countries
 
 
Notes: 
NA stands for "no data available". 
1. 2 confirmed cases for Pertussis. 
2. Pertussis' figure for 2006 is 142 per 100 000. 
3. Hepatitis B for 2001 refers to 2002. 
4. See footnotes 2 and 3 on page 3. 
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Incidence of vaccine preventable diseases (Pertussis, measles, hepatitis B), sources and methods  
Country Source Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated? 
Comments 
Australia National Notifiable Diseases Surveillance 
System, www.health.gov.au/cda, viewed 8 
December 2006 
     
Austria Federal Ministry of Health and Women 
 
    No differentiation of Hepatitis B (acute), 
preliminary data. 
Canada Public Health Agency of Canada 
 
 
 
Confirmed 
cases only 
The National Advisory 
Committee has a national 
guideline for Measles and 
Pertussis. HBV vaccine is 
now given routinely in most 
provinces and territories to 
young adolescents or to 
both infants and young 
adolescents. Hepatitis B 
vaccine is also 
recommended for certain 
groups at higher risk of 
infection with HBV. 
   
Cyprus∗ Medical and Public Health Services, 
Ministry of Health 
 
  Since 1980   
Czech 
Republic 
National Institute of Public Health 
 
 Hepatitis is not part of the 
general vaccination 
programme. 
Hepatitis B 
since 1980 
 Preliminary results. Pertussis (A37-ICD-
10); Measles (B05-ICD-10); Hepatitis B 
(B16-ICD-10). 
Denmark Statens Serum Institut Suspected and 
confirmed cases 
 Acute hep. B 
from 1985, 
measles from 
1994 and 
Pertussis 
since 1980 
 Pertussis is only reportable by law if the 
person in-question is under 2 years old. 
Hepatitis is not part of the general 
vaccination programme 
Finland National Infection Register at the National 
Institute of Public Health 
In Finland the 
national 
    
                                                     
∗ See footnotes 2 and 3 on page 3. 
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Country Source Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated? 
Comments 
 infection register 
registers 
confirmed cases 
only, suspected 
cases are not 
registered. 
France Réseau sentinelle for measles. disease 
surveillance national institut (in VS) for 
hepatitis B 
 
   Yes for 
hepatitis, No 
for others. For 
measles is 
mandatory 
since 2005. 
 
Hepatitis B: 158 cases notified in the 
whole country from 1/03/2003 to 
1/03/2004. No incidence data for 
Pertussis; RENACOQ, which is a 
hospitals network created in 1996, 
including 44 hospitals with paediatrics 
units, monitors Pertussis cases. Its goal 
is to describe epidemiological 
characteristics of children Pertussis, from 
a hospital point of view, and not to 
calculate an incidence rate. Réseau 
sentinelle is a General practitioners 
network, on voluntary basis, which 
collects and analyses epidemiological 
data on GP activity. GPs are included on 
a voluntary basis. Data concern 
transmissible diseases that are frequent 
in general practice: Influenza, acute 
diarrhoea, measles, mumps, varicella, 
hepatitis A, B, C. But now, as cases have 
became rarer and rarer, exhaustive 
cases notification is required for hepatitis 
B (since march 2003) and measles 
(2005). Incidence of measles and 
hepatitis B decreases as vaccination rate 
increases. However, hepatitis B 
vaccination rate does not increase as 
much as measles rate. 
Germany Robert Koch Institute 
 
   Yes for 
measles and 
Hep B. No for 
Pertussis. 
Mandatory reporting is regulated on a 
federal state but not on a national level, 
hence data representative on a national 
level cannot be provided. 
Iceland Directorate of Health      
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Country Source Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated? 
Comments 
Ireland HSE Health Protection Surveillance 
Centre 
 
 
The results are 
based on 
suspected 
cases. 
   Notified cases: Pertussis: 90, 
measles:327, hep B: 701.for Hep B, see 
paper submission 
Italy Ministry of Health 
 
The results are 
based on 
suspected and 
confirmed 
cases. 
 
 2002-2003. Yes Missing cases treated as: Dropped out 
Japan Calculated from Taniguchi K. Evaluation 
and Improvement for effective infectious 
disease surveillance system. Health, 
Labour & Welfare research grant report 
2006. P65 and P68. 
     
Mexico 
 
Ministry of Health (Secretaría de Salud), 
Mexico, SUIVE: Sistema Único de 
Vigilancia Epidemiológica, Indicator 
coverage: total population, national level. 
     
Netherlands 
 
National Institute for Public Health and the 
Environment, Centre for Infectious 
Disease Epidemiology, 2006. Website: 
http://www.rivm.nl/isis/ggd/openbaar/tot/tb
_lj.html. 
 
. 
The results are 
based on 
confirmed 
cases. 
   Pertussis: every period of 2 to 3 years an 
epidemiologic increase occurs. Country-
wide immunisation for children against 
was introduced in 1952. Measles: every 
period of 5 to 7 years an epidemiologic 
increase occurs. Country-wide 
immunisation for children against 
measles was introduced in 1976. 
Hepatitis B: In 2003 1,877 cases of 
hepatitis B were reported (afterwards 
corrected to 1,900) of which 319 acute 
and 1,445 chronic cases (Koedijk et al., 
2005). Of 113 cases the type of hepatitis 
B infection was unknown. In 2002 the 
number reported cases of acute hepatitis 
B was 265. In November 2002 
vaccination for groups with high risk 
behaviour was introduced. The Municipal 
Public Health Services performs the 
tracing of these groups: homo- and 
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Country Source Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated? 
Comments 
bisexual men, prostitutes, heterosexual 
persons with a health care consult 
related to a sexual transmitting disease, 
and drug users. Since 2000 employers in 
health care have the obligation to give 
their health care workers (including 
students) the opportunity to have a 
vaccination. In January 2003, hepatitis B 
vaccination was added to the National 
Immunisation Programme (NIP) for 
children born to parents from middle or 
high endemic countries (birth cohort 1st 
January 2003 onwards). Vaccination 
against hepatitis B for children born to 
mothers tested positive for HBsAg was 
introduced in 1989. In January 2006 
vaccination at birth was added to the NIP 
for these children. 
New 
Zealand 
 
Numerator: ESR Annual Surveillance 
Report 2005. Denominator: Statistics New 
Zealand, usually resident population from 
the 2001 Census. 
 
    Figures are based on Notifications 2000 
(some laboratory confirmed for Measles). 
Hepatitis B was the only vaccine 
preventable disease to show a significant 
increase in notification rate compared 
with 2004 (1.0 per 100 000). Measles: 
one outbreak in 19 cases. Pertussis: 
during the latter part of 2004 and the first 
three months of 2005 New Zealand 
experienced an epidemic of Pertussis. By 
comparison, the annual rate was 15.7 
per 100 000. 
Norway 
 
MSIS: The Norwegian System for 
Notification of Infectious Diseases 
 
 
The results are 
based on 
confirmed 
cases. 
    
Poland National Institute of Hygiene, Department 
of Epidemiology 
 
According to EU 
definitions the 
reported cases 
are suspected 
and/or probable 
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Country Source Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated? 
Comments 
and/or 
confirmed for 
Pertussis and 
Measles, 
probable and/or 
confirmed for 
Hepatitis B. 
Portugal DGS      
Slovak 
Republic 
Public Health Office      
Spain Ministry of Health and Consumer Affairs 
(Ministerio de Sanidad y 
Consumo.Instituto de Salud Carlos IIII) 
 
  Pertussis 
since 1983, 
Measles 
suspected 
cases since 
1994, and 
registered 
cases since 
2002, acute 
Hepatitis B 
since 1995. 
  
Sweden 
 
Swedish Institute for Infectious Disease 
Control. 
     
Switzerland Notifications/sentinel surveillance      
United 
Kingdom 
 
Health Protection Agency 
 
   Yes Measles in UK is not always lab 
confirmed, notifications are reported on 
clinical suspicion, if lab test shows it is 
not measles then it is supposed to be 
denotified, but this often doesnt happen, 
so measles incidence is likely to be an 
overestimate. 
United 
States 
 
CDC's Notifiable Disease Surveillance 
System. 
 
    As of March 2004, all 50 states allow 
vaccination exemptions for medical 
reasons; 48 states allow exemptions for 
religious reasons; and 20 states allow 
exemptions for philosophical reasons. 
Please comment on potential effects of 
national/regional vaccination policies on 
this indicator, if applicable: it is the 
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Country Source Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated? 
Comments 
responsibility of individual states to 
determine which vaccines are required 
by law. Currently all 50 states have 
school immunisation laws, although there 
are differences in what may be required 
in different states. 
 
 
Non-OECD EU countries 
 
Country Source 
Confirmed or 
suspected 
cases? 
National/regional 
variation of 
vaccination policies: 
Additional 
years 
available: 
Reporting 
Mandated?: Comments 
Latvia 
 
Public Health State Agency 
 
 
 
The results are 
based on 
suspected and 
confirmed 
cases. 
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Coverage for basic vaccination programme, age 2, (Pertussis, measles, hepatitis B) 
Operational Definition 
Numerator: Number of children who are fully immunised at age 2 for basic vaccination programme. 
Denominator: Number of children age 2 years. 
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Table 11. Coverage for basic vaccination programme, age 2, (Pertussis, measles, hepatitis B) 
Country Data year Overall % Hepatitis B % Measles (MMR) %
Pertussis (DPT) 
%
Australia 2006 92.2 95.8 93.9 95.1
2005 92.1 95.9 93.8 95.2
2004 91.7 NA 93.6 95.0
Austria 2004 NA 86.0 57.0 87.0
Canada 2004 NA NA 94.0 74.0
2002 NA NA 94.5 75.2
Czech Republic 2005 NA 98.5 96.6 98.7
Denmark 2005 NA NA 95.5 95.6
2001 NA NA 96.0 95.0
Finland1 2005 NA NA 97.0 97.0
2002 93.3 NA 96.6 95.6
France 2004 NA 30.0 87.1 90.3
2001 NA 28.0 84.6 87.9
Germany 1999 NA 73.0 73.0 89.0
Iceland 2005 NA NA 94.0 97.0
2004 NA NA 94.0 NA
2003 NA NA 93.0 97.0
1999 NA NA 92.0 98.0
Ireland 2004 90.0 NA 83.0 91.0
Italy 2005 NA 95.7 87.3 96.2
2004 NA 96.3 85.7 94.0
2003 NA 95.3 83.9 95.8
2002 NA 95.7 81.1 94.2
Japan 2005 NA NA 95.6 97.7
2004 63.9 NA 85.8 82.7
2003 NA NA 88.8 85.0
2001 NA NA 80.9 83.3
Mexico 2005 99.3 99.4 98.5 99.4
2004 NA 99.5 98.6 99.5
Netherlands2 2005 NA NA 96.3 97.8
2001 NA NA 95.6 95.3
New Zealand 2005 77.4 86.5 82.0 88.6
Norway 2005 89.0 NA 89.0 91.0
2004 NA NA 88.0 91.0
2001 NA NA 90.0 91.0
Poland 2005 NA 99.8 98.2 98.8
Portugal 2004 NA 96.0 94.8 97.8
2003 NA 96.6 95.6 96.8
2001 NA 94.7 87.7 98.1
Slovak Republic 2005 NA 99.2 98.4 98.7 - 99.2
2004 98.0 NA NA NA
Spain3 2005 NA 96.1 96.8 96.2
2004 NA 98.2 97.3 97.0
2001 NA NA 97.3 96.0
Sweden 2005 95.6 2.6 95.4 98.7
2004 NA NA 94.5 98.4
2002 NA NA 88.4 98.8
Switzerland 2005 73.0 NA 86.0 96.0
2000-2002 76.0 NA NA NA
United Kingdom 2004-2005 NA NA 81 94
2003-2004 NA NA 80.0 93.0
United States 2004 80.9 92.4 93.0 85.5
2003 79.4 92.4 93.0 96.0
2001 78.6 93.0 91.4 94.3  
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Country Data year Overall % Hepatitis B % Measles (MMR) %
Pertussis (DPT) 
%
Cyprus5 2006 86.0 93.2 39.5 96.8
Latvia 2005 NA 98.1 95.0 95.6
Malta4 2005 NA 77.5 86.0 92.4
Non-OECD EU countries
 
NA stands for "no data available". 
1. Overall rate refers to 2002. 
2. DTP rate comprises complete first series offered at 2, 3 and 4 months, assessed at 24-36 months. 
3. Children under 1 year old. 
4. Rates for Hepatitis B and Pertussis (DPT) refer to percentage of children up to their first birthday, whereas rate for 
Measles (MMR) refers to percentage children up to their second birthday. 
5. See footnotes 2 and 3 on page 3.  
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Coverage for basic vaccination programme, age 2, (Pertussis, measles, hepatitis B), sources and methods  
Country Source Description of the basic immunisation 
program: 
Additional 
years 
available: 
Comments 
Australia Australian Childhood Immunisation 
Register (ACIR) 
  Data are for birth cohorts 1 July to 30 September 
2003, assessed 31 December 2005 
Austria Federal Ministry of Health and Women Mumps, Measles, Rubella, Diphtheria, Pertussis, 
Tetanus, Poliomyelitis, Hepatitis B, Heamophilus 
influenza - no compulsory vaccination in Austria. 
 
  
Canada Public Health Agency of Canada (2004 
National Immunization Coverage Survey 
(NICS)) 
   
Czech 
Republic 
Department of Chief Public Health Officer 
of the CR 
DTP: 1st dose - 9th-12th week, 2nd dose - 13th-16th 
week, 3rd dose - 17th-20th week, 4th dose - 18th-20th 
month; MMR: 1st dose - 15th month, 2nd dose - 21st-
25th month; Hepatitis B: 3 doses in the interval 0-1-6 
months, 1st dose - in the first months of live, usually 
1st and 2nd doses are given in conjunction with DTP-
HiB. 
 
 Data for DPT vaccination rate relates to 4 doses 
Denmark Statens Serum Institut 
 
The basic program includes 3 vaccinations before 12 
month for Diptheria, Tetanus, Poliomyelitis, Pertussis 
given in one shot and another shot for Haemophilus 
influenza b. The Diptheria and Tetanus vaccine is 
followed up by a shot at age 5. At age 15 month a 
vaccine for Measles, Mumps and Rubella is given. This 
is followed up at age 12. 
 DPT 93%, Polio 93%, Measles 95%, Rubella 95%, 
Mumps 95%, HiB 93%. 
The vaccination program is free of cost but some 
parents choose not to let their children be 
vaccinated, because they believe that it will 
strengthen the child's immune system if the child 
has the disease. 
Finland National Public Health Institute 
 
  The vaccination coverage study is done in Finland in 
systematic regular intervals. The vaccination 
coverage studies are done by the National Public 
Health Institute. The over all vaccination figure 
coverage is from the previous study, from year 
2002. The other figures from the following study. 
France French Ministry of Health, DREES 
(Statistics Department) 
 
Program Description: Vaccination against Diphtheria  
tetanus, Poliomyelitis, BCG is mandatory. Vaccinations 
against Pertussis, Haemophilus influenzae b, Hepatitis 
B, Measles, Mumps, Rubella are not mandatory, but 
strongly recommended. MMR booster has been 
recommended at age. 2 since 2005. These 
 Vaccination rates for Diphtheria  tetanus and 
Poliomyelitis are calculated for a full vaccination 
(including 3 doses + booster). So are calculated 
Pertussis and H. Influenzae vaccination rates. 
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Country Source Description of the basic immunisation 
program: 
Additional 
years 
available: 
Comments 
percentages concern 24 months children (+/- 1 month). 
4 doses Diphtheria, Tetanus, Poliomyelitis, HiB; 3 
doses Hepatitis B; 1 dose Measles, Mumps, Rubella 
Germany Lauberau et al. (2001) 
Durchimpfungsraten bei Kindern in 
Deutschland 1999, Monatsschr 
Kinderheikd 149, 367-372 
 
Program Description: Diphtheria (D/d), acellular 
Pertussis (aP), Tetanus (T), Haemophilus influenzae 
Type b (Hib), Hepatitis B (HB), Poliomyelitis (IPV) , 
measles, mumps, rubella (MMR), are recommended by 
Standing Committee on Vaccination (STIKO) by 2 
years. 
 Regional non-representative survey data not 
generalisable to national level. 
According to recommendations of the Standing 
Committee on Vaccination (STIKO) at the Robert 
Koch Institute (www.rki.de) basic childhood 
immunisation up to the age of 2 years includes 
vaccinations against the following diseases: 
diphtheria (D), tetanus (T), Pertussis (aP), 
poliomyelitis (IPV), haemophilus influenzae (HiB), 
hepatitis B (HB), measles, mumps, rubella (MMR 
combination vaccine), and varizella zoster virus 
(VZV) infections. The recommended time schedule 
is: DTaP, Hib, IPV, HB at ages 2,3,4, and 11-14 
months; MMR at ages 11-14 and 15-23 months; 
VZV at ages 11-14 months.Approximately 90% of 
vaccinations are administered by privately practising 
physicians in Germany. In general, vaccination is 
covered by statutory health insurance when 
recommended by the STIKO. Small sample size, not 
representative.  
Iceland Directorate of Health    
Ireland HSE, Health Protection Surveillance 
Centre 
 
Program Description: DTP is tracked separately for 
diphtheria, Pertussis and tetanus (3 doses of each 
antigen by age 2). 
  
Italy Ministry of Health The basic immunisation program in Italy comprises 
mandatory and recommended vaccines. The 
mandatory ones are: diphtheria, tetanus, polio and 
hepatitis B; the recommended are measles, mumps, 
rubella, MMR, Pertussis, haemophilus influenzae type 
B. The immunisation schedules have been updated 
with the Ministerial decrees of 7 April 1999 (concerning 
the passage from an all OPV immunisation schedule to 
a sequential schedule) and of 18 June 2002; (this last 
concerning the shift from a sequential polio schedule to 
an all IPV immunisation schedule). The shots are given 
at 3,5,11 months for DTP, Hib, polio, hepatitis B, and at 
2000-2005  
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Country Source Description of the basic immunisation 
program: 
Additional 
years 
available: 
Comments 
12-15 months for MMR. A booster dose of polio 
vaccine is scheduled during the third year of age. The 
vaccines are administered by the personnel of the local 
health units. 
Japan Administrative reports of the Community 
and Elderly Health. The data covers only 
vaccination provided by municipal 
governments and may be underestimated 
because privately-paid vaccination is not 
included (privately-paid vaccination is 
small, though). 
DPT 3 times + 1 booster shot by 7.5 years old, Polio 2 
times, Measles and Rubella by 7.5 years old. 
 Data are not available with unique identifier. So the 
lowest rate (% people who completed DPT, 63.9%) 
was adopted as an overall rate. % of Polio 85.7%, 
Measles 85.8%, Rubella 78%. 
Mexico 
 
Vaccination Programme. Ministry of Health 
(Secretaría de Salud), Mexico. 
 
Includes: DPT, Mumps, Measles, Rubella, anti-
Haemophilus influenzae b, Poliomyelitis, Hepatitis B, 
BCG (anti-TB). 
  
Netherlands 
 
Abbink F, Oomen PJ, Zwakhals SLN, 
Melker HE de, Ambler-Huiskes A. 
Vaccinatietoestand Nederland per 1 
januari 2005. [Immunisation coverage in 
the Netherlands as at 1 January 2005]. 
RIVM rapport 210021005/2006. Bilthoven: 
RIVM, 2006. Developments in 2006. RIVM 
report xxxx/2007. Bilthoven: The 
Netherlands. In preparation 
 
Vaccination schedule: DTPA and IPV at 2, 3, 4 and 11 
months; MMR at 14 months; Hepatitis B (risk groups 
only) at birth, 2, 3, 4 and 11 months. At the age of 4 
DTPA and IPV are offered, and at the age of 9 DT, IPV 
and MMR. Also included in the immunisation 
programme are vaccinations against pneumococcal 
disease (2, 3, 4, 11 months), Haemophilus influenzae 
type b (2, 3, 4, 11 months), and infections with 
meningococci serogroup C (14 months). Every child is 
offered vaccination from birth to 13 years on a 
voluntary basis and free of charge. The Ministry of 
Public Health, Welfare and Sports decides on the 
vaccination policy, the Netherlands Vaccine Institute is 
responsible for delivering all vaccines and the National 
Institute of Health and the Environment (RIVM) advises 
the Ministry. The execution of the Dutch National 
Immunisation Programme is coordinated by the Centre 
for Infectious Disease Control (CIb) of the RIVM. For 
children up to the age of 4 years the programme is 
usually implemented by the network of Maternal and 
Child Health Clinics, for school-aged children by the 
Municipal Public Health Services. 
The Regional Vaccination Administration Centres 
(since April 2007 forming a part of the CIb of the RIVM) 
 Data about the immunisation rate for hepatitis B in 
children are not available yet, because this 
vaccination is introduced recently (2003). Hepatitis 
B vaccination within the framework of the basic 
immunisation programme is administered to risk 
group only (children of whom at least one parent 
was born in a country where hepatitis B is 
moderately or highly endemic and children of whom 
the mother is hepatitis B carrier). 
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Country Source Description of the basic immunisation 
program: 
Additional 
years 
available: 
Comments 
maintain a database of vaccination records for each 
child living in the region. These centres take care of 
updating the database by processing records from the 
Municipal Basis Registry about birth, deaths and 
removal. 
New 
Zealand 
 
National Immunisation Coverage Survey 
2005 
National Immunisation Schedule effective from 1 
February 2006: 6 weeks  DTaP-IPV (diphtheria, 
tetanus, acellular Pertussis, inactivated polio vaccine) , 
Hib-Hep B (haemophilus influenzae type b, hepatitis 
B); 3 months - DTaP-IPV, Hib-Hep B; 5 months  
DTaP-IPV, Hep B; 5 months  Hib, MMR (measles, 
mumps, rubella); 4 years  DTaP-IPV, MMR; 11 years 
 dTap-IPV* (adult diphtheria, tetanus, adult acellular 
Pertussis, inactivated polio vaccine until the end of 
2007 for those who have not previously had four 
doses) Special programme: 6 weeks  MeNZB 
(meningococcal B); 3 months  MeNZB; 5 months  
MeNZB; 10 months  MeNZB (those who received the 
3rd dose between 5-6 months of age, otherwise 
minimum 4 months after the 3rd dose). 
 Data from the National Immunisation Register (NIR) 
will be available in late 2007. 
 
Norway 
 
SYSVAK: National electronic vaccination 
register in Norway 
The Norwegian Childhood Vaccination Schedule: 3 
months: DTP, Hib, Polio (IPV), Pneumococcal 
conjugate vaccine (Pn7v). 5 months DTP, Hib, Polio 
(IPV), Pneumococcal conjugate vaccine (Pn7v). 12 
months DTP, Hib, Polio (IPV), Pneumococcal 
conjugate vaccine (Pn7v). 15 months MMR. 7-8 years 
DTP, Polio (IPV). 11-12 years dT (for children born 
before 1998). 12-13 years MMR. 13-15 years BCG. 15-
16 years Polio (IPV), dT (for children born in 1998 or 
later).. 
  
Poland National Institute of Hygiene, Department 
of Epidemiology 
Tuberculosis, Hepatitis B, Tetanus, Diphteria, 
Pertussis, Poliomyelitits, Measles, Rubella, Mumps 
1980+  
Portugal "Direcção Geral de Saúde" - Health 
Ministry. 
Till 12 months: DTP (Diphtheria, Tetanus, Pertussis); 
Polio; BCG; HIB; Hepatitis B. Between 12 and 23 
months: VASPR (Measles, Mumps, Rubella). 
1985+ Last available data - 2004. 
Slovak 
Republic 
 
Public Health Office Immunisation program in the Slovak rep is realised 
since 1954 by low. IP included vaccination against 10 
antigens: TB, poliomyelitis, VHB, diphtheria, Pertussis, 
Tetanus, Haemophilius influenza type B, Measles, 
  
 DELSA/HEA/WD/HWP(2007)4 
 67
Country Source Description of the basic immunisation 
program: 
Additional 
years 
available: 
Comments 
mumps, rubella..; 
Spain Ministry of Health and Consumer Affairs. 
(Ministerio de Sanidad y Consumo. 
Dirección General de Salud Pública) 
http//www.msc.es/ciudadanos/proteccionSalud/infancia
/docs/c2006.Pdf 
 Vaccinations by private sector are not included. 
Vaccinations rate - Percentage of infants reaching 
their first birthday who have been fully immunised 
Sweden 
 
Swedish Institute for Infectious Disease 
Control 
Nationwide reports in January 2006 from all child 
health centres in Sweden regarding vaccination that 
passed their 2 year during the preceding calendar year 
(Sweden Data Year 2004-2005 - birth cohort born in 
2003 vaccinated during the period from birth up to 
January 2006). 
  
Switzerland Monitoring in 9 cantons    
United 
Kingdom 
 
Department of Health Program Description: It is not possible to give an 
aggregated proportion of children who have had all the 
standard vaccinations, so we have reported a rate for 
each of the standard vaccination programs.  
Description of the basic immunisation program: 
DTaP/IPV/Hib is a primary immunisation given to 
babies when they are 2, 3 and 4 months old. The 
DTaP/IPV/Hib vaccine protects against five different 
diseases: diphtheria (D); tetanus (T); Pertussis.  
Meningitis C is a primary immunisation given to babies 
when they are 2, 3 and 4 months old. 
 Data are for England only.  
United 
States 
 
CDC National Immunization Survey It is the responsibility of individual states to determine 
which vaccines are required by law, although most look 
to the schedule of recommended childhood vaccines 
established and updated each year by the Committee 
on Infectious Diseases of the American Academy of 
Pediatrics. The Advisory Committee on Immunization 
Practices of the Centers for Disease Control and 
Prevention, and the American Academy of Family 
Physicians. Currently all 50 states have school 
immunization laws, although there are differences in 
what may be required in different states. 
Deviation from age at measurement (2 years)? 19-35 
months. 
 As of March 2004, all 50 states allow vaccination 
exemptions for medical reasons; 48 states allow 
exemptions for religious reasons; and 20 states 
allow exemptions for philosophical reasons. 
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Non-OECD EU countries 
Country Source Description of the basic immunisation 
program: 
Additional 
years 
available: 
Comments 
Cyprus∗ Medical and Public Health Services, 
Ministry of Health 
The childhood immunisation programme in Cyprus∗ is 
set at national level by the Ministry of Health. In the 
public sector immunisation is carried out by the health 
visitors in the child health centres and the school 
health services under the guidance of the public health 
doctors while in the private sector vaccines are given 
by the paediatricians. In the public sector the following 
vaccinations are given free of charge to all the citizens 
regardless of their socioeconomic status: DPT, 
Poliomyelitis (IPV/OPV), MMR, Hepatitis B and 
Heamophilus Influenza type b (Hib). 
Deviation from age at measurement (2 years): Yes. 
 Due to lack of statistical information from the private 
sector, the Ministry of Health and particularly the 
Medical and Public Health Services perform a 3 
year survey for the immunisation coverage at 
national level in children 17-24 months. This survey 
is carried out in accordance with the 
recommendations and a relevant protocol of the 
World Health Organisation to determine vaccine 
coverage and the degree of correct timing of the first 
and subsequent vaccination administration 
according to the WHO guidelines. According to the 
results of the last survey which was carried out in 
May 2006 among children 17-24 months, the 
coverage for DTP3 was 96%, for OPV3 96,5%, for 
DTP and OPV3 was 96,5%, for DTP3, OPV3 and 
MMR was 86,2% and for Hepatitis B 93,2%. The 
given values are estimations rely on those 
percentages. 
 
Latvia 
 
Public Health State Agency 
 
The Basic immunisation program contains children's 
vaccination against Tuberculosis, Tetanus, Diphtheria, 
Whooping cough, Poliomyelitis, Measles, Rubella, 
Mumps, Hepatitis B, B type Haemophilus influenzae. 
 Measles vaccination at the age 16-23 months; DT - 
95,6 and P 95,6; Hepatitis B - 1 year. 
Malta WHO-HFA: http://data.euro.who.int/hfadb/    
                                                     
∗ See footnotes 2 and 3 on page 3. 
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Asthma mortality rate, ages 5-39 
Operational Definition 
 Numerator: Number of people dying from asthma as a primary cause, age 5-39  
 [Asthma diagnostic codes ICD-9-493 or ICD-10-J45, J 46]. 
 
 Denominator: 100 000 people age 5-39. 
 
Table 12. Asthma mortality rate, ages 5-39 
1998 1999 2000 2001 2002 2003 2004 2005
Australia 0.61 0.56 0.41 0.37 0.40
Austria 0.10 0.11
Canada 0.11 0.20
Czech Republic 0.10
Denmark 0.41 0.17
Finland 0.26 0.00 0.04 0.00
France 0.92 0.30
Germany 0.16
Iceland 0.00 0.00 0.00
Ireland 0.38
Italy 0.13 0.14 0.11
Japan 0.28 0.27 0.26 0.19
Korea 0.09
Mexico 0.32 0.30
Netherlands 0.15 0.13 0.11
New Zealand 0.80 0.35
Norway 0.05 0.18 0.05
Poland 0.08
Portugal 0.10 0.16 0.08
Slovak Republic 0.11
Spain 0.19 0.17
Sweden 0.07 0.12
Switzerland 0.20 0.00
United Kingdom 0.58 0.40 0.49
United States 0.47 0.33
Asthma mortality per 100 000 peopleCountry
 
 
Country
1998 1999 2000 2001 2002 2003 2004 2005
Cyprus1 0.25
Latvia 0.37
Malta 0.00
Asthma mortality per 100 000 people
Non-OECD EU countries
 
Note: 
1. See footnotes 2 and 3 on page 3. 
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Asthma mortality rate, ages 5-39, sources and methods  
Country Source Diagnoses 
code(s) 
Additional 
years 
available: 
Reference 
population 
Comments 
Australia AIHW Mortality Database 
 
ICD-10 J45, 
J46. 
 1980 OECD  
Austria Statistics Austria. ICD-10 J45, 
J46. 
   
Canada Canadian Vital Statistics Mortality 
Database 
ICD-10 J45, 
J46. 
 1991 Canada 
Census 
 
Czech 
Republic 
Vital Statistics (Czech Statistical 
Office) 
ICD-10 J45, 
J46. 
   
Denmark National Causes of Death Register ICD-10 J45, 
J46. 
  Denmark wishes to make sure that the possibility of underreporting for 
this indicator is recognised. The underreporting makes comparisons 
difficult and could be misleading. 
Finland National Cause of Death Register, 
Statistical Institution of Finland 
ICD-10 J45, 
J46. 
   
France Numerator: national exhaustive 
mortality data (centre for 
epidemiology of medical causes of 
deaths  INSERM-CépiDc)  for 
numerator, INSEE (Statistics 
National Institute) for population) 
 
ICD-10 J45, 
46 
  1999 (0.8376) 
Germany Todesursachenstatistik (causes of 
death statistics) 
ICD-10 J45, 
J46 
  Value for ICD-10 J40-J47 is: 0.28. 
Iceland Directorate of Health     
Ireland PHIS ICD-9-493  PHIS 
Population 
Data 
 
Italy Italian mortality database collected 
by ISTAT and processed by Istituto 
Superiore di Sanità. 
ICD-9 493.  1991 Italian 
Census 
 
Japan vital statistics ICD-10 J45, 
J46. 
   
Korea Annual Report on the Cause of 
Death Statistics. Korea National 
Statistical Office, 2006. 
 
ICD-10 J45, 
J46. 
  1. Number of people dying from asthma as a primary cause (J45, J46), 
age 5-39: 24 2. Chronic lower respiratory disease mortality (J40-47) 
was 0.16. 
Mexico Mortality figures: Mortalidad 2005, ICD-10 J45,    
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Country Source Diagnoses 
code(s) 
Additional 
years 
available: 
Reference 
population 
Comments 
 Instituto Nacional de Estadística, 
Geografía e Informática y Dirección 
General de Información en Salud, 
Secretaría de Salud. Population 
figures: Instituto Nacional de 
Geografía, Estadística e 
Informática. 
 
J46. 
Netherlands 
 
National Institute for Public Health 
and the Environment 
 
  OECD 1980  
New Zealand 
 
Numerator: NZHIS Mortality Data 
Collection 2003. Denominator: 
Statistics New Zealand, estimated 
resident mean population year 
ended 31 December 2003. 
ICD-10-AM 
(Australian 
Modification) 
J45, J46. 
 OECD 1980  
Norway 
 
Statistics Norway (SSB) ICD-10 J45, 
J46. 
   
Poland Data from Central Statistical Office 
processed by National Institute of 
Hygiene 
ICD-10 J45, 
J46. 
1999-2003 Standard 
Population 
1990 
Figure represents crude and age-standardised rate. 
Portugal DGS/INE ICD-10 J45, 
J46. 
  The age groups 10-14; 20-24; 25-29; 30-34, do not have any registered 
cases of death. 
Slovak 
Republic 
 
Statistical Office of SR 
 
ICD-10 J45, 
J46. 
 Standard 
European 
population 
 
Spain Ministry of Health and Consumer 
Affairs. (Ministerio de Sanidad y 
Consumo. Instituto de Información 
Sanitaria. Indicadores de salud 
2006). 
ICD-10 J45, 
J46. 
 
   
Sweden 
 
The Swedish Cause of Death 
Register 
ICD-10 J45, 
J46. 
 European (not 
OECD) and 
the Swedish 
gave the same 
results. 
 
Switzerland Federal Office of Statistics ICD-9 493.    
United 
Kingdom 
Department of Health Mortality 
Extract 1993-04, Office for National 
ICD-10 J45-
J46 
 OECD 1980 Data are for England only 
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Country Source Diagnoses 
code(s) 
Additional 
years 
available: 
Reference 
population 
Comments 
 Statistics; Mid-year Population 
Estimates 1993-04, Office for 
National Statistics; Calculations by 
National Centre for Health 
Outcomes Development. 
United States 
 
National Vital Statistics System 
Mortality 
 
ICD-9 493.  OECD 1980 Age specific rates provided 
 
 
Non-OECD EU countries 
Country Source Diagnoses 
code(s) 
Additional 
years 
available: 
Reference 
population 
Comments 
Cyprus∗ Cyprus* Death Registry ICD-10 J45, 
J46. 
   
Latvia 
 
Death Causes Database ICD-10 J45, 
J46. 
   
Malta National Mortality Registry, dept. of 
Health Information, Malta 
    
                                                     
∗ See footnotes 2 and 3 on page 3. 
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In-hospital mortality rate within 30 days of hospital admission for AMI 
Operational Definition 
Numerator: Number of deaths in the hospital that occurred within 30 days of hospital admission with 
primary diagnosis of acute myocardial infarction (ICD-9 410 or ICD-10 I21, I22). 
Denominator: Number of people hospitalised with primary diagnosis of acute myocardial infarction. 
Table 13. In-hospital mortality rate within 30 days of hospital admission for AMI 
Hospital 
admissions-
based 
Unique 
identifiers
Australia 6.4 2004-2005
8.8 2000-2001
Austria 12.0 2004
Canada 9.3 2004-2005
Czech Republic 8.9 2004
Denmark 6.4 2005
6.5 2004
Finland 11.1 16.2 2005
11.1 15.7 2004
13.0 18.0 2003
14.0 16.3 2001
France 7.6 2005
8.0 2003
10.9 2001
Germany 11.9 1999
Iceland2 6.4 2005
6.7 2004
11.6 2002
Ireland 10.7 2003
Italy2 9.2 2004
9.6 2003
15.4 2001
Japan 10.5 2005
10.3 1999
Korea1 18.6 2004
Mexico 24.5 2005
23.1 2004
14.3 1999
Rate
Country Data year
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Hospital 
admissions-
based 
Unique 
identifiers
Netherlands 8.4 9.2 2005
9.3 9.9 2004
11.0 2001
New Zealand 5.4 7.6 2005-2006
8.9 10.9 2000-2001
Norway 8.0 2005
10.0 2004
Poland 8.0 2004-2005
Portugal 11.8 2005
12.0 2004
12.6 2001
Slovak Republic2,3 12.0 2005
11.9 2004
Spain 10.3 2004
Sweden 8.3 2005
8.5 2004
10.3 2001
Switzerland4 8.1 2005
6.9 2004
United Kingdom2 11.8 2003-2004
5.2 2002-2003
cont.
Rate
Country Data year
 
 
 
Country
Hospital 
admissions-
based 
Unique 
identifiers Data year
Latvia 15.8 2005
Non-OECD EU countries
 
 
Notes: 
1. Data also include patients that died within 30 days after admission, out of hospital.  
2. Data with a limited generalisability to national level. See sources and methods for more information. 
3. Age-standardised to Standard European Population. 
4. In-hospital mortality, not necessarily 30-days in-hospital mortality after admission. 
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In-hospital mortality rate within 30 days of hospital admission for AMI, sources and methods  
Country Source Diagnoses 
code(s) 
ALOS 
in days 
Age 
groups 
included 
Reference 
population 
Comments 
Australia AIHW National Morbidity Database 
 
ICD-10 I21, I22 5.8    
Austria OEBIG ICD-10 I21, I22 9.4   Average length of stay excludes people not staying over night and 
excludes stays for longer than 365 days. 
Canada Hospital Morbidity Database, CIHI ICD-10 I21 and I22 7.2 20-105 
years 
Crude rate is 
provided 
ICD-9 codes (410) were used to extract cases submitted by the 
province of Quebec. Only discharge abstracts with a most 
responsible diagnosis of AMI are included in the calculation. The 
most responsible diagnosis is defined as the one diagnosis or 
condition that accounted for the longest length of stay or most 
resource intensive. Note that the in-hospital AMI mortality rate 
provided in the previous round of data collection was based on a 
different methodology and is not comparable with the rate provided 
in this round. 
Czech 
Republic 
National Registry of Hospitalized 
Patients 
 
ICD-10 I21, I22 7.3   Includes hospitalised patients in general hospitals. Discharges 
exclude transfers to other care units within the same institution. 
Denmark National Hospital Discharge Register ICD-10 I21, I22 5.2 All  The numbers provided are preliminary and will change as the 
register still receives data from the hospitals. The relevant cases 
are identified by unique identifiers 
Finland Hospital Discharge Register ICD-10 I21, I22  30+  If number of patients is used as the denominator the figure for the 
year 2005 will be 16.2 (2004 was 15.7). This denominator is used in 
the NOMESKO Statistics. 
France Hospital Morbidity Database, PMSI 
 
 
ICD-10 I21, I22 7.1 All   
Germany 10%-sample of all hospital cases in 
German. 1999 
"Krankenhausdiagnosestatistik by 
the Statistisches Bundesamt 
ICD-9 410  10+  10% discharge sample. 
Iceland National University Hospital for 
survival rates, Directorate for Health 
for ALOS 
ICD-10 I21, I22 7.3 
(2004) 
All   
Ireland      Not age standardised 
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Country Source Diagnoses 
code(s) 
ALOS 
in days 
Age 
groups 
included 
Reference 
population 
Comments 
Italy Ministry of Health 
 
ICD-9 410 8.43 All   
Japan Patient Survey 2005. Specially tallied 
by the Ministry of Health, Labour and 
Welfare 
     
Korea Research on National Surveillance 
for Cardiovascular disease 
I21, I22, I23, I250, 
I251 
9.2 days All  1. Case definition: cases with I21, I22, I23, I250 and I251 were 
selected from the 2004 National Health Insurance Data. Medical 
records have been reviewed to identify cases compatible with AHA-
EPI or ESC/ACC criteria. 2. We calculated AMI 28 day in -Hospital 
case fatality rate. 
Mexico 
 
Sistema Automatizado de Egresos 
Hospitalarios, Dirección General de 
Información en Salud, Secretaría de 
Salud 
 
ICD-10 I21, I22. 6.5   Indicator coverage: discharges recorded in all hospitals providing 
care to the uninsured population that is the population without 
access to social security (approximately 50% of the total Mexican 
population). The complete 2005 database analysed comprises 
1 980 962 discharges reported by 596 hospitals run by the State 
Health Services, 10 National Institutes of Health (Federal Tertiary 
Care Hospitals) and 6 federal hospitals located in Mexico City and 
run by the federal government. Federal psychiatric hospitals are 
excluded from this database. It is estimated that this hospital 
activity represents 41% of the total activity recorded by public 
hospital facilities comprised in the National Health System (figure 
estimated on the basis of 2004 data). It is expected that the 
corresponding 2005 percentage will be slightly higher. 
Netherlands 
 
National Medical Registry, owned by 
PRISMANT. Calculations and 
methods by Statistics Netherlands in 
cooperation with Institute for Public 
Health and the Environment 
ICD-9 410 7.56 All  Based on admissions, although figures based on patients are 
available. Rate defines: in-hospital mortality rate within 30 days of 
admission, among all discharges with AMI as reason for admission. 
Includes clinical admissions (with one overnight stay or more) and 
admissions without an overnight stay (=day care). Discharges from 
small specialised hospitals are excluded. 
New 
Zealand 
 
National Minimum Data Set (NMDS) 
2005/2006 
 
ICD-10-AM 
(Australian 
Modification) I21-
I22. 
5.5 All  Publicly funded events. If compared to unique patients, rather than 
admissions, the rate is 7.64%. 
Norway 
 
Norwegian Patientregister. ICD-10 I21, I22    Norwegian Patient register has no unique patient identifier. This 
means that the same person may appear in the statistics several 
times during the year if this person gets treatment in different 
hospitals during the year. 
Poland Polish Registry of Acute Coronary ICD-10 I21, 7.5 days   Data based on 59761 patients registered in Polish Registry of 
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Country Source Diagnoses 
code(s) 
ALOS 
in days 
Age 
groups 
included 
Reference 
population 
Comments 
Syndromes PL-ACS I22.Diagnosis 
based on clinical 
definitions of 
STEMI and 
NSTEMI 
Acute Coronary Syndromes with diagnosis of STEMI or NSTEMI in 
years 2004-2005. 
Portugal "Instituto de Gestão Informática e 
Financeira da Saúde" - Health 
Ministry 
ICD-9 410  15-105  This indicator was calculated with data from Diagnosis Related 
Groups (DRGs) a national data base from "Instituto de Gestão 
Informática e Financeira da Saúde" - Health Ministry. 
Slovak 
Republic 
 
NHIS 
 
 
ICD-10 I21, I22   Standard 
European 
population 
 
Spain Hospital Discharge Minimum Data 
Set (Conjunto Mínimo Básico de 
Datos CMBD). Ministerio de Sanidad 
y Consumo. Instituto de Información 
Sanitaria. Registro de altas 2004 
ICD-9 410 9.36 All  Public hospitals (75% discharges of total country). 
Sweden 
 
The Swedish Hospital Discharge 
Register 
ICD-10 I21, I22 5.3 0-85  The value for the standardised death rate was around 0.08 due to 
two very high death rates for the youngest age groups with very few 
AMI's. Crude (non standardised) death proportion almost the same: 
0.082630168. 
Switzerland AMIS-plus ICD-10 I21, I22. 
Acute myocardial 
infarction: defined 
by characteristic 
symptoms and or 
ECG changes and 
enzyme rises (total 
creatine kinase or 
creatine kinase MB 
fraction) at least 
twice the upper 
limit or normal 
7.7   Data show overall in-hospital mortality (not limited to 30 days); data 
not based on a comprehensive national data base, but judged to be 
representative. 
The ICD-10 I21.4 code was used only as an example, to show that 
the criteria of the AMIS-plus registry are not all exactly the same as 
in ICD.  In the AMIS-plus data registry are all cases with acute 
coronary syndrome (but our expert extracted the cases for AMI).  
The patients data are entered in the data registry regardless if its a 
first infarction or a re-infarction. 
United 
Kingdom 
 
Hospital Episode Statistics (covers 
all NHS trusts in England) 
 
 
ICD-10 I21-I22  All  Based on in hospital mortality during the last finished consultant 
episode in an inpatient spell. The data are for England only. The 
age adjusted figure above is distorted by the fact that there was a 
single admission in the 10-14 age group who died. 
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Non-OECD EU countries 
Country Source Diagnoses code(s) 
ALOS 
in days 
Age 
groups 
included 
Reference 
population Comments 
Latvia 
 
Health Statistics and medical 
technology state agency 
ICD-10 I21, I22 11.7 18+  Indicator - mortality of adolescents and adults (%) in the hospital 
from acute myocardial infarction. Numerator: deceased with 
diagnosis acute myocardial infarction in the hospital. Denominator: 
Number of hospitalised with diagnosis of acute myocardial 
infarction. 
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In-hospital mortality rate within 30 days of hospital admission for stroke 
Operational Definition 
Numerator: Number of deaths in the hospital that occurred within 30 days of hospital admission with 
primary diagnosis of  
a) hemorrhagic stroke (ICD-9 430-432 or ICD-10 I61-I62)  
and b) ischemic stroke (ICD-9 433, 434, and 436 or ICD-10 I63-I64). 
 
Denominator: Number of people hospitalised with primary diagnosis of stroke. 
Table 14. In-hospital mortality rate within 30 days of hospital admission for stroke 
Hospital 
admissions-
based 
Unique 
identifiers
Hospital 
admissions-
based 
Unique 
identifiers
Australia 2004-2005 24.9 11.9
2000-2001 25.0 13.0
Austria 2004 17.0 8.0
Canada 2004-2005 29.9 13.1
Czech Republic 2004 28.4 12.0
Denmark 2005 23.6 7.2
2004 25.4 7.0
Finland 2005 12.5 22.9 6.3 10.5
2004 13.7 24.5 6.5 10.6
2003 24 11
France 2005 27.3 11.2
2003 27.5 13.5
2001 27.6 13.4
Germany2 1999 21.0 10.9
Iceland 2005 30.6 5.8
2004 39.2 6.3
2002 19.2 4.1
Ireland 2003 23.9 11.3
Italy2 2004 24.3 8.5
2003 24.6 9.4
2001 29.5 12.2
Japan 2005 10.9 3.3
1999 5.3 3.2
Korea1 2004 35.0 15.2
Mexico 2005 32.0 20.1
2004 29.3 19.6
Hemorrhagic mortality rate Ischemic mortality rate
Country Data year
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Hospital 
admissions-
based 
Unique 
identifiers
Hospital 
admissions-
based 
Unique 
identifiers
Netherlands 2005 29.9 33.9 9.2 9.3
2004 30.5 33.8 10.6 10.8
2001 35.0 16.0
New Zealand 2005-2006 30.9 11.9
1999-2000 32.3 13.9
Norway 2005 19.0 8.0
2004 25.0 9.0
Poland 2004-2005 36.9 11.6
Portugal 2005 26.9 9.4
2004 25.0 12.2
Slovak Republic3 2005 28.5 12.2
2004 29.8 12.7
Spain 2004 28.6 11.5
Sweden 2005 18.6 8.4
2004 18.1 9.2
2001 24.3 10.6
United Kingdom2 2003-2004 15.6 5.5
2002-2003 16.5 9.9
Hemorrhagic mortality rate Ischemic mortality rate
cont.
Country Data year
 
Notes: 
NA stands for non available. 
1. Data also include patients that died within 30 days after admission, out of hospital.  
2. Data with a limited generalisability to national level. See sources and methods for more information. 
3. Age-standardised to Standard European Population. 
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In-hospital mortality rate within 30 days of hospital admission for stroke, sources and methods 
Country Source Hemorrhagic Diagnostic 
Code 
ALOS 
in 
days
Ischemic Diagnostic Code ALOS 
in 
days
Ages in 
years 
Comments 
Australia AIHW National Hospital 
Morbidity Database 
ICD-10 I61-I62 11.0 ICD-10 I63-I64 11.5  How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
Austria OEBIG ICD-10 I61-I62 
Hospital discharge data. 
Denominator: all I61 and I62 
primary diagnosis - Average 
length of stay excludes people 
not staying over night and 
excludes stays for longer than 
365 days. 
20.39 ICD-10 I63-I64 
Hospital discharge data. 
Denominator: all I63 und I64 
primary diagnosis. Average 
length of stay excludes people 
not staying over night and 
excludes stays for longer than 
365 days. 
18.63  How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
 
Canada Hospital Morbidity 
Database, CIHI 
ICD-10 I61-I62 
ICD-9 codes (430-432) were 
used to extract cases submitted 
by the province of Quebec. 
Only discharge abstracts with a 
most responsible diagnosis of 
stroke are included in the 
calculation. Note that the in-
hospital mortality rate provided 
in the previous round of data 
collection were based on a 
different methodology and are 
not comparable with the rate 
provided in this round. 
 
15.1 ICD-10 I63-I64. 
 
ICD-9 codes (433-434 and 
436) were used to extract 
cases submitted by the 
province of Quebec. These 
data used the most 
responsible diagnosis field 
only. The most responsible 
diagnosis is defined as the 
one diagnosis or condition 
that can be described as 
being the most responsible for 
the patients stay in hospital. 
In the event that multiple 
diagnoses are listed, select 
the most responsible 
diagnosis from the condition 
associated with the longest 
length of stay or most 
resource intense. Note that 
the in-hospital mortality rate 
provided in the previous round 
16.0 20-105 Reference population: Crude rate is provided. 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Not 
applicable: All patients were followed-up until 
death, discharge or at the end of the 30 day 
follow-up period if still in the hospital. Deaths 
that occurred in a non-acute care setting, e.g., 
rehabilitation specialty hospital, nursing home 
etc, are not captured. 
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Country Source Hemorrhagic Diagnostic Code 
ALOS 
in 
days
Ischemic Diagnostic Code ALOS in 
days
Ages in 
years Comments 
of data collection were based 
on a different methodology 
and are not comparable with 
the rate provided in this 
round. 
Czech 
Republic 
National Registry of 
Hospitalized Patients 
ICD-10 I61-I62 
 
18.3 ICD-10 I63-I64 19.1  Includes hospitalised patients in general 
hospitals. Discharges exclude transfers to 
other care units within the same institution 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Usually no 
missing cases in hospital records. 
 
Denmark National Hospital 
Discharge Register 
ICD-10 I61-I62 
 
10.2 ICD-10 I63-I64 4.5 All The numbers provided are preliminary and will 
change as the register still receives data from 
the hospitals. All relevant cases are identified 
by unique identifiers 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
 
Finland Hospital Discharge 
Registry 
ICD-10 I61-I62 
 
31.85 ICD-9 433-434 and 436 34.13 30+ If number of patients is used as the 
denominator the figure for 2005 will be 22.9 
(hemorrhagic) / 10.5 (ischemic) (2004 was 
25.0 (hemorrhagic) / 10.6 (ischemic)). This 
denominator is used in the NOMESKO 
Statistics. 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
 
France Hospital Morbidity 
Database 
ICD-10 I61, I62. 14.2 ICD-10 I63, I64 13.1 All  
Germany 10%-sample of all 
hospital cases in German 
     10% discharge sample 
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Country Source Hemorrhagic Diagnostic Code 
ALOS 
in 
days
Ischemic Diagnostic Code ALOS in 
days
Ages in 
years Comments 
1999 
"Krankenhausdiagnosest
atistik by the 
Statistisches Bundesamt 
Iceland National University 
Hospital for survival rates, 
Directorate for Health for 
ALOS 
ICD-10 I61, I62. 11.5 
(2004) 
ICD-10 I63, I64 13.8 
(2004) 
All How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
Italy Ministry of Health ICD-9-430-432 15.89 ICD-9 433, 434, and 436. 10.87 All How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
Japan Patient Survey 2005. 
Specially tallied by the 
Ministry of Health, Labour 
and Welfare 
      
Korea Research on National 
Surveillance for 
Cerebrovascular disease 
ICD-10 I61-I62 
 
1. Case definition: Cases with 
I60, I61, and I62 were selected 
from the 2004 National Health 
Insurance Data. And medical 
records have been reviewed to 
identify cases compatible with 
the stroke diagnostic algorithm 
that has been developed by 
representatives of Korean 
Stroke Society. 
 
2. We calculated hemorrhagic 
stroke 28 day in -Hospital case 
fatality rate. 
17.7-
27.7 
ICD-10 I63-I64. 
 
1. Case definition: Cases with 
I63, I64 were selected from 
the 2004 National Health 
Insurance Data. And medical 
records have been reviewed 
to identify cases compatible 
with the stroke diagnostic 
algorithm that has been 
developed by representatives 
of Korean Stroke Society. 
 
2. We calculated ischemic 
stroke 28 day in -Hospital 
case fatality rate. 
14.3 - 
24.9 
 How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
Mexico Sistema Automatizado de 
Egresos Hospitalarios y 
Bases de datos de 
egresos hospitalarios de 
los Institutos Nacionales 
ICD-10 I61, I62. 7.18 ICD-10 I63, I64 6  Rates per 1 000 hospital discharges. Indicator 
coverage: discharges recorded in all hospitals 
providing care to the uninsured population (ie 
without access to social insurance). These 
include hospital facilities run by States Health 
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Country Source Hemorrhagic Diagnostic Code 
ALOS 
in 
days
Ischemic Diagnostic Code ALOS in 
days
Ages in 
years Comments 
de Salud, Secretaría de 
Salud 
Services, National Institutes of Health and a 
few hospitals run by the Federal government in 
Mexico City. Therefore, hospital activity 
undertaken at IMSS, ISSSTE, and other social 
insurance schemes is not included in these 
figures. Data reported in this table reflect about 
50% of the total hospital activity undertaken by 
public institutions in Mexico. 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
 
Netherlands National Medical Registry, 
owned by PRISMANT. 
Calculations and methods 
by Statistics Netherlands 
in cooperation with 
Institute for Public Health 
and the Environment 
ICD-9 430, 431 and 432 12.53 ICD-9 433, 434 and 436 11.71 All Based on admissions, although figures based 
on patients are available. Rate defines: in-
hospital mortality rate within 30 days of 
admission, among all discharges with AMI as 
reason for admission. Includes clinical 
admissions (with one overnight stay or more) 
and admissions without an overnight stay 
(=day care). Discharges from small specialised 
hospitals are excluded. 
New Zealand National Minimum Data 
Set (NMDS) 2005-2006 
ICD-10-AM (Australian 
Modification) I61-I62 
6.72 ICD-10-AM (Australian 
Modification) I63-I64 
7.22 All How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? All patients 
were followed-up until death or 30 days from 
admission if still in the hospital (including 
rehabilitation). New Zealand has a unique 
patient identifier and ability to follow-up 
patients who suffered a stroke in any 
setting until either their death or 30 days 
after the admission. This includes 
rehabilitation episodes and readmissions 
irrespective of the reason. 
Comments: Publicly funded events. 
Norway Norwegian Patientregister ICD-10 I61-I62  ICD-10 I63-I64   Norwegian Patientregister has no unique 
patient identifier. This means that the same 
person may appear in the statistics several 
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Country Source Hemorrhagic Diagnostic Code 
ALOS 
in 
days
Ischemic Diagnostic Code ALOS in 
days
Ages in 
years Comments 
times during the year if this person gets 
treatment in different hospitals during the year. 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Dropped out. 
 
Poland Data from POLKARD 
20032005 (full name: 
National Cardiovascular 
Disease Prevention and 
Treatment Program for 
2003-2005) 
ICD-10 I61-I62 17.23 ICD-10 I63-I64 12.41  Data are from hospital based registry - 73 
stroke centres (out of 78) included that met 
inclusion criteria and 2478 ischemic stroke 
patients. Mortality rates represent only in-
hospital mortality not 30 days mortality. 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Excluded 
from numerator and denominator. 
 
Portugal Instituto de Gestão 
Informática e Financeira 
da Saúde, Health 
Ministry 
ICD-9-430-432  ICD-9 433, 434, and 436   Missing cases are returned to the reporting 
unit for correction, therefore we do not have 
missing cases. 
 
Denominator: Number of hospital admissions 
with primary diagnosis, of respectively 
hemorrhagic and ischemic stroke. 
Slovak 
Republic 
NHIS ICD-10 I61-I62  ICD-10 I63-I64   Reference population: Standard European 
population. 
 
Spain Hospital Discharge 
Minimum Data Set 
(Conjunto Mínimo Básico 
de Datos CMBD). 
Ministerio de Sanidad y 
Consumo. Instituto de 
Informcaión Sanitaria. 
Registro de altas 2004 
ICD-9-430-432  ICD-9 433, 434, and 436   Public hospital only (75% of total national 
discharges). 
 
How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
system, but are lost to follow-up? Only in-
patients deaths. 
 
Sweden The Swedish Hospital ICD-10 I61-I62  ICD-10 I63-I64   How are missing cases treated, i.e. patients 
who are diagnosed and entered into the 
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Country Source Hemorrhagic Diagnostic Code 
ALOS 
in 
days
Ischemic Diagnostic Code ALOS in 
days
Ages in 
years Comments 
Discharge Register The crude rate was 
0.186004677 compared with 
0.078264327 when 
standardised to OECD 1980 
population which gives 
difference due to strange 
standard population that gives 
enormous weights to strata 
below 45 with very few strokes. 
In Sweden no stroke patients 
died at ages below 35. 
The crude rate was 
0.084118575 compared to 
only 1.3% when standardised 
to OECD 1980 population. 
Difference due to strange 
standard population that gives 
enormous weights to strata 
below age 45 with very few 
strokes. In Sweden no stroke 
patients died at ages below 
35. 
 
system, but are lost to follow-up? Treated as 
survivors. 
 
United 
Kingdom 
Hospital Episode 
Statistics (covers all NHS 
trusts in England) 
ICD-10 I61-I62  ICD-10 I63-I64  All Based on in-hospital mortality during the last 
finished consultant episode in an in-patient 
spell 
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In-hospital waiting time for surgery after hip fracture, over age 65 
Operational Definition 
Numerator: The number of patients with surgery initiated within 48 hours. 
Denominator: The number of patients age 65 and older admitted to the hospital with a diagnosis of 
upper femur fracture (ICD-10 S72.0, S72.1, S72.2 or ICD-9 820). 
Table 15. In-hospital waiting time for surgery after hip fracture, over age 65 
Country
Femur fracture 
operated within 48 
hours, age 65+ per 100 
Data year
Austria 80.0 2004
Canada 77.8 2004-2005
79.5 2002
Czech Republic 44.4 2004
Denmark 57.6 2005
74.0 2004
Finland 87.9 2005
86.1 2004
86.0 2003
87.7 2001
Iceland1 72.6 2002-2004
73.1 1999-2003
Italy 33.8 2004
32.7 2003
31.2 2001
Mexico 50.0 2005
65.1 2003
Netherlands 79.6 2004
80.4 2001
New Zealand 72.3 2005-2006
Norway 91.0 2005
93.0 2004
99.0 2003
Portugal 47.4 2005
50.1 2004
32.1 2001
Spain 32.9 2004
Sweden 92.6 2004
93.5 2003
United Kingdom 61.5 2002-2003  
Note: 
1. Three-year average 
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In-hospital waiting time for surgery after hip fracture, over age 65, sources and methods 
Country Source Diagnosis Code(s) Comments 
Austria Diagnoses and procedures 
report 
ICD-10 S72.0, S72.1, S72.2 In hospital waiting times in Austrian hospitals are not reported by the hour; but by the day. A waiting time of 
two days can therefore in one case be longer than 48 hours, in another shorter. 
Canada Discharge Abstract 
Database, CIHI 
ICD-10 S72.0, S72.1, S72.2 The crude rate is 0.7782, and the age-standardised rate (using the 1980 OECD population) is 0.7813. In the 
Discharge Abstract Database, the day on which the surgery occurred is recorded. The hour of the surgery is 
not provided. Therefore the numerator is defined as the number of patients with surgery initiated within 3 days 
of admission. Rate excludes Quebec-submitting hospitals. Cases are selected based on the relevant code 
appearing in the most responsible diagnosis field. In-hospital hip fracture cases were excluded. The most 
responsible diagnosis is defined as the one diagnosis or condition that can be described as being the most 
responsible for the patients stay in hospital. In the event that multiple diagnoses are listed, select the most 
responsible diagnosis from the condition associated with the longest length of stay or most resource intense. 
Czech 
Republic 
National Registry of 
Hospitalized Patients 
ICD-10 S72.0, S72.1, S72.2 3 days between date of arrival and date of surgery are used (based on dates not hours) included are 
hospitalised patients in general hospitals. About half of patients with the diagnosis were not operated. 
Denmark National Hospital 
Discharge Register 
ICD-10 S72.0, S72.1, S72.2  
Finland Hospital Discharge 
Registry 
ICD-10 S72.0, S72.1, S72.2  
Iceland Directorate of Health in 
Iceland 
ICD-10 S72.0, S72.1, S72.2 or 
ICD-9 820. 
No missing cases. Indicator tracks surgery within two calendar days e.g. admission on January 1st, surgery 
before January 3rd. 
Italy Ministry of Health ICD-9 820  
Mexico Estadísticas Hospital de 
Traumatología y Ortopedia 
"Lomas Verdes" 
ICD-10 S72.0, S72.1, S72.2 It represents 7.23% of total cases occurred in IMSS during 2005 and the 50% value it is for 24 hours and not 
for 48 hours period mentioned. On the hospital the intervals measured to initiate surgery go from 0 to 24 hrs, 
24 to 72 hours and more than 72 hours to a week. The total cases obtained in this indicator was 486 it 
represents 7.23% of the total cases during 2005 6,719. The result could be extensible to all the institution 
Netherlands National Medical Registry, 
owned by PRISMANT. 
Calculations and methods 
by Statistics Netherlands in 
cooperation with Institute 
for Public Health and the 
ICD-9-CM code 820 The Dutch National Medical Registry does not have exact time of admission and time of operation. 
Consequently we use calendar days, and this indicator does not exactly measure surgery initiated within 48 
hours but overestimates this percentage. We are able to calculate this indicator based on 1. Hospital 
admissions, 2. Each first admission of a patient within a one-year period, and 3. First admission of a patient 
not admitted in the 5 preceding years (thus, readmissions excluded). Also, reoperations can be excluded by 
counting patients instead of admissions. Figures are based on first admissions within a on-year period for 
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Country Source Diagnosis Code(s) Comments 
Environment hip fracture, acute and elective surgery. Includes clinical admissions (with one overnight stay or more) and 
admissions without an overnight stay (=day care). Discharges from small specialised hospitals are excluded. 
We use a data file obtained by record linkage of the National Medical Registry to the Municipality Basis 
Registry. Discharges were linked by date of birth, sex, date of admission and postal code. About 85% of all 
discharges could be linked, so we could calculate rates on the basis of persons instead of discharges. 
Because some groups do have a smaller probability of being linked, a correction is applied. As a 
consequence, the calculated rates are representative for all patients discharged because of hip fracture in the 
Netherlands. 
New Zealand National Minimum Data Set 
(NMDS) 2005-200 
ICD-10-AM (Australian 
Modification) S72.0, S72.1, 
S72.2 
In-hospital hip fracture cases were excluded. The hour of the admission and surgery is not recorded in the 
NMDS. This indicator refers to surgery within two calendar days of admission. The rate for the same or next 
day surgery is 55.6% 
Norway Norwegian Patientregister ICD-10 S72.0, S72.1, S72.2 Numerator: The number of patients with surgery initiated within 48 hours (ICD-10 S72.0, S72.1, S72.2) 
Portugal "Instituto de Gestão 
Informática e Financeira da 
Saúde, Health Ministry 
ICD-9 820 This indicator was calculated with data from Diagnosis Related Groups (DRGs) a national data 
base from "Instituto de Gestão Informática e Financeira da Saúde" - Health Ministry 
Spain Hospital Discharge 
Minimum Data Set 
(Conjunto Mínimo Básico 
de Datos CMBD). 
Ministerio de Sanidad y 
Consumo. Instituto de 
Información Sanitaria. 
Registro de altas 2004 
ICD-9 820 Calculated only for the cases with date of procedure (15% of total fractures). Public hospitals represent only 
(75% of total national discharges). 
Sweden National Hip Fracture 
Register 
ICD-10 S72.0, S72.1, S72.2 The register does not measure the exact time of arrival to hospital only the date 
United 
Kingdom 
Hospital Episode Statistics 
(covers all NHS trusts in 
England) 
ICD-10 S72.0, S72.1 S72.2 Based on admission (epiorder = 1) finished (epistat = 3) consultant episodes. Numerator is calculated as the 
number of primary operations (oper_1) carried out on date op_dte_1 within 48 hours of admission date 
(admidate). We only include those who have either HRG chapter of H or primary operation OPCS-4 chapter of 
W. The data are for England only 
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Influenza vaccination, over age 65 
Operational Definition 
Numerator: Number offered an annual influenza vaccination. 
Denominator: Number of adults over 65 years of age. 
Table 16. Influenza vaccination, over age 65 
Country  Annual percentage % Data year
Australia 79.1 2004
Austria 23.7 1999
Belgium 59.6 2005
Canada 66.5 2005
Czech Republic 16.5 2002
Denmark 55.3 2005
Finland 52 2005
France 68 2004
Germany 63 2005
Hungary 37.1 2005
Ireland 63 2005
Italy 68.3 2005
Japan 48 2004
Korea 77.2 2005
Mexico 29.1 2003
Netherlands 77 2005
New Zealand 60.6 2005
Portugal 41.6 2005
Slovak Republic 22.9 2004
Spain 70.1 2005
Switzerland 54 2005
United Kingdom 75 2005
United States 64.6 2005  
Source: OECD Health Data 2007, July 07 
Influenza vaccination, sources and methods 
http://www.ecosante.org/OCDEENG/310030.html  
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Smoking rate 
Operational Definition 
Numerator: Number of smokers. 
Denominator: Total population. 
Table 17. Smoking rate 
Country  Smoking Rate % Year
Australia 17.7 2004
Austria 36.3 1999
Belgium 20.0 2005
Canada 17.3 2005
Czech Republic 24.3 2005
Denmark 26.0 2004
Finland 21.8 2005
France 23.0 2004
Germany 24.3 2003
Greece 38.6 2004
Hungary 30.4 2003
Iceland 19.3 2006
Ireland 27.0 2002
Italy 23.0 2006
Japan 26.3 2006
Korea 25.3 2005
Mexico1 26.4 2002
Netherlands 31.0 2005
New Zealand 22.5 2005
Norway 24.0 2006
Poland 26.3 2004
Portugal 17.0 2005
Slovak Republic 24.3 2002
Spain 28.1 2003
Sweden 15.9 2005
Switzerland 26.8 2002
Turkey 32.1 2003
United Kingdom 24.0 2005
United States 16.9 2005  
Country  Smoking Rate % Year
Malta2 23.4 2002
Non-OECD EU countries
 
Note: 
1. Data refer to urban population only. 
2. Data are specific to HCQI Project. Source: EUROSTAT: 
http://epp.eurostat.ec.europa.eu/portal/ 
Source: OECD Health Data 2007, July 07 
Smoking rate, sources and methods  
http://www.ecosante.org/OCDEENG/813030.html 
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TWO NEW INDICATORS CONSIDERED FIT FOR INTERNATIONAL COMPARISONS: 
CLINICAL IMPORTANCE, SCIENTIFIC SOUNDNESS, SPECIFICATIONS AND DATA 
RESULTS  
46. This section presents information on two indicators that were reviewed by the HCQI Expert 
Group and found to be ready for publication in a working paper format. The decisions were guided by a 
review of the indicators according to criteria for scientific soundness, clinical and policy importance of the 
indicator and the comparability across countries of the indicators data sources.  
47. Since these indicators are being published for the first time, a full account is given here of their 
description and definition, scientific soundness, importance and data comparability issues related to the 
indicator. Also presented are the national estimates and the sources and methods for each indicator.  
48. The following table presents a summary of the data availability for the two indicators presented 
in this section.  
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Table 18. Summary of data availability for two new indicators in the 2006 HCQI Project indicator set 
Country 
/Indicator Retinal Exams in Diabetics Asthma Admission Rate 
Australia   
Austria   
Belgium   
Canada   
Czech Republic   
Denmark   
Finland   
France   
Germany   
Greece   
Hungary   
Iceland   
Ireland   
Italy   
Japan   
Korea   
Mexico   
Netherlands   
New Zealand   
Norway   
Poland   
Portugal   
Slovak Republic   
Spain   
Sweden   
Switzerland   
Turkey   
United Kingdom   
United States   
 
Non-OECD EU countries 
Country 
/Indicator Retinal Exams in Diabetics Asthma Admission Rate 
Cyprus∗   
Latvia   
Malta   
 
 (Blank/white cells indicate unavailability of data) 
 
                                                     
∗ See footnotes 2 and 3 on page 3. 
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Retinal exam in diabetics 
Operational Definition 
Numerator: Number of diabetic patients who received a dilated eye exam or evaluation of retinal 
photography by an ophthalmologist or optometrist in a given year. 
Denominator: Number of patients with diabetes (type I and type II) age 18-75 years. 
49.  Importance: Diabetes has become one of the most important public health challenges of the 
21st century. Over 150 million adults are affected worldwide with the number expected to double in the 
next 25 years (King et al., 1998; Zimmet et al., 2001). For example in the US an estimated 15.7 million 
people suffers diabetes, including an estimated 5.4 million people not yet diagnosed. The prevalence of 
diabetes in the US is projected to increase from the present rate of 5.9% to 8.9% by 2025.20 This rise is 
fuelled largely by the rise in obesity. The epidemic of diabetes requires resources to be devoted to the 
management of diabetes and its complications. Diabetes is the leading cause of blindness in industrialised 
countries in people ages 20-74 (Ghafour et al., 1983) and the most common cause of end-stage renal 
disease in the United States, Europe, and Japan. Individuals with type II diabetes have a 2-4 times greater 
risk of cardiovascular disease compared with people who do not have diabetes (Haffner, 2000). Non-
traumatic amputations are 15 times more frequent in diabetic patients than in the general population 
(Ollendorf et al., 1998). While recent medical advances have led to a reduction in mortality from 
cardiovascular disease in OECD countries, such a positive trend has not been documented for diabetic 
patients, suggesting that these advances may be less effective for diabetics (Gu et al., 1999).  Diabetes 
mellitus was responsible for an estimated 21 deaths per 100,000 people in WHO Euro A countries in 2000. 
This represents 2% of all deaths. 
50. Retinopathy poses a serious threat to vision. In the United States, diabetes is responsible for 8% 
of legal blindness, making it the leading cause of new cases of blindness in adults 20-74 years of age. 21 
Each year, between 12,000 and 24,000 people lose their sight because of diabetes. Nearly all patients who 
have type I diabetes for about 20 years will have evidence of diabetic retinopathy. Up to 21% of people 
with type II diabetes have retinopathy when they are first diagnosed with diabetes, and most will 
eventually develop some degree of retinopathy.  
51. Cost: In 2002, the cost of diabetes in the United States was an estimated USD 92 billion in 
medical expenditures and USD 40 billion in lost productivity (ADA, 2003). According to projections by 
the International Diabetes Federation, countries will be spending 7-13% of their healthcare budgets on 
diabetes care by the year 2025 (IDF, 2003).  
Scientific Soundness  
52. Face validity: The prevalence of retinopathy is strongly related to the duration and control of 
diabetes, rendering adequate glycemic control the key measure to prevent retinopathy. But even in patients 
with manifest retinopathy, treatment modalities exist that can delay progression and eventual blindness.22 
                                                     
20 American Diabetes Association Facts and Figures, http://www.diabetes.org; NIDDK Diabetes Overview, 
http://www.niddk.nih.gov/health/diabetes/pubs/dmover/dmover.htm. 
 
21 American Diabetes Association, http://www.diabetes.org/diabetes-statistics/eye-complications.jsp. Accessed, 
28/07/04. 
 
22  American Diabetes Association: Clinical Practice Recommendations 2002. Diabetic Retinopathy (Position 
Statement).2002;25(sup.1):90-93. Available at: http://care.diabetesjournals.org/cgi/content/full/25/suppl_1/s90. 
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People with proliferate retinopathy can reduce their risk of blindness by 95% with timely treatment and 
appropriate follow-up care.23 Because a person can be unaware of having retinopathy and not realise it, a 
regular check-up with an eye care professional is essential for early detection and treatment. Additionally, 
there have been several cost-effectiveness analyses of screening for diabetic retinopathy. Even though 
modelling techniques and component costs have differed substantially, the result of all the analyses is the 
same: screening for diabetic retinopathy saves vision at a relatively low cost, and the cost is less than the 
disability payments provided to people who would go blind in the absence of a screening programme.24 
53.  Construct validity: A number of associations, such as the American Association of Clinical 
Endocrinologists/American College of Endocrinology, American Diabetes Association, and American 
Academy of Ophthalmology, offer clinical guidelines recommending that annual eye exams be performed 
for patients with diabetes. In addition, annual retinal exams are one of five diabetes management tests 
recommended by the US Alliance on Diabetes Quality Improvement (which includes the American 
Diabetes Association). They recommend that for the patient group 29 years or younger that the first 
examination be made within 3-5 years after diagnosis of diabetes once the patient is age 10 or older, with a 
minimum routine of yearly follow-up. For the patient group 30 years an older, it is recommended that the 
first examination be conducted at the time of diagnosis of diabetes and with yearly minimum routine 
follow-ups. Women with diabetes who are planning to become pregnant should have a comprehensive eye 
examination and be counselled on the risk of developing retinopathy, and also have a comprehensive eye 
examination in the 1st trimester with close follow up throughout pregnancy.  
54. Reliability: Countries use national surveys to determine eye exam rates. These rates will be 
affected by national aspects of survey design such as the question used, sampling, and method of 
administering the survey. Survey questions are also sensitive to cultural differences in survey responses in 
different countries, potentially leading to recall bias. 
Feasibility 
55. Data availability: Retinal eye exam rates are available for ten countries (Table 19). Data are 
provided for the years 1999 to 2005. Some countries use slightly different age ranges. One country could 
only provide regional data. Another country provided data for retinal exams in the last two years. One 
country could only provide the rate of eye exams by diabetics. Countries obtained their data from 
population surveys, from patient records, or clinical surveys.  
56. Comparability issues: The deviations in age and years are minor. Another minor problem is 
comparing a country using rate of eye exams in diabetics to the dilated eye exam. The different methods 
of collecting data represent major threats to comparability. There are two basic ways to obtain estimates for 
this indicator, population based surveys, and surveys at clinical sites or a review of patient records. 
Population based surveys rely on respondents to self-report their diabetes diagnosis and their most recent 
eye exam. Population based surveys are likely to capture diabetics who might not be regularly seeing a 
physician. However, there may be recall bias associated with these surveysin that respondents may not 
accurately be able to remember their last exam. Data obtained from patient records are likely to be more 
accurate with respect to the frequency of tests, but exclude diabetics who do not seek regular medical care. 
For these reasons rates obtained from population based surveys should be compared with caution to rates 
obtained from clinical surveys or clinical records.  
                                                     
 
23 National Eye Institute, http://www.nei.nih.gov/health/diabetic/retinopathy.asp#15. Accessed, 28/07/04. 
 
24  American Diabetes Association: Clinical Practice Recommendations 2002. Diabetic Retinopathy (Position 
Statement).2002; 25(sup.1):90-93. Available at: http://care.diabetesjournals.org/cgi/content/full/25/suppl_1/s90. 
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57. Overall assessment: Only ten countries were able to provide data for this indicator. Not many 
countries routinely survey diabetics, or include such detailed questions in general population surveys. 
Obtaining data from patient records can be burdensome.  
Table 19. Retinal exam in diabetics 
Country
Rate for 
diabetics per 
100
Data year
Australia 72.5 1999-2000
Canada 48.6 2005
France 45.1 2002
43.0 2001
Germany 49.0 1998
Italy1 56.0 2003
Japan 37.0 2005
59.0 2002
Korea 38.1 2005
New Zealand 65.5 2005
Slovak Republic 47.0 2005
Sweden 77.8 2005
82.6 2003
United Kingdom 83.4 2004-2005
United States 67.6 2002
69.0 2001  
 
Latvia 54.3 2005
Retinal exams in diabetics
Non-OECD EU countries
 
 
Notes: 
1. Italy's figure refers to diabetic patients attending specialised clinics (estimated 60% of total 
diabetic population).
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Retinal exam in diabetics, sources and methods  
Country Source 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Diabetes Diagnosis 
Criteria: All registered 
patients of diabetes 
(type 1 and type II) 
from Diabetic Register 
Additional 
years 
available 
Comments 
Australia Australian Diabetes, Obesity 
and Lifestyle Study (AusDiab) 
 
25+     Numerator includes those screened in the last 2 years, as 
that is the Australian recommendation. Nationally 
representative sample 
Canada Canadian Community Health 
Survey 
 Diabetic status 
was self-
reported 
Numerator 
comprised of 
self-reported 
diabetics who 
have ever had 
a dilation eye 
exam. For the 
2005 CCHS 
survey, 68.2% 
of diabetics 
reported ever 
having eye 
dilation. 
  The Diabetes Care module is optional content and 
therefore, the results only represent diabetes care practices 
in the participating health regions. In the 2005 CCHS, the 
module was selected by all health regions in Newfoundland 
and Labrador, Prince Edward Island, New Brunswick, 
Ontario, and Manitoba. The ability to generalise these 
results to other non-participating provinces is limited. 
Please describe the sample on which the indicator is 
based: Data are from the 2005 Canadian Community 
Health survey, a telephone survey conducted by Statistics 
Canada from January to December 2005. Diabetes-related 
questions are from the Diabetes module. The diabetes 
module was optional content and was selected by all 
regions in the provinces of Newfoundland and Labrador, 
Prince Edward Island, New Brunswick, Ontario, and 
Manitoba. Only respondents in health regions where the 
module was selected were administered the diabetes care 
questions. All responses were voluntary. 
 
France Entred (survey based upon a 
national sample of diabetic 
patients whose health 
insurance is Caisse nationale 
des travailleurs salariés) 
18+     National, generalisable sample 
Germany German National Health 
Interview and Examination 
Survey 1998; Thefeld W. 
18-75     The validity of a self-reported diagnosis of diabetes mellitus 
is compromised by potential misclassification bias (Thefeld 
W. Prevalence of diabetes mellitus among adults in 
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Country Source 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Diabetes Diagnosis 
Criteria: All registered 
patients of diabetes 
(type 1 and type II) 
from Diabetic Register 
Additional 
years 
available 
Comments 
Prevalence of diabetes mellitus 
among adults in Germany. 
Gesundheitswesen 1999; S85-
S8 - the data presented here 
are recalculated to the age 
range 18-75 years. 
 
Germany. Gesundheitswesen 1999; S85-S89).  Detailed 
information on research on this topic has been provided to 
the OECD by German representatives and is available 
upon request. Self-reported diagnosis by a physician. 
Nationally representative sample 
Italy QuED study, Quality of Care 
and Outcomes in Type 2 DB 
All     Comments: Based on sample of 25274 diabetic persons 
attended in primary care-- data base of medical records. 
National, generalisable sample 
 
Japan Japan Medical Data Center       
Korea Korea National Health and 
Nutrition Examination Survey 
30-39     National representativity of the registry: National 
representative sample. 1. Diabetes diagnostic criteria: 
Persons who answered "yes" to the questions: Have you 
ever been told by doctor that you have diabetes? 2. Age: 
19+ 3. Age group specific rate: 19~29:37.13, 30~39:17.56, 
40~49:37.80, 50~59:38.20, 60~69:39.90, 70+: 39.75 
New 
Zealand 
National Get Checked Quality 
Program for diabetics 
 
 Approximately 
70 000 diabetic 
patients were 
seen in the year 
2005 with Get 
Checked data 
reported. 
Yes, diabetics 
in New 
Zealand are 
screened 
every second 
year, hence 
the rate differs 
to the 
retinopathy 
screening 
within 
preceding 2 
years. 
   
Slovak 
Republic 
Institute of health statistics      Data is not identical to request. Instead of number of retinal 
exams is used number of retinopathy detected 
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Country Source 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Diabetes Diagnosis 
Criteria: All registered 
patients of diabetes 
(type 1 and type II) 
from Diabetic Register 
Additional 
years 
available 
Comments 
Sweden NDR Sweden       
United 
Kingdom 
Quality and Outcomes 
Framework (QOF), Health and 
Social Care Information Centre 
16+      
United 
States 
Agency for Healthcare 
Research and Quality, Center 
for Financing and Cost Trends, 
Medical Expenditure Panel 
Survey 
18+     Persons answering "yes" to the following question: Have 
you ever been told by a doctor or other health professional 
that you have diabetes or sugar diabetes? Nationally 
representative sample 
 
 
Non-OECD EU countries 
Country Source 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Diabetes Diagnosis 
Criteria: All registered 
patients of diabetes 
(type 1 and type II) 
from Diabetic Register 
Additional 
years 
available 
Comments 
Latvia Register of the Patients of 
Diabetes Mellitus 
   All registered patients of 
diabetes (type 1 and 
type II) from Diabetic 
Register. 
 Diabetic Register does not cover all population of diabetics, 
because there are unregistered cases yet. It includes the 
patients who are in primary care and those in hospitals who 
are registered by their physician as a diabetic in the 
register. 
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Asthma admission rate 
Operational Definition 
Source: AHRQ Prevention Quality Indicators. 
Numerator: All non-maternal discharges of age 18 years and older with ICD-9-CM principal 
diagnosis code of asthma.  
Denominator: Total population.  
58.  Importance: Asthma is the most common chronic disease in childhood, with increasing prevalence in 
recent decades. Research suggests that asthma may in fact be a collection of different diseases with similar 
symptoms (Wenzel, 2006). Asthma is an inherently treatable disease through appropriate medical care. In 2002, 
the estimated annual cost of treating asthma in the United States was USD 14 billion, of which hospital care 
accounted for almost a third of direct costs (NHLBI, 2002). Estimates for the European Union suggest annual 
medical costs of EUR 17.7 billion and productivity losses of EUR 9.8 billion (ERS, 2003). The cost of asthma 
treatments accounts for close to 2% of annual expenditures for medical care in Japan (Tanihara and Kobayashi, 
2004). Analysis from Korea has shown that hospitalisations for asthma were a significant health care cost 
however hospitalisations and trips to the emergency department were only a small fraction of the total health 
care cost of uncontrolled asthma (Park, 2006). 
59. Clinical significance of process or outcome: Avoidable hospitalisations are those conditions that could 
have been avoided if proper ambulatory care had been received and can thus be seen as a measure of access to 
appropriate medical care. While not all admissions for ambulatory care sensitive conditions are avoidable, 
appropriate prior ambulatory care can prevent most cases of the onset of this type of illness or condition, control 
an acute episodic illness or condition, or manage a chronic disease or condition. Hence a disproportionately high 
rate is presumed to reflect problems in obtaining access to primary care (Weisman, 1992). Admission rates for 
asthma have been shown to be associated with lower socioeconomic status (AHRQ, 2006).  
60. Identification of process/outcome as quality problem: The rate of Ambulatory Care Sensitive (ACS) 
hospitalisations is considered an index of access of a population to adequate primary care. Primary care should 
be able to effectively manage both adults and children with asthma. Treatment with anti-inflammatory agents, 
such as inhaled corticosteroids and leukotriene inhibitors, are largely able to prevent exacerbation and, when it 
occurs, systemic corticosteroids and bronchodilators should preclude any need for hospitalisation. While current 
protocols and guidelines provide clear guidance for the treatment of asthma, studies suggests that treatment 
often falls short of recommended care (Mattke et al., 2006b; Halterman, 2001; and AAFA, 2005). As a 
consequence of insufficient treatment, patients with asthma may need to be hospitalised. Admission rates for 
asthma and asthma mortality rates have been used to assess quality of care. For example, the UK National 
Health Service has designated asthma admission as a High Level Performance Indicator, and both paediatric and 
adult admission rates are part of the US National Healthcare Quality Report (AHRQ, 2006). Asthma mortality 
rates have been used as an indicator to assess the quality of care for health system comparison in the European 
Community, United Kingdom, Australia, and several other countries (Charlton et al., 1998; Holland et al., 1997; 
Manuel and Mao, 2002; AIHW; 2003).  
61. Policy importance: Given the high cost of hospital care and the high prevalence of asthma, elevated 
ACS hospitalisation rates could point not only towards possibilities to improve quality but also to substantial 
cost savings, if better primary care were provided. In addition, the ACS hospitalisation rate appears sensitive to 
the presence or absence of economic barriers to access. It has been reported to be lower and/or less correlated 
with socioeconomic status in countries with national health insurance (Billings, 1996).  
62. Susceptibility to being influenced by the health system: Appropriate prior ambulatory care could 
prevent the onset of an illness or condition; control an acute episodic illness or condition; or manage a chronic 
disease or condition (Anderson, 1996). According to the National Asthma Education Program, asthma is a 
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readily treatable chronic disease that can be managed effectively in the outpatient setting (NHLBI, 1997). In a 
US-based study of asthma in urban settings, low cost primary care and preventive measures significantly 
decreased the incidence of severe asthma episodes and hospitalisations (Houck, 2006). Observational studies 
offer some evidence that inhaled steroids may decrease risk of admission by up to 50% (Blaise, 1998).  
Scientific Soundness 
63. Face validity: Managing chronic diseases to prevent complications and exacerbations is regarded 
as a core task of the primary health care system. Little empirical evidence exists as to the validity of the 
asthma avoidable hospitalisations indicator in particular. The AHRQ study group developing this indicator 
found that the indicator was adequately precise in measuring true differences across areas or regions 
(AHRQ, 2006). However, there are important differences across race and socioeconomic groups and 
proper adjustment techniques when looking at sub national data is recommended (Ray, 1998). 
64. Content validity: As mentioned above, several groups have advocated measures of ACS 
hospitalisation rates. The fact that hospital admission diagnoses are readily available in most countries 
implies that the indicator can be easily constructed. However, it should be mentioned that there remains 
some controversy about this (and similar) measures as a quality indicator, because ACS hospitalisation 
rates reflect access to, as well as quality of, primary care. Also, defining the appropriate level of hospital 
admission rates for those conditions is difficult, because in a subset of cases an admission is clearly 
warranted.  
Table 20. Asthma admission rate per 10 000 discharges, (primary care and prevention, ambulatory sensitive 
conditions) 
Country Rate per 10 000 Data year
Australia 10.05 2004-2005
Austria 6.97 2004
Canada 3.73 2004-2005
Czech Republic 6.30 2004
Denmark 5.64 2005
Finland 13.23 2005
Iceland 1.69 2005
Italy 3.82 2004
Japan 6.72 2005
Mexico 1.82 2005
Netherlands 2.78 2005
New Zealand 8.13 2005-2006
Norway 4.54 2005
Portugal 3.88 2004
Spain 4.40 2004
Sweden 3.30 2004
United States 12.00 2002  
 
Country Rate per 10 000 Data year
Latvia1 16.13 2005
Non-OECD EU countries
 
 
Notes: 
1. Data from hospital administered statistics 
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Asthma admission rate, sources and methods 
Country Source Diagnosis code(s) 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Additional 
years 
available 
Comments 
Australia AIHW National Hospital 
Morbidity Database 
 
   Data are for 
ICD-10-AM 
J45, J46 
  
Austria Statistics Austria 
 
 15+  Principle 
diagnoses 
given in ICD-
10 codes: 
J450, J451, 
J458, J459, 
J46 
 No exclusions were made, all discharges with principle 
diagnosis of the given codes. 
Canada Discharge Abstract Database, 
CIHI 
 
 
     Cases were extracted based on a most responsible diagnosis 
of the condition of interest. The most responsible diagnosis is 
defined as the one diagnosis or condition that can be 
described as being the most responsible for the patients stay 
in hospital. In the event that multiple diagnoses are listed, 
select the most responsible diagnosis from the condition 
associated with the longest length of stay or most resource 
intense. 
Czech 
Republic 
National Registry of Hospitalized 
Patients 
 20+ Population 20+ 
as of 1st of 
July 
Includes all 
hospitalised 
patients in 
general 
hospitals for 
diagnoses of 
J45, J46. 
  
Denmark National Hospital Discharge 
Register 
 
     There have been no exclusions in the numerator (it is not 
possible to write in the numerator box). The numbers provided 
are preliminary and will change as the register still receives 
data from the hospitals. It should be kept in mind, when 
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Country Source Diagnosis code(s) 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Additional 
years 
available 
Comments 
interpreting this indicator that the indicator is strongly 
dependent on how the health system is organised. 
Finland Hospital Discharge Register      Overall number of cases was 5893. In this all referred cases 
are included. The number of cases admitted to hospital from 
ER's was 4214. Other cases were referrals. 
Italy Ministry of Health - National 
discharges database 
    2001+  
Japan Patient Survey 
 
 20+    Since the Patient Survey covers only one month, the 
numerator (estimated 7 300) was multiplied by 12. The decline 
of the rate (with respect to 2002) indicates improved quality of 
care for asthma. Quoting the actual data provided by the 
Patient Survey in 2002 and 2005, the estimated number of 
discharges over 20 years with primary Dx of asthma was 7 
300 in 2002 and 5 800 in 2005. The rate was calculated as 
follows: 5 800X12months/103.56 million population. 
Mexico SIAIS.- Sistema de Información 
de Atención Integral a la Salud. 
IMSS (DTIES) División Técnica 
de Información Estadística en 
Salud 
 
 
 20+ 20 years and 
older. 
20 years and 
older and ICD-
10 codes. 
(Unofficial 
table of ICD-9 
and ICD-10 
codes). 
 Nationwide representative. 
Netherlands National Medical Registry, 
owned by PRISMANT. 
Calculations and methods by 
Statistics Netherlands in 
cooperation with Institute for 
Public Health and the 
Environment 
 
 18+    The Dutch National Medical Registry does not use the 
following asthma diagnoses: 493.x2, 493.2x, 493.8x, (493.81, 
and 493.82). Consequently, our selection is based on ICD-9-
CM code 493 (493.0, 493.1 and 493.9). A fifth digit 
differentiates between without mention of status asthmaticus 
and with status asthmaticus (respectively codes 0 and 1). 
Major Diagnostic Categories (MDCs) are not used in all 
countries, at least not in the Netherlands. We assume that 
MDC 14 refers to health status described in Chapter 11 of 
ICD-9 (codes 630-676) and several V-codes (V22-V24, V27, 
V28). Secondary diagnoses excluded from the numerator: 
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Country Source Diagnosis code(s) 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Additional 
years 
available 
Comments 
277.0, 747.21, 748.3, 748.4, 748.5, 748.6, 748.8, 748.9, 
750.3, 759.3, 770.7, ICD-9 codes: 630-676 or V22-V24, V27, 
V28. Discharges from small specialised hospitals are 
excluded. We only present data from general acute care 
hospitals (including university hospitals). Data from seven 
specialised clinics for rehabilitation of chronic diseases like 
lung disease were excluded. In these clinics patients are 
admitted with the goal to learn to manage their disease. The 
length of stay can be one day (day care) to several weeks. In 
general, patients are not admitted in these clinics because of 
acute exacerbations or complications. In all rates, clinical 
admissions (with one overnight stay or more) and admissions 
without an overnight stay (=day care) were included. 
Transfers are included in the nominator. Consequently, 
discharges from secondary hospitals are included. 
New 
Zealand 
National Minimum Data Set 
(NMDS) 2005-2006. 
 
ICD-10-
AM 
(Australian 
Modificatio
n) J45-J46 
  Yes, excludes 
pregnancy, 
childbirth, 
puerperium 
(MDC14) and 
emergency 
specialty 
(M05-08) with 
a length of 
stay < 1 day. 
 Publicly funded events. 
Norway Norwegian Patientregister.      Diagnoses codes ICD-10: J45, J46 
Portugal DRGs       
Slovak 
Republic 
      Our records do not work with four digits ICD; therefore it is not 
possible to consider exclusions. 
Spain Hospital Discharge Minimum 
Data Set (Conjunto Mínimo 
Básico de Datos CMBD). 
     only public hospitals (75% of total country discharges) 
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Country Source Diagnosis code(s) 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Additional 
years 
available 
Comments 
Ministerio de Sanidad y 
Consumo. Instituto de 
Información Sanitaria. Registro 
de altas 2004 
Sweden The Swedish Hospital Discharge 
Register 
      
United 
States 
Healthy People 2010, measure 
24-2 (modified age group). 
Agency for Healthcare Research 
and Quality (AHRQ) Prevention 
Quality Indicators (PQ 
  U.S. 
population age 
18+ 
Number of 
discharges 
with first listed 
diagnosis of 
asthma (ICD-
9-CM code 
493) among 
adults age 18 
and over. 
Excludes 
obstetric 
admissions 
and transfers 
from other 
institutions 
 Rates are adjusted by age and gender, using the total U.S. 
population for 2000 as the standard population. Although not 
all States participate in the HCUP database, the Nationwide 
Inpatient Sample is weighted to give national estimates using 
weights based on all U.S. community, non-rehabilitation 
hospitals in the American Hospital Association Annual Survey 
of Hospitals. 
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Non-OECD EU countries 
Country Source Diagnosis code(s) 
Age 
groups 
included 
Deviations 
from the 
definition of 
the 
denominator 
Deviations 
from the 
definition of 
the numerator 
Additional 
years 
available 
Comments 
Latvia Health statistics and medical 
technology state agency 
   Numerator is 
hospital 
statistics rate, 
not in primary 
care. 
Hospitalised 
discharges of 
age 18 years 
and over with 
asthma (ICD-
10 J45, J46) 
 At this moment, we have only information from branch 
statistical report about discharged rate, but in the future it will 
be able from the Management Information System. 
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INDICATORS NOT SELECTED FOR INCLUSION IN 2006 HCQI INDICATOR SET 
65. This section presents information on the clinical importance, scientific soundness together with 
specifications and data results for the 7 indicators which are not yet considered suitable for international 
comparisons by the HCQI Expert Group and which are still under review. The criteria applied for this 
assessment of the indicators were either the lack of availability of the indicator across a sufficient number 
of countries or some major divergences in the methodology of calculation between countries hampering 
seriously the comparability of figures. The comparability problems underlying this judgement are 
presented and possible solutions suggested. The section offers information about the 4 indicators already 
tested in the previous data collection for which the availability and comparability problems have not yet 
been satisfactorily solved and 3 new indicators tested for the first time in 2006 data collection, for which 
the HCQI Expert Group recommended further work before inclusion in the HCQI indicators set.   
Annual HbA1c test for patients with diabetes 
NOTE that this indicator was already tested in (2003-2005) HCQI data collection and it is not yet 
considered suitable for international comparisons by the HCQI Expert Group. It is included in this paper 
to illustrate current data concerns with the indicator and possible future solutions 
Operational Definition 
Numerator: Number of patients with at least one test of HbA1c levels in the reporting year. 
Denominator: People age 18-75 with diabetes mellitus type I or II, defined as: at least one physician visit 
with a diagnosis of diabetes or patient dispensed insulin and/or hypoglycaemic agent, excluding those with 
gestational diabetes and those not seen for continuing care. 
Importance 
66. Mortality: Diabetes mellitus was responsible for an estimated 21 deaths per 100 000 people in 
WHO Euro A countries in 2000. This represents 2.1% of all deaths. 
67. Prevalence: Diabetes mellitus affected an estimated 3 of every 100 people living in WHO Euro 
A countries in 2000. Diabetes mellitus constitutes a major public health burden in the industrialised 
countries, affecting, for example in the US an estimated 15.7 million people, including an estimated 5.4 
million people not yet diagnosed. In addition to being the seventh leading cause of death in the US (ADA, 
2006), diabetes mellitus is also the leading cause of blindness in people ages 20-74, the leading cause of 
end-stage renal disease (ESRD), the most frequent cause of non-traumatic lower limb amputations, and a 
major risk factor for heart disease and stroke. The prevalence of diabetes in the US is projected to increase 
from the present rate of 5.9% to 8.9% by 2025 (ADA, 2006). 
68. Cost: Endocrine diseases, of which diabetes is the most common, are the 12th attributable 
contributor to cost of illness in Canada (2.2% of direct and indirect costs). In the United States, the costs of 
diabetes totalled $132 billion in 2002, including about $92 billion in direct medical expenditures and about 
$40 billion in lost productivity and premature death (Hogan, 2003).  
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Scientific Soundness 
69. Face validity: There is now strong evidence that reducing blood glucose to normal levels can 
reduce the risk of complications associated with both type I and type II (ADA, 2001) diabetes. Severity of 
complications associated with chronic diabetes, lack of symptoms in initial stages of disease, and long 
period between the commencement of sustained hyperglycaemia and observable complications make this 
disease a prime candidate for aggressive, outpatient based, primary preventive care. Blood glucose testing 
using HbA1c is recommended as a quality indicator by the American Medical Association and is used by 
the US Veterans Administration. The American Diabetes Association and many other national scientific 
societies have issued guidelines for the management of diabetes that reflect the implications of this 
research (ADA, 2001). These guidelines have been disseminated widely, and adapted by many health care 
provider organisations to reflect local practice. Yet as in other areas of clinical practice, numerous studies 
have documented that the level of clinician adherence to diabetes practice guidelines recommendations for 
routine monitoring and screening remains variable and often quite low (Streja, 1999; Lawler, 1997).  
70. Content validity: Reviews of the evidence from clinical trials of diabetes management, including 
those conducted by the Cochrane Collaboration, the American Diabetes Association, the New Zealand 
Guidelines Group, and others, have all concluded that good glycemic control reduces the occurrence of 
retinopathy, nephropathy, and neuropathy, and improves functional status and well-being among people 
with type I and type II diabetes (Renders, 2002; Nathan; 2002).  
71. Reliability: Data on the frequency of HbA1c testing is usually derived from studies using medical 
chart review or prospective data collection. International comparison of these studies is therefore affected 
by all differences in study design. 
Feasibility 
72. Data availability: HbA1c test rates are available for eight countries (Table 21). The HbA1c 
screening data supplied were for 2000-2005. Five countries provided data that slightly deviated from the 
requested OECD age range. Countries provided data based on samples from primary care clinics, and from 
patient surveys. Countries that reported from general surveys also reported a problem that many diabetics 
are not familiar with the term of HbAc1. 
73. Comparability issues: Detailed documentation and assessment is provided in Table 22. There 
should be concern over comparing the results of patient surveys to a review of patient records. A major 
challenge for this indicator relates to fielding surveys that might be able to accurately collect information 
on HbAc1 testing. Because diabetics are not always familiar with the term HbAc1, self-reported data may 
not be reliable, resulting in one country not reporting their data. Data derived as part of research project 
may not be generalisable to a country, because care patterns and patient characteristics may be 
systematically different from the general population.  
74. Overall assessment: Only eight countries could provide data on this indicator. It also appears that 
some of the data comes from research projects and may not be regularly collected. However, during the 
course of the project, data availability improved for this indicator and it may warrant examination in future 
HCQI efforts. 
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Table 21. Annual HbA1c test for patients with diabetes 
Country
Diabetic 
patients tested 
for HbA1c in the 
last year (%)
Data year Age
Finland 98.0 2000
France 82.6 2002 >=18 years
Italy
Type I 91.0 
Type II 88.0 2004 14+
Norway 93.0 2000
Spain 77.4 2000 14+
Sweden 97.0 2003
United Kingdom 94.4 2004-2005 16+
United States 90.4 2002 18 and over  
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Annual HbA1c test for patients with diabetes, sources and methods 
Country Source Age groups included Comments 
Finland A survey conducted in 
2000 
 Data come from a research project, and are a representative sample of diabetics in Finland. The objective was to 
describe the level of diabetic care in Finland. The criteria were HbA1c levels, blood pressure and lipid level. 3580 
diabetic took part, 3462 had had their HbAc1 level measured. The results are 97% in patients on oral medication, 99% in 
patients on insulin, and 100% in patients on combination medication. 
France "Entred" (survey based 
upon a national sample 
of diabetic patients 
whose health 
insurance is Caisse 
nationale des 
travailleurs salariés) 
18+ Patients repaid for insulin or hypoglycaemic agents 
Italy Associazone medici 
diabetologi 
1-100 Based on sample of 120.000 diabetic persons of any age. The information has been derived from electronic records of 
86 diabetes outpatient clinics. In Italy 50-70% patients are followed by diabetes clinics 
Norway Unpublished data from 
an epidemiological 
study carried out in two 
parts of Norway 
 A sample of 2000 patients with diabetes attending primary care in Norway had their HbA1c tested at least once during 
the year 
Spain GEDAPS (Study Group 
of Diabetes in Primary 
Health Care) 
14+ This indicator was based in a sample of 6202 people with diabetes mellitus aged 14 years and older. This sample was 
obtained from the morbidity registries in several centres of primary health care by physicians who participate voluntarily 
in a program to improve care quality 
Sweden National Diabetic 
Register, covering 
approximately 30% of 
all diabetics in Sweden 
 In Sweden the focus has shifted to monitoring evidence-based practice and outcomes of care. Only patients with type I 
diabetes or type II diabetes and at least one test of HbA1c levels were reported this year 2003. 
United 
Kingdom 
Quality and Outcomes 
Framework (QOF), 
Health and Social Care 
Information Centre 
16+ The data provided represents "the percentage of diabetic patients who have a record of HbA1c or equivalent in the 
previous 15 months. As the care of children with diabetes mellitus is generally under the control of specialists, the 
register should exclude those patients age 16 and under. Likewise, the indicators are not intended to apply to patients 
with gestational diabetes and relate to patients with both type I and type II diabetes. Data does not adjust for age or 
gender-they are crude rates. No allowance is made for e.g. deprivation and ethnicity. And importantly, there are 
"exclusions" from QOF e.g. if a patient fails to show for repeat requests for annual review, GPs can and do exclude them 
from the denominator. 
United 
States 
MEPS 18+ Research for the Medical Expenditure Panel Survey (MEPS) at US DHHS AHRQ has shown that there are a large 
number of non-respondents to questions about whether the individual had an HbA1C test due to lack of knowledge 
about HbA1C. 
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Table 22. Annual HbA1c test for patients with diabetes, comparability issues 
  Comparability Implications
  Minor Severe 
Possible Age ranges vary  
Po
ss
ib
ili
ty
 to
 c
or
re
ct
 th
e 
de
vi
at
io
n?
 
Unlikely Data available for different years 
 
Diabetics often are unfamiliar with the 
term HbAc1 leading to potential bias 
in population surveys. 
Comparability between 
population/patient surveys and review 
of patient records is unknown. 
Data derived from research studies 
may not be generalisable 
 
Possible solutions: 
• Footnotes can indicate the year and age range 
• OECD could investigate the comparability between in-person surveys and a review of patient 
records. 
• Tables should separate results based on population-level data and research studies as well as those 
based on survey data and patient records. 
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HbA1c level indicating poor glucose control 
NOTE that this indicator was already tested in (2003-2005) HCQI data collection and it is not yet 
considered suitable for international comparisons by the HCQI Expert Group. It is included in this paper 
to illustrate current data concerns with the indicator and possible future solutions. 
Operational Definition 
Numerator: Number of patients with HbA1c level greater than 9.5% at the most recent test given in 
the reporting year. 
Denominator: People age 18-75 with diabetes mellitus type I or II who had HbA1c levels tested 
within the reporting year (Diabetes defined as: at least one physician visit with a diagnosis of diabetes 
OR patient dispensed insulin and/or hypoglycaemic agent, excluding those with gestational diabetes). 
Importance (for a more detailed discussed, please see above under HbA1c test rate) 
75. Mortality: Diabetes mellitus was responsible for an estimated 21 deaths per 100 000 people in 
WHO Euro A countries in 2000. This represents 2.1% of all deaths. 
76. Prevalence: Diabetes mellitus affected an estimated three of every 100 people living in WHO 
Euro A countries in 2000. 
77. Cost: Endocrine diseases, of which diabetes is the most common, are the 12th highest contributor 
to cost of illness in Canada (2.2% of direct and indirect costs). In the United States, the costs of diabetes 
totalled $132 billion in 2002, including about $92 billion in direct medical expenditures and about $40 
billion in lost productivity and premature death (Hogan, 2003). 
Scientific Soundness 
78. Face validity: HbA1c has been termed the memory of glucose control. Chronically elevated 
blood glucose levels, indicating poor glycemic control, lead to chemical alterations of the haemoglobin, the 
component of the red blood cells that transport oxygen. By measuring HbA1c-levels, clinicians gain 
insight into the glycemic control of a patient over the last couple of weeks. Thus, the test determines how 
well a patients diabetes has been managed with elevated values indicating uncontrolled diabetes.  
79. Content validity: Reviews of the evidence from clinical trials of diabetes management, including 
those conducted by the Cochrane Collaboration, the American Diabetes Association, the New Zealand 
Guidelines Group, and others, have all concluded that good glycemic control reduces the occurrence of 
retinopathy, nephropathy, and neuropathy, and improves functional status and well-being among people 
with type I and type II diabetes (Renders, 2002; Nathan, 2003). Many diabetic patients have poor glycemic 
control (Renders, 2002). The threshold for this indicator, 9.5% (indicating very poor glycemic control), is 
based on a recommendation from a group of 15 experts in developing clinical diabetes indicators for the 
National Committee for Quality Assurance (NCQA, 2003). This threshold, however, will need to be 
updated periodically as numerous organisations, including the US National Quality Forum and the Alliance 
on Diabetes Quality Improvement (representing the American Medical Association, the American Diabetes 
Association and the Joint Commission on the Accreditation of Healthcare Organisations) have updated this 
threshold to a more stringent level.  
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80. Reliability: Different HbA1c tests could provide different results. However, the threshold chosen 
was judged high enough so that no patient, regardless of the test used or health condition should exceed the 
threshold. 
Feasibility 
81. Data availability: HbA1c levels are available for eleven countries (Table 23). The screening data 
are supplied for a range of years. Some countries provided data that slightly deviated from the OECD age 
range requested. Some countries used population surveys, and others sampled from clinics or hospitals. 
One country used a sample from a specialty clinic, which may not be representative of diabetes care 
nationally. One country provided data with a definition that was significantly more rigorous than the 
OECD definition. (Although another country, while supplying the data as requested, regularly uses the 
more rigorous target as well.) One country provided data for a specific ethnic group that is not 
generalisable to the national level. 
82. Comparability issues: Detailed documentation and assessment is provided in Table 24. The 
differences in years provided at age deviations do not appear to be significant threats to validity. The 
variation in definition of poor glucose control (HbAc1>9.5%) is a significant problem with respect to 
international comparability. The differing sampling techniques are likely to pose threats to comparability. 
83. Overall assessment: Eleven countries could provide data on this indicator. It appears that some of 
the data stem from research studies and may not be regularly collected. Data would be available in patient 
records, but would require a review of patient records which currently is not routinely done in most 
national data collection systems. 
 
Table 23. HbA1c level indicating poor glucose control 
Country Diabetic patients with HbA1c levels >9.5% Data year Age
Australia 10.9 1999-2000 25-75
Finland
17.7 
type 1 diabetics: 28.1 
type 2 diabetics: 12.5
2000
France
missing: 7.9  
<=6.5: 26.6 
[6.5-8]: 40.3 
[8-10]: 20.9 
>10: 4.3
2001
Germany 16.4 1998 18-75
Italy 10.7 2003 14+
Mexico 20.8 2002 18-75
New Zealand 9.9 2001 18-75
Spain 9.5 2000 14+
Sweden PHC 60.0 Hospital Clinics 31.0 2001
United Kingdom 10.6 2004-2005 16+
United States 21.0 1999-2002 18+  
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HbA1c level indicating poor glucose control, sources and methods 
Country Source 
Age 
groups 
included 
Comments 
Australia Australian Diabetes Obesity, 
and Lifestyle Study (AusDiab) 
25-75 Data were weighted to match the age and sex distribution of the 1998 residential population of Australia aged 25 and older. 
Finland A survey among Finnish 
diabetics (a representative 
sample of 3580, of whom 3462 
had their HbAc1 measured) 
  
France "Entred" (survey based upon a 
national sample of diabetic 
patients whose health 
insurance is Caisse nationale 
des travailleurs salariés) 
 Sample of 1 718 patients repaid for insulin or hypoglycaemic agents: a questionnaire was sent to patients and then another to their 
practitioner 
Germany German National Health 
Interview and Examination 
Survey 1998 (Bundes-
Gesundheitssurvey 1998) 
18-75 The result is based on data of a population survey, which included 298 diabetic persons in accordance with the definitions stated above. 
Italy Study "SFIDA" 35-70 Information on metabolic control comes from cross-sectional study involving 12 222 patients with type 2 DB enrolled by 261 DB outpatient 
clinics (more than 1 third of Italian DB outpatient clinics). Data refers to individuals with levels >8% HbA1c. 
Mexico Unidad de Investigación en 
Epidemiología Clínica, Hospital 
de Especialidades Centro 
Médico Nacional Siglo XXI 
18-75 Data based on a representative sample of 1082 type 2 diabetes patients. 
New 
Zealand 
Annual Check Program 18-75 NZ uses proportion with HBA1c>8% as a performance indicator for District Health Boards. This is reported, and targets are set, by ethnicity. 
Spain GEDAPS (Study Group of 
Diabetes in Primary Health 
Care) 
14+ This indicator was based in a sample of 6202 people with diabetes mellitus aged 14 years and older. This sample was obtained from the 
morbidity registries in several centres of primary health care by physicians who participated voluntarily in a program to improve care quality. 
 
Sweden National Diabetes Register  The difference between PHC and hospital clinics is likely to depend on patient selection. The measure can be reported, e.g., per type of 
diabetes, age and sex. 
United 
Kingdom 
Quality and Outcomes 
Framework (QOF), Health and 
Social Care Information Centre 
16+  
United 
States 
National Health and Nutrition 
Examination Survey 
(NHANES), NHQR 
18+ Non-institutionalised diagnosed diabetics 
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Table 24. HbA1c level indicating poor glucose control, comparability issues 
  Comparability Implications 
  Minor Severe 
Possible 1. Age ranges vary 
2. Data available for different years 
 
 
1. Data provided for different definition 
of poor glucose control (HbAc1 > 8%, 
compared to HbAc1 > 9.5%) 
2. Some countries obtain samples from 
population based surveys and some 
from specialised clinics. The 
generalisability of such selected 
samples is unknown.  
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Unlikely  1. Some countries obtain samples from 
population based surveys and some 
from specialised clinics. The 
generalisability of such selected 
samples is unknown. 
 
Possible solutions: 
 
• Footnotes can indicate the year and age range 
• In the future, OECD can work with countries to provide data that is consistent with HCQI 
definition of poor control. 
• Drop or report separately data from countries that cannot provide data that is generalisable to the 
national level. 
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Major amputation in diabetics 
NOTE that this indicator was already tested in (2003-2005) HCQI data collection and it is not yet 
considered suitable for international comparisons by the HCQI Expert Group. It is included in this paper 
to illustrate current data concerns with the indicator and possible future solutions. 
Operational Definition 
Numerator: Number of diabetic patients with major (above or below knee) amputations in a given 
year. 
Denominator: Number of patients with diabetes (type I and type II) ages 18-75 years. 
Importance25 
84. Mortality: Diabetes mellitus was responsible for an estimated 21 deaths per 100,000 people in 
WHO Euro A countries in 2000. This represents 2% of all deaths. 
85. Prevalence: Each year, more than 10,000 Americans with diabetes face decisions related to 
amputation. Two of the main complications of longstanding inadequate glycemic control (indicating poor 
diabetes management) are peripheral vascular disease, the chronic deprivation of blood supply of the legs 
due to arteriolosclerosis, and peripheral neuropathy, damage to the peripheral nervous system. The 
combination of those two complications put diabetics at greater risk for lower extremity lesions. Loss of 
sensation in the foot increases likelihood that minor trauma goes unnoticed, while inadequate blood supply 
results in impaired healing of the wound and greater risk of infection. Thus, osteomyelitis (severe 
infections of the bone) and gangrene (infection induced tissue necrosis) may result. For about 75% of the 
cases, a partial amputation of a foot may be enough to stop the foot ulcer from progressing, but for the 
remaining 25%, it will be necessary to remove the leg from below the knee (Mundell, 2004). Diabetics are 
also at higher risk of developing uninfected necroses of the lower extremities because of vascular 
complications. In the US, minority populations have had the highest rates of amputations and it is thought 
that socioeconomic status is a major factor leading to amputations. Thus, differences in level and 
distribution of wealth may be reflected in the measure together with differences in quality of care.  
86. Cost: Amputations have a large impact on health, particularly on quality of life, and result in 
substantial follow-up cost in the form of rehabilitation, prostheses and disability. 
Scientific Soundness  
87. Face validity: Adequate glycemic control has been shown to reduce the risk and severity of 
neuropathy and vascular complications in diabetics (Renders, 2002). It is also widely believed that careful 
monitoring for an intensive treatment of minor lesions in the presence of neuropathic and arterial disease of 
the extremities can prevent amputations, but only a few randomised trials have been conducted to support 
this (Lavery, 2000). 
88. Construct validity: The main challenge to the construct validity of this indicator is a certain 
disjoint of the underlying concept and the operationalisation. Precisely speaking the concept behind the 
indicator is that proper diabetes management should reduce the risk of severe tissue damage to lower 
extremities. However, the indicator measures amputation rates, a closely related but slightly different 
                                                     
25 For additional discussion on the importance of diabetes, please refer to the discussion above under the retinal exam 
indicator. 
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concept that captures the typical consequence of severe tissue damage. One could also argue that, while 
severe tissue damage is unambiguously negative, the decision to amputate is not so that the indicator does 
not clearly indicate better or worse quality of care. However, many regard major amputation rates as 
reasonable proxy for severe tissue damage rates and thus a valid quality indicator.26 Because of the 
importance of this complication and plausibility of the concept behind the indicator, this measure has great 
potential. But it needs to be further studied before adopting it for international comparisons.  
89. Reliability: As this indicator is derived from hospital discharge information, the ability to 
construct it reliably for international comparisons depends on the comparability of coding and reporting 
practices across countries. Amputation rates should be ascertainable in a reliable fashion in administrative 
data, as is done currently in the US by the Centers for Disease Control and Prevention (NCQA, 2003), 
because such major procedures usually influence hospital payments and are thus reliably reported. But it 
may be difficult to reliably identify the diabetic population, because diabetes may only be recorded as 
comorbid condition rather than the primary reason for admission and coding of such secondary diagnoses 
may vary across countries.  
Feasibility 
90. Data availability: Major amputations in diabetics rates are available for 14 countries (Table 25). 
The data were reported for years ranging from 1994 to 2004. The OECD definition is for all ages, and five 
countries had deviations in the age range. All countries use hospital records for the numerator, but the 
method of estimating the denominator varied. Some countries used previous estimates or population 
surveys to obtain the denominators. Other countries used administrative data to obtain the denominator, 
which would not capture all diabetics but only the diabetics receiving hospital or other medical care, and 
the diagnostic codes to capture the diabetic population varied. One country indicated that hospital records 
may be incompletely coded, and may underestimate the amputations on diabetics. Countries used different 
procedure codes, and even some using the same coding system included different (more or less) 
procedures. Countries used varying inclusion criteria for the procedure, even accounting for differences in 
national coding systems. This is of serious concern to comparability. 
91. Comparability issues: Detailed documentation and assessment is provided below. There are 
serious concerns about comparability, both from the estimation of the denominator, and because different 
procedures are being included, the HCQI project will have to ensure that countries are reporting the same 
type of amputations. 
92. Overall assessment: Fourteen countries provided data on this indicator. While information for 
this indicator might exist in hospital records of other countries as well, it is unclear how many countries 
would be able to construct this indicator on a routine basis. Additionally, a significant amount of analytic 
work will have to be done in order to ensure that the data are internationally comparable. However, data 
comparability and availability for this indicator improved during the project and the indicator may warrant 
examination in the future as part of HCQI indicator updates.  
 
 
 
                                                     
26 The situation is clearly different for minor amputations (e.g., toes), where timely amputations can avoid progression 
of the disease.  
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Table 25.   Major amputation in diabetics, per 10 000 diabetics 
Country
Incidence of 
amputations 
per 10 000 
Data year
Australia 6.3 1999-2000
Austria 13.2 2004
Canada 8.5 1999-2000
Czech Republic 106.3 2005
Finland 27.8 2005
7.0 2004
5.0 2002
France 15.0 2001
Italy 0.1 2004
Mexico 11.8 2005
7.9 2003
Netherlands 7.8 2004
35.0 2000
New Zealand 14.6 2005-2006
68.0 2002-2003
Norway 50.0 1994
Portugal 40.0 2004
51.0 2002
Slovak Republic 138.0 2004
Spain 18.4 2004
Sweden 101.2 2005
87.0 2003
United Kingdom 17.8 2003-2004
23.0 2002-2003
United States 44.0 2002-2004
56.0 1999-2001  
 
Country
Incidence of 
amputations 
per 10 000 
Data year
Latvia 62.8 2005
Non-OECD EU countries
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Major amputation in diabetics, sources and methods 
Country Source 
Age 
groups 
included 
Deviations from 
the definition of 
the denominator 
Deviations from the 
definition of the 
numerator 
Additional 
years 
available 
Comments 
Australia AIHW National Morbidity Database 
 
25+    Measured diabetics (Prevalence from Diabetes and Associated 
Disorders in Australia 2000). Procedures Included: E10-E14 
(diabetes); 44367-02, 44367-01, 44367-00, 44370-00, 44373-00 
(lower extremity excluding toe and foot amputation) 
Austria Numerator: hospital discharge 
statistics, denominator: estimate 
according diabetes report 2004. 
15+     
Canada Numerator: HMDB 1999, CIHI; 
Denominator: National Diabetes 
Surveillance System, 2003, Health 
Canada 
 
20-74  We are using an 
Austrian specific 
classification for 
coding procedures 
(MEL), included are 
amputations of the 
upper leg and of the 
thigh. 
 Includes toes, foot, and ankle. Standardised to OECD Standard 
population. Diabetic Diagnostic Criteria: a. One hospitalisation with an 
ICD-9 code of 250 (diabetes mellitus), selected from the first three 
diagnosis codes on the hospital files or b. Two medical claims with an 
ICD-9 code of 250 within 730 day, selected from the first diagnostic 
code. National, full population. Procedures Included: 1. Numerator 
CCP codes: 96.14 amputation of lower leg; 96.15 amputation of thigh 
and articulation of knee in conjunction with ICD-9 code 250 
Czech 
Republic 
National Health Information System 
(Annual report on outpatient care for 
diabetics) 
Total 
population 
    
Finland Hospital Discharge Registry     This number comes if persons are named diabetics if they have had 
the diagnosis at any previous visit to hospital in spite of the fact that it 
is not mentioned at the discharge letter from the amputation surgery in 
all cases. The corresponding number is 12.43 if only those cases are 
included where diabetes is mentioned in the discharge letter from the 
amputation surgery care. Denominator: number of diabetics who get 
reimbursed for medication, age 18 and older. 
France "Entred" (survey based upon a 
national sample of diabetic patients 
whose health insurance is Caisse 
nationale des travailleurs salariés) 
18+    Currently the use of exhaustive data from the national hospital 
information system (PMSI MCO) is studied. 
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Country Source 
Age 
groups 
included 
Deviations from 
the definition of 
the denominator 
Deviations from the 
definition of the 
numerator 
Additional 
years 
available 
Comments 
Italy Ministry of Health / ISTAT   Main procedure 
codes: 84.15; 
84.17. All the major 
amputations rates 
for the years 2002-
2004 are expressed 
per 10 000 
diabetics. The 
denominator source 
is the National 
hospital discharges 
database for the 
years 2002-2003 
and for the year 
2004 it is the multi-
purpose survey on 
health status of the 
population and use 
of health services 
conducted by the 
National Institute of 
Statistics. 
The numerator 
represents the 
number of the in-
patients, being no 
less 18 years old, 
with the main surgical 
procedure 84.15 or 
84.17 by ICD-9-CM 
and having the codes 
250.7* as main 
diagnosis and at least 
one secondary 
diagnosis with the 
code 443.81 by 
ICD-9-CM 
2001+ The denominator used for this indicator has been modified. It has 
been supplied by the National Institute of Statistics and it represents 
the estimate of the Italian people suffering from diabetes. 
Multipurpose survey on "health status of the population and use of 
health services" National Institute of Statistics 
Mexico Sistema de Información de Atención 
Integral a la Salud SIAIS-IMSS. 
División Técnica de Información 
Estadística en Salud (DTIES) 
 Population estimate 
based on the data 
include only once 
Diabetic patients 
type I and II over 20 
years that had at 
least one 
consultation during 
2005. 
 
Yes, the age included 
is Intervals are 20 
years and older. 
 Numerator includes ICD-9 84.10, 84.15 and 84.17 codes and these 
are all de procedures effectuated during 2005 in the diabetic 
population. 
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Country Source 
Age 
groups 
included 
Deviations from 
the definition of 
the denominator 
Deviations from the 
definition of the 
numerator 
Additional 
years 
available 
Comments 
Netherlands National Medical Registry, owned by 
PRISMANT. Calculations and 
methods by Statistics Netherlands in 
cooperation with Institute for Public 
Health and the Environment 
 
18+ number of diabetes 
patients, registered 
by GPs. 
Number of patients 
discharged in a one-
year period, with a 
primary or secondary 
diagnosis of diabetes 
mellitus, and who had 
an amputation of the 
leg (Amputation 
through tibia/fibula or 
femur). 
 In the Netherlands we do not have a registry of patients who ever had 
an amputation. However, we can calculate the number of amputations 
done in the hospital in a year among patients with diabetes mellitus. 
So we measure the hospital discharge rate, instead of a prevalence 
ratio. We do not have a diabetes register, either. However, we can 
make an estimation of the prevalence of diabetes on the basis of 
registries in general practice. In the Netherlands people are listed by 
name in a general practice, so that the underlying practice population 
by age and sex is known and the denominator of the epidemiological 
fraction can be determined. Direct access to a medical specialist and 
other forms of care is only possible after a referral from the general 
practitioner, except for emergency care. Besides, medical specialists 
inform the GP about the diagnoses made. Consequently, most health 
problems presented to health care are known by GPs.  The 1-year 
prevalence is the average of the prevalence ratios of five registries in 
general practice. For most registries, average prevalence ratios are 
computed for 2000-2004. In total 128 general practices of 4.533 Dutch 
practices (2005 January 1st) took part in these registries (2.8%). In all 
rates, clinical admissions (with one overnight stay or more) and 
admissions without an overnight stay (=day care) were included. 
Discharges from small specialised hospitals are excluded. We used a 
data file obtained by record linkage of the National Medical Registry to 
the Municipal Basis Registry. Discharges were linked by data of birth, 
sex, date of admission, and postcode. About 85% of all discharges 
could be linked, so we could calculate rates on the basis of persons 
instead of discharges. Because some groups do have a smaller 
probability of being linked, a correction is applied. As a consequence, 
the calculated rates are representative for all patients discharged 
because of an amputation in the Netherlands. To get an idea of the 
extent of the completeness of the medical registry with regard to 
registration of diabetes as primary or secondary diagnosis among 
patients with an amputation, we computed the numbers of discharges 
(not patients!) for amputation with or without diabetes and traumas. 
Conclusion: for 2,529 cases, nor diabetes neither a trauma is 
registered as the cause of amputation. Other causes can be 
expected, but it is also possible that diabetes is underreported as a 
primary or secondary diagnosis in these cases. 
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Country Source 
Age 
groups 
included 
Deviations from 
the definition of 
the denominator 
Deviations from the 
definition of the 
numerator 
Additional 
years 
available 
Comments 
New 
Zealand 
National Minimum Data Set (NMDS) 
2005-2006 
 
 An estimate based 
on the 2002-2003 
New Zealand 
Health Survey and 
an assumed 4% 
annual increment. 
Major amputation is 
defined as an 
amputation below 
knee (44367-02), 
disarticulation at knee 
(44367-01), 
amputation above 
knee (44367-00), 
amputation at hip 
(44370-00) and 
hindquarter 
amputation (44373-
00). 
 Publicly funded events. 
 
Norway Hospital records in the form of patient 
journals and operation theatre 
protocols, compared to national 
statistics on amputations, from 4 
counties. The county records show 
that the national statistics. (from the 
NPR, Norwegian Patient Register) 
are of very high quality. The national 
statistics for 1994, the only year 
reviewed in detail, showed 94-98% of 
the actual amputations performed on 
diabetics in 4 counties. 
18+    Criteria: ICD-10 codes. Regional population, generalisable to nation. 
Procedures Included: ICD9-250 + procedure code O 8716-19-
Diabetes+non-traumatic major amputation. 
Portugal Hospital discharges-- annual data 
from diagnosis related groups 
(DRGs) 
19-74    Only the data from the hospitals belonging to the National Health 
Services are included. Discharges with principal and associated 
diagnosis-- Diabetes Mellitus, code 250- IDC9-CM. National, full 
population. Procedures Included: ICD9.CM code 84.1 
Slovak 
Republic 
NHIC      
Spain Numerator: Hospital Discharge 
Minimum Data Set (Conjunto Mínimo 
Básico de Datos CMBD). Ministerio 
de Sanidad y Consumo. Instituto de 
Información Sanitaria. Registro de 
altas 2004. Denominator: Health 
Interview Survey 2003. 
All  Numerator coding: 
ICD-9-Diag 250 (any 
diagnostic) + 
procedure codes 84, 
15 or 84, 16 or 84, 17 
 Discharges cover public hospital only (75% of total country 
discharges). Needs to be adjusted by others risk factors: age. Other 
data: by sex (male: 24.27, female: 13.4) 
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Country Source 
Age 
groups 
included 
Deviations from 
the definition of 
the denominator 
Deviations from the 
definition of the 
numerator 
Additional 
years 
available 
Comments 
Sweden National Diabetic Register, covering 
approximately 30% of all diabetics in 
Sweden 
18-75    Sweden does not differentiate between Type I and Type II diabetes in 
the Register. National, representative sample. 
United 
Kingdom 
Numerator: Hospital Episode 
Statistics 2002/03, OPCS procedure 
code X9-10 and any diagnosis field of 
diabetes (ICD10-E10-14). 
Denominator: Health Statistics 
Quarterly 14, estimated prevalence 
from GPRD data for 1998 
All    This indicator should be taken cautiously because (a) diabetes is 
incompletely coded in hospital admissions data and (b) the 
denominator is estimated. Data are for England only. Criteria: 
Numerator: ICD10 E10-14, for Denominator criteria see Health 
Statistics Quarterly 14. National, full population. Procedures Included: 
OPCS procedure code X9-10 and any diagnosis field of diabetes 
(ICD10 E10-14) 
United 
States 
Numerator: National Hospital 
Discharge Survey, denominator: 
National Health Interview Survey. 
CDC NCHS National Hospital 
Discharge Survey 
All    US civilian persons who report that they have ever been diagnosed 
with diabetes. National, representative sample 
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Non-OECD EU countries 
Country Source 
Age 
groups 
included 
Deviations from 
the definition of 
the denominator 
Deviations from 
the definition of 
the numerator 
Additional 
years 
available 
Comments 
Latvia Register of the Patients of 
Diabetes Mellitus 
 
 All patients of 
diabetes (type I 
and type II) in the 
age 18 and over, 
who are include 
in the Diabetic 
Register. It 
includes patients 
who are in 
primary care and 
those in hospitals 
who are 
registered by 
their physician as 
a diabetic in the 
register. 
Number of diabetic 
patients with major 
(above or below 
knee) amputations 
in given year. The 
number isn't very 
correct, because 
lower extremity 
amputations are 
defined as "yes" or 
"no" in Diabetic 
Register Card 
(procedure code is 
not included, and 
some amputations 
maybe weren't 
related to diabetes 
mellitus. 
 Diabetic Register does not cover all population of diabetics, 
because there are unregistered cases (problem with data 
collection from Family doctors). 
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Table 26.   Major amputation in diabetics, comparability issues 
 Comparability Implications
 Minor Severe 
Possible 1. Data available for different years 
2. Data available for slightly different 
age ranges 
3. Different procedure codes 
included. Unclear how comparable 
they are between countries. 
1. Different diagnostic codes 
used to capture diabetic 
population in hospital 
discharge data. 
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Unlikely  1. For the denominator, 
population based surveys and 
data obtained from clinical 
surveys or records may not be 
fully comparable.  
2. Some countries indicated 
that the administrative records 
may underreport diabetes 
because of incomplete 
records. 
 
Possible solutions: 
• Footnotes can indicate the year and age deviations 
• Footnote (or drop if serious) if there are concerns that administrative data underreport diabetes.  
• Data collected with the denominator from population surveys should be separate from those 
obtained from clinical surveys or records. 
• OECD will need to work with countries to ensure that comparable procedures are used to calculate 
this indicator. 
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Post-operative hip fracture rate 
NOTE that this indicator was already tested in (2003-2005) HCQI data collection and it is not yet 
considered suitable for international comparisons by the HCQI Expert Group. It is included in this paper 
to illustrate current data concerns with the indicator and possible future solutions. 
Operational Definition 
Source: Agency for Healthcare Research and Quality Patient Safety Indicators (AHRQ PSIs). 
Numerator: Patients experiencing an in-hospital hip fracture OR fall as defined by the CSP: 
secondary diagnosis only and excluding patients with trauma or metastatic cancer as any diagnosis; 
excluding patients with principal diagnosis of seizure, syncope, stroke, coma, cardiac arrest, or 
poisoning; excluding patients in MDC 8. 
Denominator: Inpatients undergoing major surgery OR minor or miscellaneous surgery OR invasive 
cardiac procedures OR invasive radiologic procedures OR endoscopy OR medical patients OR all 
patients as defined by the CSP.  
Importance 
93. Clinical significance: Falls are a leading cause of adverse event in acute care hospitals. Up to 20% 
or 1 in 5 elderly people fall during recovery from illness (many patients are at risk because of 
problematic medication effect, rehabilitation, etc). Falls are associated with functional disability and injury, 
increased length of stay, and risk of nursing home placement from hospital. Patient falls are also a 
significant liability issue for hospital risk-management, because many falls and their damaging 
consequences are preventable. Falls may be caused by the persons health status, response to medication or 
anaesthesia, external factors (wet floor, etc.) or other factors. Reducing risk of falls is an important quality 
of care issue for hospitals (Iezzoni, 1994). 
94. The incidence of hip fracture is related with demographic factors (and others) such as: age, gender, 
racial difference, rural vs. urban, institutional vs. community dwelling and family history. Two thirds of all 
hip fractures occur among women. Hip fracture incidence rate from different countries within Europe 
appear to vary substantially with the highest incidences found in Northern Europe and the lowest in 
Mediterranean area. Highest rates are found in white populations and lower rates are found in Asian and 
developing countries. Rural population have lower incidence than urban population. Institutionalised 
elderly people also have higher rates. 
95. Policy importance: Prevention of falls is an important factor in hospital management. Its an 
important aspect for patients, hospital managers, and visitors. Failure to provide safe conditions in hospital, 
and a safe environment can lead to falls, which may result in injuries. These injuries may lead to 
complications and decrease in mobility. In other hand, falls may have impact in patients perception of 
safety and psychological well-being. 
Scientific Soundness 
96. Evidence supporting indicator validity: The review of this indicator by the AHRQ study group 
constructing the AHRQ PSIs found post-operative hip fracture generally performs well on several different 
dimensions, including reliability, bias, relatedness of indicators, and persistence over time (AHRQ, 2005). 
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A study conducted a study in Canadian province of Saskatchewan from 1983 through 1985. They found six 
factors independently associated with a significant increased risk of in-hospital hip fracture: impaired 
vision; unassisted ambulation, confusion, psychotropic drug use, lowest height tercile and prior in-hospital 
fall (Lichenstein, 1994). Another study from Canada noted the preventability of falls in the hospital setting 
(OConnor, 2006). The American Nurses Association, its state associations, and the California Nursing 
Outcomes Coalition have identified the number of patient falls leading to injury per 1,000 patient days 
(based on clinical data collection) as a nursing-sensitive quality indicator for acute care 
settings(McDonald, 2002).  
Feasibility 
97. Data availability: Postoperative hip-fractures or fall rates are available for 13 countries (Table 
27). The data were reported for years ranging from 2002 to 2005. The OECD definition is for all ages, and 
five countries had deviations in the age range. All countries use hospital records for the numerator and 
denominator, but the exclusion criteria of OECD definition were not apply in most of the countries and the 
codes included varied widely across reporting countries. Several countries expressed their concern about 
the underestimation of these events due to the scarce codification of patient safety issues. Thus hospital 
records may be incomplete. All this is of serious concern to comparability. 
98. Comparability issues: Detailed documentation and assessment is provided in Table 28. There are 
serious concerns about comparability both from the estimation of the denominator, and the numerator, the 
HCQI project will have to ensure that countries apply the same inclusion and exclusion criteria in their 
calculations. Also some countries rely on ICD9 for codification while others do on ICD10, the impact of 
this choice in the rates yielded needs to be evaluated by the Secretariat.  
99. Overall assessment: thirteen countries provided data on this indicator. While information for this 
indicator might exist in hospital records of other countries as well, it is unclear how many countries would 
be able to construct this indicator on a routine basis. Additionally, a significant amount of analytic work 
will have to be done in order to ensure that the data are internationally comparable. However, data 
comparability and availability for this indicator is likely to improve due to the work of the Patient Safety 
Expert Subgroup and the indicator may warrant examination in the future as part of HCQI indicator 
updates.  
 
Table 27. Post-operative hip fracture rate per 100 discharges 
Country Rate  per 100 Data year
Australia 0.77 2004-2005
Canada 0.07 2004-2005
Denmark 0.63 2005
Finland 0.28 2005
Italy 0.07 2004
Japan 0.01 2005
Mexico 0.08 2005
Netherlands 0.05 2004
Norway 0.57 2005
Portugal 1.76 2004
Spain 0.08 2004
Sweden 0.05 2004
United States 2.60 2002  
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Post-operative hip fracture rate, sources and methods 
Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the 
definition of the numerator 
Additional years 
available Comments 
Australia AIHW National Hospital 
Morbidity Database 
 
 Australian definitions of Medical, 
Surgical and Other discharges based 
on Australian Refined Diagnosis 
Related Groups (AN-DRG) version 
5.1 have been used. These may not 
match international definitions. 
 2004-2005 Discharges as principal diagnosis or any 
diagnosis also available. 
Austria       
Canada Discharge Abstract 
Database 
 Cases from Quebec are excluded due 
to differences in data collection. ICD-
9-CM codes used: 304.00-02, 304.10-
12, 304.20-22, 304.30-02, 304.40-02, 
304.50-52, 304.60-62, 304.70-72, 
304.80-82, 304.90-92, 305.20-22, 
305.30-32, 305.40-42, 305.50-52, 
305.60-62, 305.70-72, 305.80-82, 
305.90-92, E9500, E9501, E9502, 
E9503, E9504, E9505, E9506, E9507, 
E9508, E9509, E9510, E9511, E9518, 
E9520, E9521, E9528, E9529, E9530, 
E9531, E9538, E954, E9550, E9551, 
E9552, E9553, E9554, E9555, E9554, 
E956, E9570, E9571, E9572, E9580, 
E9581, E9582, E9583, E9584, E9585, 
E9586, E9587, E9588, E9589. ICD 10 
codes used:F112, F132, F142, F122, 
F152, F162, F182, F192, F192, F192, 
F121, F161, F131, F111, F141, F151, 
F131, F191, F55, X60, X61, X61, X61, 
X64, X64, X68, X69, X68, X69, X66, 
X66, X67, X67, X67, X67, X67, X70, 
X70, X70, X71, X72, X73, X73, 
X7408, X7408, X75, X7409, X78, 
X80, X80, X80, X81, X76, X76, X83, 
X83, X82, X83, X83, X83, X84. 
We used ICD-10-CA codes 
instead of ICD-9-CM. 
 
1995-1996 to 2004-
2005. 
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Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the 
definition of the numerator 
Additional years 
available Comments 
Denmark National hospital discharge 
register 
 
    The numbers provided are preliminary and will 
change as the register still receives data from 
the hospitals. 
Finland Hospital Discharge Register      
Italy Ministry of Health - National 
discharges database 
 All surgical discharges (18+) without 
any exclusion. 
 2001+ Numerator: count of different patients with code 
for hip fracture in any secondary diagnosis 
field. Value: numerator/denominator*100. 
Japan Japan Medical Data Center, 
Inc 
 
All     
Mexico SIAIS.- Sistema de 
Información de Atención 
Integral a la Salud IMSS 
(DTIES) División Técnica de 
Información Estadística en 
Salud 
20+ 20 years and older and it refers to ICD 
10 Codes equivalent (unofficial ICD-9, 
ICD-10 codes 
20 years and older and to ICD 
10 Codes S720-22 
 Nationally representative 
Netherlands National Medical Registry, 
owned by PRISMANT. 
Calculations and methods by 
Statistics Netherlands in 
cooperation with Institute for 
Public Health and the 
Environment 
18+ All discharges with surgery excluding 
discharges with the following reasons 
for admission: poisoning due to 
anaesthetics, drug dependence, drug 
abuse or self-inflected injury. 
Following ICD-9-CM codes: 304, 
305.2-305.9, 968.1-4, 968.7, E855.1, 
E950-E958. 
  In calculating the rate of post-operative hip 
fracture, three selection steps were made: 1. 
selection of discharges with surgery (Dutch 
Classification of Medical Specialist CMSV, 
version 2.6: 5011-5719, 5738-5999, 8724-, 
8851, 9277. Surgery of the hip CMSV 2.6 
codes: 5789.54, 5790.06, 5790.13, 5790.24, 
5792.06, 5792.16, 5792.23, 5792.33, 5792.34, 
5792.6, 5815, 5816. 2. Exclusion of discharges 
with drug dependence, drug abuse or self-
inflected injury as primary reason for 
admission. 3. Calculating all discharges with a 
hip fracture as secondary diagnosis. Hip 
fractures as a secondary diagnosis after hip 
surgery, were included. Includes clinical 
admissions (with one overnight stay or more) 
and admissions without an overnight stay (=day 
care). Discharges from small specialised 
hospitals are excluded. 
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Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the 
definition of the numerator 
Additional years 
available Comments 
Norway Norwegian Patientregister    2001+ Numerator: ICD-10 codes which are 
comparable with the given ICD-9 codes are 
used. Diagnoses: S72.0, S72.1, S72.2. 
Norwegian Patientregister has no unique 
patient identifier. This means that the same 
person may appear in the statistics several 
times during the year if this person gets 
treatment in different hospitals during the year. 
Portugal DRGs    1993-2004 Numerator: Discharges with ICD-9-CM for hip 
fracture in any diagnosis field; denominator: all 
surgical discharges 81.53 age 18 and over 
Spain Hospital Discharge Minimum 
Data Set (Conjunto Mínimo 
Básico de Datos CMBD). 
Ministerio de Sanidad y 
Consumo. Instituto de 
Información Sanitaria. 
Registro de altas 2004 
  Only discharge age > 18 and 
surgical DRG (no exclusions 
1997 No indications about the hip fracture being 
suffered after o earlier than the main surgical 
procedure. 
United 
States 
Agency for Healthcare 
Research and Quality 
(AHRQ) Patient Safety 
Indicators (PSI) 
 Inpatient hospital surgical discharges 
age 18 and over who were not 
susceptible to falling, excluding 
patients with diseases and disorder of 
musculoskeletal system and 
connective tissue; patients admitted 
for seizures, syncope, stroke, coma, 
cardiac arrest, poisoning, trauma, 
delirium, psychoses, or anoxic brain 
injury; patients with metastatic cancer, 
lymphoid malignancy, bone 
malignancy, or self-inflicted injury; and 
obstetrical patients. 
Subset of the denominator with 
any secondary diagnosis 
indicating hip fracture (ICD-9-
CM code 82008203, 8208, 
8209). 
 Rates are adjusted by age, gender, age-gender 
interactions, comorbidities, and Diagnosis 
Related Groups (DRG) clusters. When 
reporting is by age, the adjustment is by 
gender, comorbidities, and DRG clusters; when 
reporting is by gender, the adjustment is by 
age, comorbidities, and DRG clusters. Although 
not all States participate in the HCUP 
database, the Nationwide Inpatient Sample is 
weighted to give national estimates using 
weights based on all U.S. community, non-
rehabilitation hospitals in the American Hospital 
Association Annual Survey of Hospitals. 
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Table 28.   Post-operative hip fracture rate, comparability issues 
  Comparability Implications
  Minor Severe 
Possible 1. Data available for different years 
2. Different procedure codes included. Unclear 
how comparable they are between countries. 
1. Different diagnostic codes and code 
systems used across countries (ICD-9 
versus ICD-10). 
Po
ss
ib
ili
ty
 to
 c
or
re
ct
 th
e 
de
vi
at
io
n?
 
Unlikely  1. Some countries indicated that empirical 
testing of this indicator has indicated the 
administrative records may underreport 
safety issues because of incomplete 
records. 
 
Possible solutions: 
• Footnotes can indicate the year and age deviations 
• Footnote (or drop if serious) if there are concerns that administrative data underreport particular 
safety issue.  
• OECD will need to work with countries to ensure that comparable procedures are used to calculate 
this indicator. 
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Transfusion reaction rate 
NOTE that this indicator is new; it has been incorporated for the first time in the 2006 HCQI data 
collection. It is included in this paper to illustrate current data concerns with the indicator and possible 
future solutions.   
Operational Definition 
Source: AHRQ/CIHI Safety Indicators. 
 
Numerator: Discharges with ICD-9-CM codes for transfusion reaction in any secondary diagnosis 
field per 100 discharges. 
 
Denominator: All medical and surgical discharges, 18 years and older or MDC 14 (pregnancy, 
childbirth or puerperium). 
Importance  
100. Clinical significance: Transfusion of wrong blood type to the wrong person may have serious 
effects. The risk of adverse outcome from erroneous transfusion rivals or exceeds current estimates of the 
risk of acquiring infectious disease by transfusion (Linden, 2000). According the same authors the systems 
must be redesigned to allow minor fluctuations in human performance, especially in routine tasks. The use 
of systems designed to prevent specific errors may be helpful (such as convenient access to standard 
operating procedures instructions in work areas, a blood component lock system that will not allow the 
access of a component unless there is patient wristband and blood component match, etc.). 
101. Recent studies on human error in medicine followed methods derived from the experience gained 
while analysing large-scale technological disasters (Eagle, 1992; Reason, 1990). They recognised that 
medical, like technological, accidents nearly always require the conjunction of two types of failures: active 
failures, mistakes happening while performing a task, and latent failures, or management system errors. 
The latter ones are more difficult to perceive, because they constitute silent failures residing in a system 
until human error allows the expression resulting in a major accident (Baele, 1994). According to the 
author the detection and the correction of the latter type failure, ideally before the occurrence of accidents, 
is more efficient in improving the overall quality of a system than any action aiming at only active failures. 
Clinician panellists from AHRQ consider that this indicator very likely reflects actual medical errors. As 
expected, this indicator proved to be very rare with less than 1 per 10 000 cases at risk. 
102. Scientific Soundness  
103. Evidence supporting indicator validity: This indicator was originally proposed by Iezzoni et 
al.(1992) as part of the Complications Screening Programme (CSP sentinel events), along with gas 
gangrene, CNS abscess, anoxic brain injury, accidental puncture or laceration, wound dehiscence, and 
foreign body left in (all of which were omitted from this indicator). It was also included as one component 
of a broader indicator (adverse events and iatrogenic complications) in AHRQs original HCUP Quality 
Indicators. It was proposed by Miller et al. (2001) in the original AHRQ PSI Algorithms and Groupings, 
although their definition also includes minor transfusion reactions (999.8), which were omitted from this 
indicator. 
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Operational Issues 
104. Some countries have been made efforts to quantify the magnitude of the non-infectious risks of 
transfusions include the voluntary SHOT programme; the New York State Department of Health 
mandatory reporting programme of transfusion  related incidents, accidents and errors; the French 
Haemovigilance System; and the Belgium SANGUIS Group (Callum, 2001). However, the data may not 
be available in countries without similar programmes. Moreover, experience in a number of countries as 
well as in the US has shown that transfusion reactions are very rare events, even within the patient safety 
indicator group. A study applying the AHRQ PSIs to the US Veterans Administration hospital data found 
that the transfusion reactions only occurred at a rate of 0.007 per 1000 discharges, the least frequent event 
across the PSIs (Rosen, 2005).  
Feasibility 
105. Data availability: transfusion reaction rates are available for 10 countries (Table 29). The data 
were reported for years 2004-2005. Five countries reported deviations from OECD definitions in the 
calculation of numerator and or denominator. The main issue in many of the countries seems to be the 
restriction of the codes for the numerator to those corresponding to major severe reactions to transfusion. 
The age related criteria were also unclear for some countries.  
106. Also some countries used different procedure codes. This is of serious concern to comparability. 
107. Comparability issues: Detailed documentation and assessment is provided in Table 30. There are 
serious concerns about comparability, both from the estimation of the denominator and numerator because 
different codes are being included; the HCQI project will have to ensure that countries are reporting the 
same type of amputations. Some countries indicated that empirical testing of these indicators has indicated 
the administrative records may underreport safety issues because of incomplete records 
108. Overall assessment: Ten countries provided data on this indicator. While information for this 
indicator might exist in hospital records of other countries as well, it is unclear how many countries would 
be able to construct this indicator on a routine basis. Additionally, a significant amount of analytic work 
will have to be done in order to ensure that the data are internationally comparable. However, data 
comparability and availability for this indicator is likely to improve due to the work of the Patient Safety 
Expert Subgroup and the indicator may warrant examination in the future as part of HCQI indicator 
updates.  
Table 29. Transfusion reaction rate per 100 000 discharges 
Country Rate per 100 000 Data year
Australia 0.31 2004-2005
Canada 1.09 2004-2005
Czech Republic 0.08 2005
Denmark 0.58 2004
Finland 0.08 2004
Italy 1.05 2004
Netherlands 0.21 2005
Portugal 19.30 2004
Spain 0.61 2004
Sweden 29.40 2004  
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Transfusion reaction rate, sources and methods 
Country Source Deviations from the definition of the denominator 
Deviations from the 
definition of the numerator 
Additiona
l years 
available 
Comments 
Australia AIHW National Hospital Morbidity 
Database 
 
Australian definitions of Medical, 
Surgical and other discharges 
based on Australian Refined 
Diagnosis Related Groups (AN-
DRG) version 5.1 have been 
used. These may not match 
international definitions. 
 2004-
2005 
Discharges as principal diagnosis or any diagnosis 
also available. 
Canada Discharge Abstract Database Cases from Quebec are 
excluded due to differences in 
data collection 
 1995-
1996 to 
2004-
2005 
The selection of surgical/medical/MDC14 was based 
on the CMG grouping 
Czech 
Republic 
UZIS CR (Annual Report on the 
activity of Transfusion Services) 
Total number of hospitalised 
persons 
Includes just number of 
serious adverse reactions - 
immunological haemolysis 
due to AB0 incompatibility, 
immunological haemolysis 
due to other allo-antibody. 
 Our Annual Reporting System was conformed to the 
European Commission Directives: 2005/61/EC and 
2002/98/EC concerning setting standards of quality 
and safety for the collecting, testing, processing, 
storage and distribution of human blood components. 
No other data concerning transfusion reactions are 
collected. 
Denmark National Hospital Discharge Register    Data is for the year 2004. The denominator does not 
include MDC 14 
Finland Hospital Discharge Register  Numerator: also age 18 and 
older. There was 1 case in 
123 203. 
  
Italy Ministry of Health - National 
database of discharges 
All surgical and medical 
discharges, 18 years and older 
Only ICD 9 CM 999.6 or 999.7 
in any secondary diagnosis 
field 
2001 +  
Netherlands National Medical Registry, owned by 
PRISMANT. Calculations and 
methods by Statistics Netherlands in 
cooperation with Institute for Public 
Health and the Environment 
Consists of all surgical and 
medical discharges (18+ or 
MDC 14). We assume OECD 
means all hospital admissions 
for persons 18 years or older 
and hospital admission among 
adolescents for MDC 14. We 
It is unclear whether 
newborns and children have 
to be included. Nevertheless, 
we decided to present only 
data for adults (18+) and girls 
of 10 years old or older. 
 From the National Medical Registry we include all 
discharges with a transfusion reaction as primary or 
secondary admission diagnosis. In all rates, clinical 
admissions (with one overnight stay or more) and 
admissions without an overnight stay (=day care) were 
included. Discharges from small specialised hospitals 
are excluded, for example eye clinics, clinics for 
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Country Source Deviations from the definition of the denominator 
Deviations from the 
definition of the numerator 
Additiona
l years 
available 
Comments 
expected as denominator the 
number of transfusions, number 
of blood units administered or 
the number of patients with a 
transfusion. Major Diagnostic 
Categories (MDCs) are not 
used in all countries, at least not 
in the Netherlands. We assume 
that MDC 14 refers to health 
status described in Chapter 11 
of ICD-9 (codes 630-676) and 
several V-codes (V22-V24, V27, 
V28). The denominator is only 
defined for persons 18 years or 
older and women admitted for 
problems occurring during 
pregnancy, childbirth and 
puerperium. 
epilepsy, asthma clinics, clinics for rehabilitation 
Portugal DGRs   1993-
2004 
The denominator represents the number of blood 
transfusions 
Slovak 
Republic 
    Alternative available source could be the record of 
patient complaints handled at the Bureau for 
Supervision of Health Care. 
Spain Hospital Discharge Minimum Data 
Set (Conjunto Mínimo Básico de 
Datos CMBD). Ministerio de Sanidad 
y Consumo. Instituto de Información 
Sanitaria. Registro de altas 2004. 
 Selected age also (same 
criteria than denominator) 
From 
1997 
The term "reaction" also includes codes (ICD9) related 
to other type of reactions, apart from incompatibility or 
mismatched blood. 
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Table 30. Transfusion reaction rate, comparability issues 
  Comparability Implications
  Minor Severe 
Possible 1. Different ages included  
2. Different procedure codes included. Unclear 
how comparable they are between countries. 
1. Different diagnostic codes and code 
systems used across countries (ICD-9 
versus ICD-10). 
Po
ss
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Unlikely  1. Some countries indicated that 
empirical testing of these indicators 
has indicated the administrative 
records may underreport safety issues 
because of incomplete records. 
 
Possible solutions: 
• Footnotes can indicate the year and age deviations 
• Footnote (or drop if serious) if there are concerns that administrative data underreport particular 
safety issue.  
• OECD will need to work with countries to ensure that comparable procedures are used to calculate 
this indicator. 
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Uncontrolled diabetes admission rate 
NOTE that this indicator is new and has been incorporated for the first time in 2006 HCQI data collection. 
It is included in this paper to illustrate current data concerns with the indicator and possible future 
solutions.   
Operational Definition 
Source: AHRQ Prevention Quality Indicators. 
 
Numerator: All non-maternal discharges of age 18 years and older with ICD-9-CM principal 
diagnosis code for uncontrolled diabetes, without mention of a short-term or long-term 
complication. 
 
Denominator: Total population.  
Importance  
109. Clinical significance of process or outcome: Avoidable hospitalisations are those conditions that 
could have been avoided if proper ambulatory care had been received and can thus be seen as a measure of 
access to appropriate medical care. While not all admissions for ambulatory care sensitive conditions are 
avoidable, it is assumed that appropriate prior ambulatory care could prevent the onset of this type of 
illness or condition, control an acute episodic illness or condition, or manage a chronic disease or 
condition. A disproportionately high rate is presumed to reflect problems in obtaining access to primary 
care (Weissman, 1992). In terms of avoiding uncontrolled diabetes admission rates, in the US, the Healthy 
People 2010 effort has set a national goal to reduce the rate of admissions for uncontrolled diabetes for 
persons 18-64 years of age from 7.2 per 10 000 to 5.4 per 10 000 population (HHS, 2000). Studies in the 
US have shown similar rates of admissions for uncontrolled diabetes for men and women and across racial 
and ethnic groups, unlike some other preventable hospitalisation indicators for diabetes care (Correa-de-
Araujo, 2006).  
110. Identification of process/outcome as quality problem: The rate of Ambulatory Care Sensitive 
(ACS) hospitalisations is considered an index of access of a population to adequate primary care. These are 
hospitalisations for selected diagnoses some of which might reasonably have been prevented if primary 
care had been received in time. ACS hospitalisations are elevated in low-income areas and in rural/frontier 
areas. 
111. Policy importance: Given the high cost of hospital care and the high prevalence of the disease 
included in this indicator, elevated ACS hospitalisation rates could point not only towards possibilities to 
improve quality but also to substantial cost savings, if better primary care were provided. In addition, the 
ACS hospitalisation rate appears sensitive to the presence or absence of economic barriers to access. It has 
been reported to be lower and/or less correlated with socioeconomic status in countries with national health 
insurance (Billings, 1996). 
112. Susceptibility to being influenced by the health system: Appropriate prior ambulatory care could 
prevent the onset of an illness or condition; control an acute episodic illness or condition; or manage a 
chronic disease or condition (Anderson, 1996). 
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Scientific Soundness  
113. Face validity: Managing chronic diseases to prevent complications and exacerbations is regarded as a 
core function of the primary health care system. Good quality outpatient care of diabetes has been shown to lead 
to reductions in a range of diabetes admissions.  
114. Content validity: As mentioned above, several groups have advocated measures of ACS 
hospitalisation rates. The fact that hospital admission diagnoses are readily available in most countries implies 
that the indicator can be easily constructed. However, it should be mentioned that there remains some 
controversy about this (and similar) measures as a quality indicator, because ACS hospitalisation rates reflect 
access to, as well as quality of, primary care. Also, defining the appropriate level of hospital admission rates for 
those conditions is difficult, because in a subset of cases an admission is clearly warranted. Based on scientific 
studies, this indicator is only moderately precise with area level rate of 34.7 per 100,000 (based on US 
estimates) and a standard deviation of 28.1.27  
Feasibility 
115. Data availability: Uncontrolled diabetes admission rates are available for 13 countries (Table 31). The 
data were reported for years 2004-2005. Eight countries reported deviations from OECD definitions in the 
calculation of numerator. All countries use hospital records for the numerator, but the diagnostic codes to 
capture uncontrolled diabetes admission varied. Countries indicated that hospital records may be incompletely 
coded, and may underestimate the number of admissions.  
116. Comparability issues: Detailed documentation and assessment is provided in Table 32. There are 
serious concerns about comparability from the estimation of the numerator; the HCQI project will have to 
ensure that countries are reporting the same type of admissions. 
117. Overall assessment: Thirteen countries provided data on this indicator. While information for this 
indicator might exist in hospital records of other countries as well, it is unclear how many countries would be 
able to construct this indicator on a routine basis. Additionally, a significant amount of analytic work will have 
to be done in order to ensure that the data are internationally comparable. However, data comparability and 
availability for this indicator is likely to improve due to the work of the Primary Care and Prevention Expert 
Subgroup and the indicator may warrant examination in the future as part of HCQI indicator updates.  
Table 31. Uncontrolled diabetes admission rate 
Country Rate per 100 000 Data year
Australia 18.9 2004-2005
Austria 34.2 2004
Canada 22.1 2004-2005
Czech Republic 364.6 2004
Finland 12.7 2005
Italy 70.9 2004
Japan 294.2 2005
Mexico 7.6 2005
Norway 90.0 2005
Portugal 23.3 2004
Spain 79.9 2004
Sweden 71.9 2004
United States 25.4 NA  
Notes: NA stands for no data available. 
                                                     
27 Agency for Healthcare Research and Quality. Guide to the Prevention Quality Indicators. (Rockville, MD: 
February 2006.) Version 3.0a. 
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Uncontrolled diabetes admission rate, sources and methods 
Country Source 
Age 
groups 
included 
Deviations from the definition of the 
denominator 
Deviations from the definition of 
the numerator 
Addition
al years 
available 
Comments 
Australia AIHW National Hospital 
Morbidity Database 
  ICD-10-AM E10.1, E11.1, E12.1, 
E13.1, E14.1 
  
Austria Statistics Austria 15+  Principle diagnoses given in ICD-10 
codes: E100, E110, E120, E130, 
E140, E101, E111, E121, E131, E141 
 Exclusion of pregnancy, childbirth and 
puerperium is not possible. 
Canada Discharge Abstract Database, 
CIHI 
 Quebec population figures are excluded 
as the numerator excludes Quebec cases 
(see Other Comments below). 
  1. For FY2004, CIHI Coding Standards state 
that a blood glucose level of less than 14 
mmol/L(PC) or 10mmol/L (fasting) in the 
presence of physician documentation that 
the patient was 'uncontrolled' would place 
the case in an 'adequately controlled' code 
because the blood sugar level was not truly 
in the uncontrolled parameters. Therefore, 
the number of cases of 'uncontrolled' 
diabetes (as per the ICD-9-CM rule of coding 
uncontrolled when stated) in Canada is likely 
to be lower than in other jurisdictions. 2. 
Cases were extracted based on a most 
responsible diagnosis of the condition of 
interest. The most responsible diagnosis is 
defined as the one diagnosis or condition 
that can be described as being the most 
responsible for the patients stay in hospital. 
In the event that multiple diagnoses are 
listed, select the most responsible diagnosis 
from the condition associated with the 
longest length of stay or most resource 
intense. 3. Due to an inability to separate 
uncontrolled diabetes cases coded in ICD-9, 
data submitted by the province of Quebec 
are excluded. 
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Country Source 
Age 
groups 
included 
Deviations from the definition of the 
denominator 
Deviations from the definition of 
the numerator 
Addition
al years 
available 
Comments 
Czech 
Republic 
National Registry of 
Hospitalized Patients 
15+ Population 20+ as of 1st of July Includes all hospitalised patients in 
general hospitals for dg. of E10-E14 
  
Finland Hospital Discharge Register    2001+ Overall number was 482 cases. The 
reliability of diagnostic notes is unclear, may 
be an over or underestimation 
Italy Ministry of Health - National 
discharges database 
     
Japan Patient Survey 20+ 20+ Includes all diabetes (ICD9 250)  According to the Patient Survey, the number 
of discharges in September 2005 over 20 
years with primary diagnosis of diabetes was 
estimated as approximately 25 400 (subject 
to wide margin of error inherent in sampling 
survey). Multiplied by 12, the annual number 
of discharges is estimated to be 304 800. 
Divided by Japan's population over 20 as of 
October 2005 [103.56 million], the rate was 
calculated as 24.52 / 100,000 monthly or 
294.24/100 000 annually. Since the Patient 
Survey covers only one month, the 
numerator (estimated 26 700) was multiplied 
by 12. 
Mexico SIAIS.- Sistema de Información 
de Atención Integral a la Salud 
IMSS (DTIES) División Técnica 
de Información Estadística en 
Salud 
20+ Only 20 years and older, exclude 18 and 
19 years old 
Work with ICD 10 Codes (Unofficial 
table ICD 9 and ICD 10 codes 
 Nationwide representative 
Norway Norwegian Patientregister     Numerator: ICD-10 codes which are 
comparable with the given ICD-9 codes are 
used. Main diagnoses: E10.9, E11.9, E12.9, 
E13.9, E14.9. 
Portugal DRGs      
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Country Source 
Age 
groups 
included 
Deviations from the definition of the 
denominator 
Deviations from the definition of 
the numerator 
Addition
al years 
available 
Comments 
Slovak 
Republic 
     Our records do not work with four digit ICD, 
therefore it is not possible to consider 
exclusions. 
Spain Numerator : Hospital Discharge 
Minimum Data Set (Conjunto 
Mínimo Básico de Datos 
CMBD). Ministerio de Sanidad y 
Consumo. Instituto de 
Información Sanitaria. Registro 
de altas 2004. Denominator: 
Health Interview Survey 2003 
  Number of transferred patients from 
other centres not known. 
 National patient records (in-patients) do not 
include information about transferred 
patients from other centres. 
Sweden The Swedish Hospital 
Discharge Register 
     
United 
States 
Agency for Healthcare 
Research and Quality (AHRQ) 
Prevention Quality Indicators 
(PQI) 
 U.S. population age 18 and over. Are 
there any deviations from the definition of 
the numerator? Discharges age 18 and 
over with principal diagnosis of 
uncontrolled diabetes (ICD-9-CM code 
250.02, 250.03) without mention of a 
short-term (ketoacidosis, hyperosmolarity, 
coma) or long-term complication (renal, 
eye, neurological, circulatory, other 
unspecified). Obstetric and neonatal 
admissions and transfers from other 
institutions are excluded. Comments: 
Rates are adjusted by age and gender 
using the total U.S. population for 2000 as 
the standard population. When reporting 
is by age, the adjustment is by gender 
only; when reporting is by gender, the 
adjustment is by age only. Although not all 
States participate in the HCUP database, 
the Nationwide Inpatient Sample is 
weighted to give national estimates using 
weights based on all U.S. community, 
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Country Source 
Age 
groups 
included 
Deviations from the definition of the 
denominator 
Deviations from the definition of 
the numerator 
Addition
al years 
available 
Comments 
non-rehabilitation hospitals in the 
American Hospital Association Annual 
Survey of Hospitals. 
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Table 32.   Uncontrolled diabetes admission rate, comparability issues 
  Comparability Implications
  Minor Severe 
Possible 1. Data available for slightly different age ranges 
2. Different procedure codes included. Unclear 
how comparable they are between countries. 
1. Different diagnostic codes used to 
capture diabetic population in hospital 
discharge data. 
Po
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Unlikely  1. For the denominator, population 
based surveys and data obtained from 
clinical surveys or records may not be 
fully comparable.  
2. Some countries indicated that the 
administrative records may 
underreport diabetes because of 
incomplete records. 
 
Possible solutions: 
• Footnotes can indicate the year and age deviations 
• Footnote (or drop if serious) if there are concerns that administrative data underreport diabetes.  
• Data collected with the denominator from population surveys should be separate from those 
obtained from clinical surveys or records. 
• OECD will need to work with countries to ensure that comparable procedures are used to calculate 
this indicator. 
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Hypertension admission rate 
NOTE that this indicator is new and has been incorporated for the first time in 2006 HCQI data collection. 
It is included in this paper to illustrate current data concerns with the indicator and possible future 
solutions.   
Operational Definition 
Source: AHRQ Prevention Quality Indicators. 
 
Numerator: All non-maternal discharges of age 18 years and older with ICD-9-CM principal 
diagnosis code for hypertension. (Excluding cases: transfer from other institution, MDC 14 
(pregnancy, childbirth, and puerperium or with cardiac procedure codes in any field.  
 
Denominator: Total population.  
Importance  
118. Clinical significance of process or outcome: Avoidable hospitalisations are those conditions that 
could have been avoided if proper ambulatory care had been received and can thus be seen as a measure of 
access to appropriate medical care. While not all admissions for ambulatory care sensitive conditions are 
avoidable, it is assumed that appropriate prior ambulatory care could prevent the onset of this type of 
illness or condition, control an acute episodic illness or condition, or manage a chronic disease or 
condition. A disproportionately high rate is presumed to reflect problems in obtaining access to primary 
care (Weissman, 1992). While not all admissions for hypertension are inappropriate, it has been shown that 
good quality primary care can keep hypertensive patients out of the hospital. Moreover, while hypertension 
is relatively common, hospitalisations for hypertension are relatively rare. One study in the US found that 
hypertension accounted for only 0.5% of total admissions for ambulatory care sensitive conditions 
(Blustein, 1998).  
119. Identification of process/outcome as quality problem: The rate of Ambulatory Care Sensitive 
(ACS) hospitalisations is considered an index of access of a population to adequate primary care. These are 
hospitalisations for selected diagnoses some of which might reasonably have been prevented if primary 
care had been received in time. ACS hospitalisations are elevated in low-income areas and in rural/frontier 
areas. A Italian study on the causes of uncontrolled hypertension concluded that, in addition to patient level 
factors, the doctor-patient relationship and a good quality of primary care were significant factors in 
avoiding adverse outcomes (Degli Esposti, 2004). 
120. Policy importance: Given the high cost of hospital care and the high prevalence of the disease 
included in this indicator, elevated ACS hospitalisation rates could point not only towards possibilities to 
improve quality but also to substantial cost savings, if better primary care were provided. In addition, the 
ACS hospitalisation rate appears sensitive to the presence or absence of economic barriers to access. It has 
been reported to be lower and/or less correlated with socioeconomic status in countries with national health 
insurance (Billings, 1996).  
121. Susceptibility to being influenced by the health system: Appropriate prior ambulatory care could 
prevent the onset of an illness or condition; control an acute episodic illness or condition; or manage a 
chronic disease or condition (Anderson, 1996).  
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Scientific Soundness 
122. Face validity: Managing chronic diseases to prevent complications and exacerbations is regarded 
as a core task of the primary health care system. Little empirical evidence exists as to the validity of the 
hypertension avoidable hospitalisations indicator in particular. However, studies have shown that there are 
significant differences across age and sex, and AHRQ recommends that this indicator be ultimately age 
and sex adjusted (AHRQ, 2006).  
123. Content validity: As mentioned above, several groups have advocated measures of ACS 
hospitalisation rates. The fact that hospital admission diagnoses are readily available in most countries 
implies that the indicator can be easily constructed. However, it should be mentioned that there remains 
some controversy about this (and similar) measures as a quality indicator, because ACS hospitalisation 
rates reflect access to, as well as quality of, primary care. Also, defining the appropriate level of hospital 
admission rates for those conditions is difficult, because in a subset of cases an admission is clearly 
warranted.  
Feasibility 
124. Data availability: Uncontrolled diabetes admission rates are available for 15 countries (Table 
33). The data were reported for years 2004-2005. Seven countries reported deviations from OECD 
definitions in the calculation of numerator. All countries use hospital records for the numerator, but the 
diagnostic codes to capture hypertension admission varied. One country indicated that hospital records 
may be incompletely coded, and may underestimate the number of admissions.  
125. Comparability issues: Detailed documentation and assessment is provided in Table 34. There are 
serious concerns about comparability from the estimation of the numerator; the HCQI project will have to 
ensure that countries are reporting the same type of admissions. Another threat for the comparability comes 
from the variation of hypertension prevalence across countries. There should be explored the need for age-
standardisation and the use of a truncated population as a proxy for disease specific population.  
126. Overall assessment: Fifteen countries provided data on this indicator. While information for this 
indicator might exist in hospital records of other countries as well, it is unclear how many countries would 
be able to construct this indicator on a routine basis. Additionally, a significant amount of analytic work 
will have to be done in order to ensure that the data are internationally comparable. However, data 
comparability and availability for this indicator is likely to improve due to the work of the Primary Care 
and Prevention Expert Subgroup and the indicator may warrant examination in the future as part of HCQI 
indicator updates.  
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Table 33. Hypertension admission rate per 100 000 discharges 
Country Rate per 100 000 Data year
Australia 43.7 2004-2005
Austria 474.8 2004
Canada 26.3 2004-2005
Czech Republic 273.0 2004
Denmark 2.9 2005
Finland 178.1 2005
Italy 174.8 2004
Japan 82.3 2005
Mexico 87.9 2005
Netherlands 35.9 2004
Norway 120.0 2005
Portugal 53.1 2004
Spain 10.4 2004
Sweden 63.8 2004 . 
 
Country Rate per 100 000 Data year
Latvia1 677.0 2005
Non-OECD EU countries
 
Notes: 
1. Data from hospital administered statistics
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Hypertension admission rate, sources and methods 
Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the definition of 
the numerator 
Additiona
l years 
available 
Comments 
Australia AIHW National Hospital 
Morbidity Database 
  Data are for ICD-10-AM I10, I11, I12, 
I13. 
  
Austria Statistics Austria 15+  Principle diagnoses given in ICD-10 
codes: I10, I110, I119, I120, I129, 
I130, I131, I132, I139 
 No exclusions were made, all discharges with 
principle diagnosis of the given codes. 
Canada Discharge Abstract Database, 
CIHI 
 Quebec population figures are 
excluded as the numerator excludes 
Quebec cases (see Other 
Comments below). 
  1. Corresponding ICD-10-CA codes were 
used. 2. Cases were extracted based on a 
most responsible diagnosis of the condition of 
interest. The most responsible diagnosis is 
defined as the one diagnosis or condition that 
can be described as being the most 
responsible for the patients stay in hospital. 
In the event that multiple diagnoses are listed, 
select the most responsible diagnosis from 
the condition associated with the longest 
length of stay or most resource intense. 3. 
Due to an inability in the ICD-9 coding 
classification to separate CHF and renal 
failure patients who also present with 
hypertension, data submitted by the province 
of Quebec were excluded (Quebec was the 
only province in Canada coding in ICD-9 in 
2004/05). 
Czech 
Republic 
National Registry of 
Hospitalized Patients 
20+ Population 20+ as of 1st of July Includes all hospitalised patients in 
general hospitals for diagnosis of I10 
  
Denmark National Hospital Discharge 
Register 
    There have been no exclusions in the 
numerator (it is not possible to write in the 
numerator box). The numbers provided are 
preliminary and will change as the register still 
receives data from the hospitals. It should be 
kept in mind, when interpreting this indicator 
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Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the definition of 
the numerator 
Additiona
l years 
available 
Comments 
that the indicator is strongly dependent on 
how the health system is organised. 
Finland Hospital Discharge Register     Number of cases was 5912. Out of these 
4326 were admitted from ER's. Others were 
via referrals. 
Italy Ministry of Health - National 
discharges database 
   2001+ We consider as "cardiac procedure codes" all 
ICD 9 CM codes between 35.** and 39.**. 
Japan Patient Survey 20+ 20+ (102 million)   Since the Patient Survey covers only one 
month, the numerator (estimated 8 400) was 
multiplied by 12. According to the Patient 
Survey, the number of discharges in 
September 2005 over 20 years with primary 
diagnosis of hypertension was estimated as 
approximately 7 100 (subject to wide margin 
of error inherent in sampling survey). 
Multiplied by 12, the annual number of 
discharges is estimated to be 85 200. Divided 
by Japan's population over 20 as of October 
2005 [103.56 million], the rate was calculated 
as 82.25/100 000 annually. 
Mexico SIAIS-Sistema de Información 
de Atención Integral a la 
Salud. IMSS (DTIES) División 
Técnica de Información 
Estadística en Salud 
20+ 20 years and older Work with OCD-10 Codes (Unofficial 
table ICD-9 and ICD 10 codes) 
 Nationwide representative 
Netherlands National Medical Registry, 
owned by PRISMANT. 
Calculations and methods by 
Statistics Netherlands in 
cooperation with Institute for 
Public Health and the 
Environment 
  Secondary diagnoses excluded from 
the numerator: health problems 
because of pregnancy, childbirth or 
puerperium; ICD-9 codes: 630-676 or 
V22-V24, V27, V28. Any cardiac 
procedures; CMSV 2.6 codes: 1273-
1278, 1580, 5350-5357, 5359-5363, 
5369-5379, 8520, 8576, 8640-8641, 
8643-8644, 8649-8658, 8660, 8837. 
 
 Benign hypertension (ICD-9-CM code 401.1) 
is not included in the OECD-selection, while 
benign hypertensive heart disease without 
heart failure or renal failure is (codes 402.10 
and 403.10). At codes 403 and 404 the 
Netherlands Medical Registry does not 
differentiate between hypertension with and 
without heart failure and renal failure. 
Consequently, we selected the following 
hypertension diagnoses: 401.0, 401.9, 
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Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the definition of 
the numerator 
Additiona
l years 
available 
Comments 
402.00, 402.10, 402.90, 403, 404. Are 
excluded: 401.1, 402.01, 402.11, 402.91. We 
assume that MDC 14 refers to health status 
described in Chapter 11 of ICD-9 (codes 630-
676) and several V-codes (V22-V24, V27, 
V28). Discharges from small specialised 
hospitals are excluded. In all rates, clinical 
admissions (with one overnight stay or more) 
and admissions without an overnight stay 
(=day care) were included. Transfers are 
included in the nominator. Consequently, 
discharges from secondary hospitals are 
included. 
Norway Norwegian Patientregister     Diagnoses codes ICD-10:I10-I15 
Portugal DRGs      
Slovak 
Republic 
     Our records do not work with four digit ICD, 
therefore it is not possible to consider 
exclusions 
Spain Hospital Discharge Minimum 
Data Set (Conjunto Mínimo 
Básico de Datos CMBD). 
Ministerio de Sanidad y 
Consumo. Instituto de 
Información Sanitaria. 
Registro de altas 2004. 
 Information not available on 
transferred patients 
  Minimum data set for in-patients discharge 
does not include data about if the patient has 
been transferred or not from other centre. 
Sweden The Swedish Hospital 
Discharge Register 
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Non-OECD EU countries 
Country Source 
Age 
groups 
included 
Deviations from the definition of 
the denominator 
Deviations from the definition of 
the numerator 
Addition
al years 
available 
Comments 
Latvia Health statistics and 
medical technology state 
agency 
  Numerator is hospital statistics rate, 
not in primary care. Hospitalised 
discharges of age 18 years and 
older with hypertensive diseases 
(ICD-10 I10, I15). 
 At this moment, we have only information 
about discharged rate, but in future it will 
be available from the Management 
Information System. 
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Table 34.   Hypertension admission rate, comparability issues 
  Comparability Implications
  Minor Severe 
Possible 1. Data available for slightly different age ranges  
2 Different procedure codes included. Unclear 
how comparable they are between countries. 
3. Hypertension prevalence rates differ across 
countries  
 
1. Different diagnostic codes used to 
capture hypertensive population in 
hospital discharge data. 
Po
ss
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Unlikely  1. Some countries indicated that the 
administrative records may 
underreport hypertension because of 
incomplete records. 
 
Possible solutions: 
• Footnotes can indicate the year and age deviations 
• Footnote (or drop if serious) if there are concerns that administrative data underreport 
hypertension.  
• OECD will need to work with countries to ensure that comparable codes are used to calculate this 
indicator. 
• Also age standardisation and adjustment by hypertension prevalence rates when reporting indicator 
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